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BIODEGRADABLE HYBRID NANOGELS FOR COMBINATION
CHEMOTHERAPY
Swapnil Desale, Ph.D.
University of Nebraska Medical Center, 2015
Advisor: Tatiana K. Bronich, Ph.D.
Combination chemotherapy is commonly used to treat cancer, because such a therapy
regimens usually involve sequential administration of multiple drugs and allow targeting
different cell signaling pathway. The co-delivery of drug combination at a controlled
ratio via the same vehicle is offering the advantages such as spatial-temporal
synchronization of drug exposure, synergistic therapeutic effects and suppression of drug
resistance. Undoubtedly, there are several molecular and pharmacological factors that
determine the effectiveness of drug combinations. A rationally designed drug
combination is required since certain drug ratios and the definitive exposure to the targets
of interest can only be synergistic while others are additive or even antagonistic. Cisplatin
(CDDP) and paclitaxel (PTX) combination has resulted in improvement in the ovarian
cancer treatment compare to individual drug with limited side effects. Multiple clinical
trials studied the overall efficacy of CDDP and PTX and found significant benefit over
the pre-existing treatments. Since then, this combination has been the treatment of choice
for both early stage as well as advanced cases of ovarian cancer. However, administration
of two different agents comes with the inconvenience of repeated or extended duration of
drug infusion in patients. Moreover, the most extensively used conventional formulation
of paclitaxel, Taxol®, utilizes Cremophor EL (polyethoxylated castor oil) that has been
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linked to significant toxicities including allergic, hypersensitivity and anaphylactic
reactions during infusion that require premedication and prolonged peripheral
neuropathy. Combining such drugs in one delivery carrier is therefore a well-suited and
convenient strategy for controlling the pharmacokinetics and co-delivery of the desired
drug ratio in vivo, to maximize the therapeutic potency and minimize drug-associated
toxicities. In an attempt to develop such multidrug vehicle, we designed a functional
biodegradable and biocompatible polypeptide-based polymeric nanogels. Triblock
copolymers containing the blocks of ethylene glycol, glutamic acid and phenylalanine
(PEG–PGlu–PPhe) were successfully synthesized via NCA-based ring-opening
copolymerization and their composition was confirmed by 1H NMR. Self-assembly
behavior of PEG–PGlu90–PPhe25 was utilized for the synthesis of hybrid micelles with
PPhe hydrophobic core, cross-linked ionic PGlu intermediate shell layer, and PEG
corona. Cross-linked micelles (nanogels, NG) were about 90 nm in diameter (ξ-potential
= − 20 mV), uniform (narrow size distribution), and exhibited nanogels-like behavior.
Degradation of NG was observed in the presence of proteolytic enzymes (cathepsin B).
The resulting NG can incorporate the combination of drugs with very different physical
properties such as CDDP (15 w/w% loading) and PTX (9 w/w% loading). Binary drug
combination in NG exhibited synergistic cytotoxicity against human ovarian A2780
cancer cells and exerted a superior antitumor activity by comparison to individual drugloaded NGs or free cisplatin in cancer xenograft model in vivo. However, this system
relies solely on the enhanced permeation and retention (EPR) effect to facilitate the
delivery of the drug combination to the tumor site. Regardless of the importance and
popularity of EPR effect-based drug delivery, this strategy has some limitations related to
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the inter- and intra-tumor heterogeneity, variations in the density as well as permeability
of the tumor vasculature that can affect the accumulation of nanocarriers. One of the
popular approaches to circumvent these problems is by surface-functionalization of the
drug carrier with ligands that can target receptors with differential expression on the
cancer cell surface, which helps in increasing the mean residence time of the delivery
system at the tumor site and improving target cell uptake.
One such receptor of interest is the folate receptor (FR). Its natural ligand, FA, comes
with the advantages of high binding affinity, stability and a simple chemical structure
together with ease of availability, making it a suitable targeting ligand for ovarian cancer
therapy. FA can thus be successfully conjugated to macromolecular systems without loss
of binding affinity to its receptor. Our group has previously demonstrated a tumorspecific delivery and improved anti-cancer effect in vivo of CDDP-loaded NGs decorated
with FA targeting groups. In the next part of our study, we designed FA-linked NGs
incorporating platinum-taxane combination, and examined whether FR-targeted
concurrent delivery of synergistic combination of CDDP and PTX can lead to enhanced
therapeutic efficacy compared to nontargeted NG system. FA-decorated NGs
significantly suppressed the growth of intraperitoneal ovarian tumor xenografts
outperforming their nontargeted counterparts without extending their cytotoxicity to the
normal tissues. We also confirmed that synchronized co-delivery of the platinum-taxane
drug combination via single carrier to the same targeted cells is more advantageous than a
combination of targeted single drug formulations administered at the same drug ratio.
Lastly, we demonstrated that the same platform can also be used for localized
chemotherapy. Our data indicate that intraperitoneal administration can be more effective
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in the context of targeted combination therapy. Our findings suggest that multifunctional
NGs are promising drug delivery carriers for improvement of current treatment for
ovarian cancer.
Combination chemotherapy is also very common in the treatment of breast cancer.
Trastuzumab (Herceptin™), in combination with chemotherapy is currently used for
treatment of ErbB2-overexpressing breast cancers, following surgical removal of the
primary tumor. However, patients either do not respond to Trastuzumab based therapies
or relapse during the course of the treatment, necessitating the development of newer
therapeutics. ErbB2 depends on heat shock protein 90 (HSP90) association for stability
and, among client proteins of the chaperone, ErbB2 is perhaps the most sensitive to
HSP90 inhibition. HSP90 inhibitors (such as the ansamycin antibiotic, Geldanamycin and
related molecules like 17-AAG) have shown significant promise in pre-clinical models of
ErbB2-driven breast cancer as well as initial phase I/II clinical trials. The mechanism
involves attenuation of oncogenic signaling via degradation of ErbB2 as well as other
critical downstream signaling mediators in the pathway, which include phospho-Akt and
c-Raf. In a cancer cell, these signaling molecules are strongly dependent on HSP90 to
maintain their stability. In a recently completed phase II study of 17-AAG and
trastuzumab, an overall clinical benefit (including stable disease) was seen in 57% of the
patients with ErbB2-positive metastatic breast cancer progressing on trastuzumab. We
therefore hypothesized that HSP90-inhibition will enhance ErbB2-targeted drug delivery
by promoting the endocytic uptake of ErbB2-bound nano-encapsulated cargo and
facilitating its re-routing from a recycling pathway to the lysosomes. Using Trastuzumabconjugated NGs (Trast-NG) encapsulating the DNA-damaging drug Doxorubicin (DOX)
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as a model chemotherapeutic, we demonstrate through both in vitro and in vivo studies
that HSP90-inhibition can indeed lead to an enhancement of targeted delivery of DOX
specifically into ErbB2-overexpressing breast cancer cells. As a consequence, a subtherapeutic and non-toxic dose of the HSP90 inhibitor 17AAG markedly improves the
efficacy of ErbB2-targetd nanogels in vivo. In a follow up study, we attempted to coencapsulate DOX and 17-AAG since combining drugs in one delivery carrier is a wellsuited strategy for controlling the pharmacokinetics and co-delivery of the desired drug
ratio

in vivo. However, co-incorporation of drug molecules with different

physicochemical properties, such as hydrophilic DOX and hydrophobic 17-AAG, has
been challenging. We have recently described biodegradable polymeric nanogels (NGs)
based on poly(ethylene glycol)-b-poly(L-glutamic acid) (PEG-b-PGA) with pendant
phenylalnine functionalities [23]. Such NGs have multiple hydrophobic domains formed
by phenylalanine moieties within the cross-linked PGA polyion cores surrounded by a
hydrophilic PEG shell. Herein, we explored these novel NGs for co-encapsulation of 17AAG and DOX. The potency of this co-delivery system was evaluated in a panel of
human breast cancer lines and in an ErbB2-driven orthotopic xenograft model. We
demonstrate that NGs-based co-delivery of synergistic combination of 17-AAG and DOX
exhibited superior antitumor efficacy compared to a combination of free drugs. The
implications of our results may support a new platform for delivery of combinations of
HSP90 inhibitors with cytotoxic agents for treatment of various types of cancers.
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CHAPTER 1

INTRODUCTION
1.1.

Cancer

Cancer is a major health problem and the second leading cause of illness-related
death. The six essential changes in cell physiology suggested to collectively contribute to
the malignant growth are self-sufficiency in growth signals, insensitivity to anti-growth
signals, tissue invasion and metastasis, limitless replicative potential, sustained
angiogenesis and evading apoptosis [1]. Currently available chemotherapeutic agents
have played a significant role in reducing mortality/morbidity and in increasing patient’s
overall lifespan [2]. Most of the chemotherapeutic agents have relatively narrow
therapeutic index; develop resistance and leads to off-target biodistribution upon
intravenous administration leading to severe side effects to healthy tissues. These
limitations of conventional chemotherapeutic strategies frequently result in suboptimal
dosing, treatment delay or discontinuance and reduced patient compliance to therapy [3].
Despite the recent advances in early diagnosis and cancer treatment, the development of
chemotherapeutic agents which can effectively deliver on efficacy, safety and
convenience for the patient remains a great challenge [3].
1.2.

Combination chemotherapy

Combination chemotherapy is medicine’s best attempt to address aforementioned
issues. In combination chemotherapy, cancer cells are attacked by drugs with synergistic
cytotoxicity by disrupting different stages of the cell reproduction cycle. Majority of
chemotherapeutic drugs act on a specific phase of the cell cycle, so it is logical to attack
multiple phases of the cell replication cycle to prevent mutation and resistance. The
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primary goals of drug combination in anticancer treatment are to overcome tumor
heterogeneity, reduce chemo-resistance and achieve additive or more desirable
synergistic anticancer efficacy without overlapping toxicity. Frei et al. proved in 1965
that a combination therapy consisting of two cytotoxic agents was therapeutically more
effective than monotherapy in children with acute leukemia [4]. Since then, clinically
effective drug combinations, that would improve the efficacy of oncology treatment, have
been widely researched. The fundamentals of combination chemotherapy development
have remained mostly unchanged over the last few decades. The general principles have
been to: i) use drugs with non-overlapping toxicities so that each drug can be
administered at near-maximal dose; ii) combine agents with different mechanisms of
action and minimal cross-resistance in order to inhibit the emergence of broad spectrum
drug resistance; iii) preferentially use drugs with proven activity as single drugs and iv)
administer the combination at early stage disease and at a schedule with a minimal
treatment-free period between cycles but still allowing the recovery of sensitive target
tissues [5-7]. In combination therapy the overall therapeutic benefit of the drugs in
combination were found to be greater than the sum of the effects of the drugs
individually. The best drug combination with maximal antitumor efficacy can be
calculated by combination index (CI) analysis, an effective way to demonstrate that drugs
are working synergistically [8]. Unlike single agent therapy, synergistic combinations of
two or more agents proved to overcome toxicity and other side-effects associated with
high doses of single drugs [9, 10]. The use of combination therapy for cancer treatment
has been well established in recent years and is depicted in figure 1.1.
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Figure 1.1. Schematic representation depicting various advantages shown by
combination drug delivery for cancer therapy. Adapted from [11].
The widely investigated drug combinations for effective cancer treatment are the
combination of multiple chemotherapeutic agents, chemotherapy with radiotherapy,
chemotherapy with hormone therapy and immunotherapy with chemotherapy [11].
Hormone therapy which involves administration of specific steroid hormones or drugs is
often given to patients with early stages of breast cancer and it act by
blocking/downregulating the estrogen receptor or by reducing the estrogen concentration
around or within the cancer cell [12, 13]. Combination of chemotherapy and radiotherapy
is one of the most promising strategies for current cancer therapeutics. It has been shown
to improve patient survival and the locoregional control of various cancers when
compared with radiotherapy alone [14-16]. Cancer treatment using different monoclonal
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antibodies is another practiced strategy for the current treatment of cancer. Antibodies
have the unique capacity to target and kill tumor cells while simultaneously activating
immune effectors to kill tumor cells through the complement cascade or antibodydependent cellular cytotoxicity. This multifaceted antibody-mediated killing mechanism
combined with chemotherapy has been taken up by various investigators to achieve
enhanced antitumor activity [17-19]. Among different combination therapies the most
practiced and well researched therapy method is co-treatment with multiple
chemotherapeutic drugs. Therefore, current trends in anticancer research have
progressively concentrated on the development of new combinations of anticancer drugs
with a view to overcoming the limitations frequently associated with conventional
chemotherapy. Considering the scope of this work, we have focused on combination
chemotherapy in leading gynecologic cancers which are ovarian and breast cancer.
1.3.

Combination chemotherapy in ovarian cancer

Ovarian cancer is the most lethal gynecologic malignancy in women and it is the
leading cause of death from gynecologic cancer. Approximately 60% of patients will
experience a relapse after the standard first-line treatment including cytoreductive surgery
and adjuvant chemotherapy [20]. At this time, when relapse occurs, the chance of cure
decreases drastically and treatment is solely palliative. Surgery is not sufficiently
validated due to the lack of phase III clinical trials, and there are no approved targeted
therapies in relapsed ovarian cancer. Therefore, chemotherapy is the only option to
achieve these objectives. Management of ovarian cancer has evolved from single agent to
combination chemotherapy. Clinical trials performed in the late 1970s demonstrated that
cisplatin (CDDP) is an active chemotherapy in advanced or recurrent ovarian cancer with
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a response rate in the range of 13–30% [21]. Subsequently, CDDP became the primary
choice for many clinical trials in ovarian cancer. Early trials also identified the toxicity
profile of this platinum agent including the risk of myelosupression and nephrotoxicity.
The next generation of ovarian cancer treatment regimens included the combination
therapy of CDDP plus other chemotherapeutic drug. One of such a research study
evaluating combination chemotherapy with CDDP plus cyclophosphamide revealed that
the tumor progression and survival were markedly improved compared with CDDP only
[22]. As a result, the standard combination chemotherapy in the late 1980s and early
1990s was CDDP plus cyclophosphamide. Discovery of paclitaxel (PTX) changed the
standard of care in ovarian cancer yet again. Clinical trials comparing cyclophosphamide
and CDDP with PTX and CDDP demonstrated that the platinum/taxane treatment
regimens had an improved outcome compared with standard combination of
cyclophosphamide and CDDP [23, 24]. After decades of clinical trials, intravenous
treatment regimens were accepted in the 1990s as the standard of care for advanced
ovarian cancer [25]. Till today, this combination is considered as standard chemotherapy
regimen in advanced ovarian cancer and suggested that a plateau has been reached for IV
chemotherapy. The typical course of platinum/taxane regimen for epithelial ovarian
cancer involves 3 to 6 cycles. A cycle is a schedule of regular doses of a drug, followed
by a rest period. In patients with advanced ovarian cancer (stages III–IV), six cycles of
chemotherapy are recommended [26]. In an attempt to deliver increased concentrations of
drugs to the ovarian tumors, intraperitoneal (IP) route of administration of chemotherapy
has been investigated which involves administration of drugs through surgically placed
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IP catheters (Fig. 1.2). The IP administration allows very large concentrations of active
agents to reach the tumor while attempting to minimize systemic toxicity.

Figure 1.2 IP administration of chemotherapy in ovarian cancer
The IP administration of CDDP resulted in a 10–20 fold greater concentration in the
tumor space compared with IV [27-29], while for paclitaxel the IP pharmacokinetics
demonstrate a 1000-fold greater IP versus IV concentration [30, 31]. Three randomized
phase III trials have demonstrated a major improvement in the treatment of advanced
ovarian cancer through the utilization of IP chemotherapy [32-34]. A phase III study
reported by Markman and colleagues in 2001 in stage III ovarian cancer patients who had
undergone optimal debulking surgery to less than 1 cm residual tumor [33]. The standard
chemotherapy arm used IV PTX and CDDP. The investigational arm utilized IV
paclitaxel followed by IP CDDP (100 mg/m2 versus 75 mg/m2 in the IV arm). This study
demonstrated an improvement in progressive free survival (22 versus 28 months,
p = 0.01) and a borderline improvement in overall survival (52 versus 63 months,
p = 0.05) in the investigational arm. The increased toxicity associated with the IP arm
prevented the routine use of this regimen despite its proven efficacy. Later a phase III
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study reported by Armstrong and colleagues in 2006 in optimally debulked stage III
ovarian cancer patients with less than 1 cm residual tumor [32], established a new
standard of care. This study randomized patients to IV PTX (135 mg/m2) over 24 h on
day 1 followed by IV CDDP (75 mg/m2) on day 2 versus IP CDDP (100 mg/m2) on day 2
and IP paclitaxel (60 mg/m2) on day 8. This study demonstrated a significant
improvement in overall survival (49.7 versus 65.6 months, p = 0.03). Significant
neurotoxicity was also observed in this study (19% in IP versus 9% in the IV group) (Fig.
1.3).

Figure 1.3. Overall survival among the 415 patients with stage III ovarian cancer who
were randomly assigned to treatment with intravenous PTX and CDDP or to treatment
with intravenous PTX, intraperitoneal CDDP, and intraperitoneal PTX. Adapted from
[32].
Although increased toxicity was noted during and following IP chemotherapy in this
study, the quality-of-life measurements returned to baseline 1 year following treatment.
Despite these phase III trials demonstrating a significant survival advantage with IP
compared with IV chemotherapy and a National Cancer Institute clinical alert supporting
IP chemotherapy, controversies regarding the use of IP chemotherapy still exist and this
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route of administration has not gained overwhelming support by the gynecologic and
medical oncology community [35]. Some of the barriers to utilizing IP therapy include IP
therapy-related side effects, complexity of IP administration, and controversies still
related to the clinical survival advantage of IP therapy.
1.4.

Combination chemotherapy in breast cancer

Breast cancer is the most frequently diagnosed cancer and the leading cause of
cancer-related death among females worldwide. The latest world cancer statistics
available from the International Agency for Research on Cancer showed that 1,677,000
women were diagnosed with breast cancer and 577,000 women died in 2012 [36].
Despite the success in early detection, up to five percent of women diagnosed with breast
cancer in the United States have metastatic disease at the time of first presentation. In
addition, up to 30 percent of women with early-stage, non-metastatic breast cancer at
diagnosis will develop distant metastatic disease [12]. Advancement in chemotherapy,
surgery, lymph node evaluation and hormone receptor blocking therapy have improved
the survival of breast cancer patients [37]. Genetic and molecular profiling of breast
cancer has revealed its profound complexity and heterogeneity [38, 39]. Such complexity
makes it challenging for clinicians to find the optimal treatment regimen in the treatment
of breast cancer. The cell surface receptors of the ErbB family including EGFR, ErbB2
(also known as Her2/neu) and ErbB3 (Her3) are over-expressed or deregulated in many
types of cancers, including breast cancers. The past two decades have seen an explosion
of activity in the development of ErbB-receptor targeted therapeutics. EGFR and ErbB2
have been the primary targets for therapeutic development. For example, the humanized
monoclonal antibodies Trastuzumab (Herceptin™; Genentech; against ErbB2) or
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Cetuximab (Erbitux™; Eli Lilly and Company; against EGFR) and the tyrosine kinase
inhibitors, Lapatinib (Tykerb; Glaxo Smithkline; dual EGFR/Her2 inhibitors) or Erlotinib
(Tarceva; Genentech; against ErbB2) are currently used clinically. However, de novo and
acquired resistance to treatment necessitate continued exploration of novel strategies.
One emerging approach is the use of antibody-drug conjugates, such as TrastuzumabDM1 (also developed by Genentech), which is an anti-mitotic fungal toxin chemically
conjugated to anti-ErbB2 monoclonal antibody. An alternative strategy involves targeted
delivery of conventional chemotherapeutic drugs (such as Doxorubicin, Paclitaxel or
Campothecin) encapsulated in anti-ErbB2 or anti-EGFR antibodies or ligands conjugated
liposomal or polymer micelle based nanoparticles are being explored at a laboratory and
pre-clinical stage. Both approaches use the overexpression of EGFR and ErbB2 as
addresses to specifically deliver cytotoxic cargo. This may be particularly useful as a
strategy for overcoming resistance to currently approved ErbB-directed targeted
therapies. However, for both antibody-drug conjugates as well as targeted nanoparticulate
drug-delivery systems, the extent of endocytosis of the receptor and its distribution
between recycling versus lysosomal pathways can limit successful delivery of the
chemotherapeutic payload into ErbB2 or EGFR overexpressing breast cancers.
Considering a scope of thesis, this section is intended to focus on use of clinical
combination therapy for the treatment of ErbB2-driven breast cancer. Although,
Trastuzumab in combination with chemotherapy has shown effectiveness in many
patients, challenges due to intrinsic or acquired therapeutic resistance have prompted the
development of Trastuzumab-MCC-DM1 (T-DM1; Genentech), which is an antibody-
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drug conjugate (ADC). DM1 is a Maytansanoid (a derivative of Maytansine; a Vinca
alkaloid), which functions as an antimitotic drug (Fig. 1.4) [40].

Figure 1.4. Schematic representation of T-DM1. The maytansine skeleton is shown in
black at left. The thioether group that makes mertansine is shown in red. The linker group
that makes emtansine is shown in blue at right, bound to the amino group (NH–) of a
lysine residue in the trastuzumab molecule (–mab).
DM1 is chemically conjugated to Trastuzumab via a non-reducible Succinimidyl-4-(Nmaleimidomethyl) cyclohexane-1-carboxylate (MCC) crosslinker, which was optimized
based on a systematic comparison of various reducible and non-reducible crosslinkers in
in vitro studies (intracellular drug release) and in vivo pharmacokinetics and toxicity
studies [41-43]. While the mechanism(s) of Trastuzumab resistance remains unclear,
several studies indicate that it is not due to loss of ErbB2 overexpression [44, 45];
consequently the rationale for T-DM1 design was to use ErbB2 as an address to deliver
the cytotoxic drug specifically to ErbB2-overexpressing breast cancers. T-DM1
demonstrated potent and selective activity against a panel of ErbB2 overexpressing breast
cancer cell lines (including several Trastuzumab-resistant model cell lines) as compared
to normal or ErbB2-low cancer cell lines [46, 47]. Most importantly, the drug exhibited
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favorable pharmacokinetics, low toxicity in mice and also inhibited growth of
Trastuzumab-sensitive as well as resistant ErbB2-overexpressing human breast cancer
cell xenografts in mice [46]. Although it was presumed that the cytotoxicity was a result
of internalization of the ADC direct data demonstrating internalization of the ADC was
lacking. The importance of this is underscored by recent studies that have shown that
ErbB2 receptor is not efficiently internalized [48, 49]. Given the numerous studies, which
suggest that ErbB2 receptor is either internalization resistant or rapidly recycles back to
the cell surface [48], data on the site of action of T-DM1 is critical in order to improve
designs for optimizing the intracellular delivery of the Maytansanoid. This will especially
become important in cases where patient-specific mutations or alterations in the activities
of regulators of endocytic trafficking (discussed above) could potentially cause
refractoriness or reduce the efficacy of T-DM1. For example, one factor that is
hypothesized to contribute to the low rate of endocytosis is the constitutive association of
ErbB2 with Heat Shock Protein 90 (HSP90) [49]. It has been demonstrated that HSP90
ATPase inhibitors such as 17-allylaminodemethoxy geldanamycin (17-AAG) induced
rapid downregulation of cell surface ErbB2 which is mediated by ubiquitin modification
of ErbB2 [50, 51]. Subsequent work has shown that 17-AAG indeed promotes the
delivery of surface ErbB2 to the lysosome [52, 53], an organelle where molecules such as
T-DM1 are intended to go. Several HSP90 inhibitors are currently in phase I and II
clinical trials and could potentially be combined with T-DM1.
1.5.

Nanocarrier-based approach for combination chemotherapy

Despite the fact that combination chemotherapeutic strategies have helped toward the
better treatment of cancer, their clinical success is largely hindered as a result of the
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inadequate accessibility of chemotherapeutic agents to tumor tissue, requiring high doses,
rapid abolition, poor solubility and inconsistent bioavailability. While in vitro cellular
studies have generated many leads for combinatorial regimens, their clinical results are
often met with little improvement in efficacy and at times higher toxicity [54-56]. One
major factor that separates in vitro success from in vivo clinical outcomes is the varying
pharmacokinetics among different drugs. Controlling the therapeutic cocktail that reach
the diseased cells and tissues therefore become a major clinical challenge. One strategy
toward more effective combination therapies thus is devising a better scheme for precise
and control delivery of multiple therapeutic agents. Thus, to mitigate the limitations
associated with conventional combination chemotherapy, there is an urgent need for
developing a drug delivery system that could enhance the delivery of drugs to the tumor
site while reducing toxic side effects.
Advances in nanotechnology have opened up infinite opportunities in controlled drug
delivery and novel combination strategies. Nano-formulated drugs have now come of age
in the clinic and are inspiring innovative investigations in drug delivery [57].
Nanoparticle therapies provide improved drug solubility, reduced systemic toxicity,
longer circulation times in the blood, controllable release profiles, and the potential to
target specific cells and tissues [58-60]. Recently, nanocarriers are gaining increasing
attention for their ability to co-encapsulate multiple therapeutic agents and to synchronize
their delivery to the diseased cells. Various nanoparticle platforms such as liposomes,
dendrimers, micelles, carbon nanotubes (CNTs), polymer–drug conjugates and nanogels
have been used to carry broad classes of therapeutics including cytotoxic agents,
chemosensitizers, small interference RNA (siRNA), and antiangiogenic agents.
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1.5.1. Liposomes
Liposomes are spherical vesicles consisting of amphiphilic phospholipid bilayers.
Phosphatidylcholine and phosphatidylethanolamine are the common building blocks for
liposomal preparation whereas cholesterol is a frequent additive that serves to modify the
rigidity of the lipid membranes. Liposomes have been pharmaceutical carriers of choice
for drug delivery applications and several liposomal drug formulations have already been
approved, and many more are under clinical evaluation [61]. One major advantage of
liposomes as a drug carrier is its ability to work with both hydrophobic and hydrophilic
drugs; hydrophobic drugs can be enclosed within the phospholipid bilayers, while
hydrophilic can drugs reside in the aqueous cavity [62]. Liposomes are typically prepared
by rehydrating lipid films to form multilamellar vesicles, which subsequently undergo
mechanical extrusions to form unilamellar vesicles [63]. Multidrug-loaded liposomes can
be prepared using either active extrusion or passive diffusion followed by filtration of
unloaded drugs. CPX-351 (cytarabine/daunorubicin liposome injection) is a liposomal
formulation of cytarabine and daunorubicin for intravenous infusion. [64]. In preparing
CPX-351, cytarabine was hydrated and extruded with the lipid components yielding
cytarabine-loaded liposomes. These liposomes were then incubated with daunorubicin to
achieve dual-drug encapsulation. The two drugs contained within the liposome in a 5:1
molar ratio, showed synergistic cytotoxicity in vitro and in murine models of
hematological malignancies Liposome-encapsulated curcumin and resveratrol were
prepared by film hydration method. Systemic administration of this formulation inhibited
prostate cancer by increasing their bioavailability synergistically and enhanced the
anticancer effects. Combination therapy of liposomal paclitaxel and cisplatin as
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neoadjuvant chemotherapy in locally advanced cervical cancer was evaluated by Li et al
[65]. Patients were administered with intravenous dose of 175 mg/m2 PTX and 75 mg/m2
CDDP. The total response rate was 86.1% (62/72) including a complete response and
partial response rate of 27.8% (20/72) and 58.3% (42/72). The study showed that
liposomal paclitaxel with cisplatin as an additional chemotherapy regimen is efficacious
and tolerable in the NACT of cervical cancer. Transferrin-conjugated liposome coencapsulating doxorubicin and varapamil proved to be effective in doxorubicin-resistant
K562 cells and showed enhanced cytotoxicity caused by overcoming P-gp-mediated
multidrug resistance [66]. A Phase I study was performed by taking a liposomal
formulation entrapped with irinotecan and floxuridine in the ratio of 1:1 and the
maximum tolerated dose and pharmacokinetic parameters of the liposomal formulation
were determined in patients with advanced solid tumors. The results demonstrated the
dual-drug-loaded liposomal formulation was well tolerated showing enhanced anticancer
activity in patients [67]. Co-delivery of the P-gp inhibitor, tariquidar, and cytotoxic drug,
paclitaxel, into tumor cells to reverse the multi-drug resistance using long-circulating
liposomes [68]. Anticancer drug combinations can act synergistically or antagonistically
in vivo against tumor cells depending on the ratios of the individual agents comprising the
combination. Mayer et al examined the liposomes for loading of various drug
combinations

(irinotecan/floxuridine,

cytarabine/daunorubicin,

and

cisplatin/daunorubicin) at different ratios (1:1, 5:1, and 10:1) [69]. The liposomes not
only maintained drug ratios in the plasma after injection, but also delivered the
formulated drug ratio directly to tumor tissue. Apart from small molecule therapeutic
combination, liposomes have been also reported to encapsulate combination of small
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molecule and oligodeoxynucleotides/siRNAs. Cationic liposomes targeted with a
monoclonal antibody against the disialoganglioside GD2 co-encapsulating c-myc
antisense oligodeoxynucleotides and doxorubicin led to the most pronounced delay in
tumor growth when administered in a sequential manner. As a result, their combination
translates into a statistically significant suppression of blood vessel density and an
enhanced apoptosis, compared to all treatments given separately. Saad et al showed an
efficient encapsulation of doxorubicin and siRNA targeted to MRP1 and BCL2 mRNA
(suppressors of pump and non-pump cellular-resistance, respectively) into the cationic
liposomes which led to enhanced cell-death induction and suppression of cellular
resistance in multi-drug resistant lung cancer cells.
Two liposomal drug combinations have entered clinical trials. First is small molecules
combinations in Phase II clinical trials, CPX-351 (cytarabine and daunorubicin) in
patients with newly diagnosed acute myeloid leukemia [70], and CPX-1 (irinotecan
HCI:floxuridine)

in

patients

with

colorectal

cancer

(http://www.celatorpharma.com/new/products.html).
1.5.2. Polymer-dug conjugates
Covalently attaching therapeutic agents to water-soluble polymers is another
approach that improves the drugs systemic circulation lifetime and reduces their exposure
to normal tissues. The advantages of polymer–drug conjugates include passive tumor
targeting by EPR effect due to its leaky vasculature which allows selective extravasation
of the conjugate in tumor tissue and retained for longer period due to its poor lymphatic
drainage [54]. Polyethylene glycol, poly (l-glutamic acid) (PGA), and N-(2hydroxypropyl)methacrylamide (HPMA) are examples of polymers that have been
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accepted into clinical practice [71]. Currently, more than fourteen polymer–drug
conjugates have undergone clinical evaluation and a polyglutamic acid (PGA)-paclitaxel
conjugate (CT-2103, OPAXIO®, previously known as Xyotax®) is expected to enter the
market in the near future [71, 72]. Since these polymers have the multivalent functional
groups, recent research efforts have synthesized conjugates with a combination of drugs
to the polymer chains and demonstrated synergistic efficacy. HPMA copolymer carrying
the combination of the aromatase inhibitor aminoglutethimide and doxorubicin was the
first report of these types of conjugates [73]. Drugs were linked through a biodegradable
linker and a loading capacity was approximately 5% w/w for aminoglutethimide and 7%
w/w for doxorubicin. The data suggested that the conjugate carrying both drugs was more
active than the combination of two polymer conjugates each carrying a single drug [73].
A follow on study investigated the mechanism of synergy and suggested that such
increased activity could be due to a variety of factors, including drug release rate,
conjugate conformation in solution and possibly, activation of certain molecular
pathways (induction of apoptosis)[74]. Santucci et al used PEG to conjugate the
chemotherapeutic agent epirubicin (EPI) and the diffusible messenger nitric oxide (NO).
Authors build a dendronised structure to one terminus of the PEG chain since unmodified
PEG has a maximum loading capacity of two drug molecules per polymer chain [75].
This strategy also allowed to obtain two chemically distinct termini i.e. a carboxylic acid
used for NO conjugation and a hydroxyl group to conjugate EPI.
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Figure 1.5. Structure of dendronized EPI-PEG-(NO)8 conjugate [75].
In cancer cells, EPI and NO act synergistically, conversely, in cardiomyocytes NO
counterbalances EPI induced cardio-toxicity. In vivo studies confirmed that this
conjugate displayed anticancer activity but was less cardio-toxic [75, 76].
Minko group synthesized a six-branched luteinizing hormone secreting hormone-targeted
conjugate containing equimolecular amounts of camptothecin and BH3. In vitro studies
showed that such multicomponent conjugate was almost 100 times more cytotoxic than
the single conjugates and displayed enhanced antitumour activity in vivo when compared
with monotherapy [77].
Segal et al. developed an HPMA copolymer containing antiangiogenic agent, TNP470 (Caplostatin) and the aminobiisphosphonate alendronate [78]. In this combination,
alendronate has the double function of targeting moiety (to promote bone targeting) and
of pharmacologically active agent. In vitro evaluation of this combination conjugate
confirmed its synergy and in vivo results showed almost complete tumour regression
observed in a human osteosarcoma model [78]. In another study, the same group
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developed HPMA conjugate of alendronate and paclitaxel. Prostate and breast cancer
cells showed anticancer and antiangiogenic activity in in vitro experiments and suggest
promising applications in bone metastasis.
Lammers et al synthesized and evaluated an HPMA-based polymer–drug conjugate
carrying 6.4 wt% of gemcitabine and 5.7 wt% of doxorubicin [79]. The resulting
construct had able to effectively kill cancer cells in vitro, to circulate for prolonged
period of time, to localize to tumors relatively selectively, and to inhibit tumor growth.
As compared to free drug, polymer-dug conjugate increased the efficacy of the
combination of gemcitabine and doxorubicin without increasing its toxicity, and it more
strongly inhibited angiogenesis and induced apoptosis [79]. Another HPMA-conjugate
carrying the doxorubicin and the anti-inflammatory agent dexamethasone was reported
[80]. The conjugate with a combination of two drugs showed better therapeutic activity
that the individual drug conjugates. Doxorubicin and a phosphatidylinositol-3 kinase
inhibitor wortmannin were conjugated alone or combination onto poly(ethylene glycol)poly(aspartate hydrazide) block copolymers through a hydrazone bond [81]. Polymer–
drug conjugates assembled into a unimodal micelle structure with a < 100 nm particle
size. Wortmannin enhanced the efficacy of doxorubicin through an efficient combination
delivery accompanied by synergistic drug action.
1.5.3. Polymeric micelles
Amphiphilic block or graft copolymers comprised of two or more chains with
different hydrophobicity have been used extensively in pharmaceutical applications
ranging from sustained-release technologies to gene delivery. These copolymers are
known to spontaneously self-assemble in an aqueous solution into nanoscopic polymeric
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micelles (10 to 100 nm) having fairly narrow size distribution. The nature of the selfassembly process allows for significant versatility in the chemical composition of the
polymeric micelles and thus permits fine tuning of the material properties, morphology
and sizes. These micelles have unique core-shell architectures with hydrophobic polymer
chains segregating into a micelle core surrounded by a shell of hydrophilic chains.
Hydrophobic drugs can be entrapped into the micelle core non-specifically through
hydrophobic interactions or specifically by chemical conjugation to the core-forming
block of the copolymer via a carefully designed pH- or enzyme-sensitive linker that can
be cleaved to release a drug in its active form. A variety of drugs with diverse
physicochemical properties can be incorporated into the core by engineering the structure
of the core-forming segment of the copolymer to attain sufficiently strong interaction
with drug molecules. These polymeric micelle systems can also be used for co-delivery
of two or more drugs with similar or different properties for combination therapy, or to
combine multiple modalities within a single carrier (Fig. 1.6).

Figure 1.6. Multi-drug polymeric micelles for drug delivery. Adapted from [82].
Simultaneous delivery of chemotherapeutic drugs by polymeric micelles improves safety,
and may permit anticancer agents to act at solid tumors at the same time, aiming for

20

synergistic drug interaction [83-85]. Multi-drug delivery is very often realized by the
step-wise physical loading of an anticancer agents in a polymeric micelle. Multi-drug
polymeric micelles may release physically loaded drug(s) by disassembly of polymeric
micelles in blood and/or by diffusion. Drug release tends to be rapid in vivo, and in vitro
results must be interpreted with caution due to poor in vitro/in vivo correlation. Thus,
while EPR targeting of solid tumors is feasible with physically loaded drug, it is regarded
as challenging, and research on multidrug polymeric micelles for tumor targeting
deserves more attention. Another way for multi-drug loading is via chemical conjugation,
a reversible covalent linkage is required between an anticancer agent and a block
copolymer. Drug release from multi-prodrug polymeric micelles may occur by simple
hydrolysis or stimuli- /environment dependent release and may be tuned by choice of
chemical linkage, e.g., esters, and spacer groups [54, 86]. Shin et al attempted to
physically co-incorporate three hydrophobic drugs, PTX, rapamycin, and 17-AAG in
Poly(ethylene glycol)-block-poly(d,l-lactic acid) (PEG-b-PLA) micelles using a simple
solvent evaporation method in various drug(s)-in-micelle combinations (Fig. 1.7) [87].

21

Figure 1.7. PEG-b-PLA micelles for the delivery of PTX, rapamycin, and 17-AAG.
Adapted from [87].
Three drug-loaded PEG-b-PLA micelles had a 10–10,000-fold increase in aqueous
solubility of PTX, rapamycin, and 17-AAG (up to 7.2, 3.3, and 7.3 mg/mL, respectively).
PEG-b-PLA micelles delayed release of three drugs compared to single drug-loaded
micelles in vitro. Simultaneous delivery of PTX, rapamycin, and 17-AAG via 3-in-1
PEG-b-PLA micelles (particle size of ca. 30–40 nm) at 60, 30, and 60 mg/kg,
respectively IV injection caused durable antitumor responses in A549 human non-small
cell lung cancer and MDA-MB-231 human breast cancer xenograft models with
acceptable acute toxicity [84]. Na et al studied the antitumor effects of 5-fluorouracil,
CDDP, CPT-11, oxaliplatin, etoposide, mitomycin-C, doxorubicin and PTX by
determination of in vitro cytotoxicity to CT-26 colorectal tumor cells or in vivo following
a subcutaneous transplant in BALB/c mice [88]. Single agent and combination in vivo
studies were performed using drug-loaded polymeric micelles composed of poly(γ-benzyl
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l-glutamate) and poly(ethylene oxide) (GEG) or poly(l-lactide)/poly(ethylene glycol)
(LE) diblock copolymer. When tumor cells were exposed to doxorubicin concurrently
with etoposide or paclitaxel, evidence of synergy was observed in CT-26 cells in vitro.
Doxorubicin and paclitaxel loaded into GEG or LE copolymers at a high concentration
(19.5 and 16.7 wt%, respectively) were almost completely released (83.2% and 93.7%,
respectively) by day 3. When tumor-bearing mice were treated in combination with
doxorubicin–paclitaxel or doxorubicin–etoposide, substantial antitumor activity was
evident compared with single therapy. These data suggest that chemotherapy using
micelle-loaded anticancer drugs represents a promising potential as a carrier system in
modulating drug delivery. In another study, wang at al reported core-shell-type micelles
that were doubly emulsified from an amphiphilic copolymer methoxy poly(ethylene
glycol)-poly(lactide-co-glycolide)

(mPEG-PLGA)

[89].

These

micelles

offered

advantages over other nanocarriers, as they were easy to fabricate by improved double
emulsion method, biocompatible, and showed high loading efficacy. More importantly,
these micelles could co-deliver hydrophilic doxorubicin and hydrophobic PTX. The drugloaded micelles possessed a better polydispersity, indicating that they are more readily
subject to controlled size distribution. Co-delivery nanocarrier suppressed tumor cells
growth more efficiently than the delivery of either doxorubicin or PTX at the same
concentrations, indicating a synergistic effect. Moreover, the drug-loaded micelles with a
DOX/PTX concentration ratio of 2:1 showed the highest anti-tumor activity to three
different types of tumor cells. Kabanov and collaborators reported amphiphilic poly(2oxazoline)s (POx)-based micelles as a promising high capacity delivery platform for
multidrug cancer chemotherapy [85]. A variety of binary and ternary drugs combinations
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of PTX, docetaxel, 17-AAG, etoposide and bortezomib were solubilized in defined
polymeric micelles achieving unprecedented high total loading capacities of up to 50 wt
% drug per final formulation. Multi-drug loaded POx micelles showed enhanced stability
in comparison to single-drug loaded micelles. Drug ratio dependent synergistic
cytotoxicity of micellar etoposide /17-AAG was observed in MCF-7 cancer cells and of
micellar bortezomib /17-AAG in MCF-7, PC3, MDA-MB-231 and HepG2 cells.
Katragadda et al developed a micellar nanocarriers for concomitant delivery of PTX
and 17-AAG for cancer therapy [90]. PTX and 17-AAG were simultaneously loaded into
polymeric micelles by a solvent evaporation method. Two candidate nanocarrier
constructs,

PEG–PLA-based

distearoylphosphatidylethanolamine/tocopheryl

micelles
polyethylene

and
glycol

PEG1000

(PEG-

DSPE/TPGS)-based mixed micelles, were assessed for the release kinetics of the loaded
drugs. Compared to PEG–PLA micelles, entrapment of paclitaxel and 17-AAG into PEGDSPE/TPGS mixed micelles resulted in significantly prolonged release half-lives.
Paclitaxel/17-AAG-loaded PEG-DSPE/TPGS mixed micelles were as effective in
blocking the proliferation of human ovarian cancer SKOV-3 cells as the combined free
drugs. There are plenty of other examples of use of micelles a carrier of drug
combinations. This section only covers the most relevant examples. For detailed
information about the application of polymeric micelles as a multi-drug vehicles, please
see the review by cho et al [82].
1.5.4. Nanogels
Nanogels are three-dimensional hydrogel materials in the nanoscale size range
formed by crosslinked swellable polymer networks with a high capacity to hold water,
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without actually dissolving into the aqueous medium. Nanogels can be composed of a
variety of naturally occurring polymers, synthetic polymers or a combination thereof.
Their characteristics such as size, charge, porosity, amphiphilicity, softness, and
degradability can be fine-tuned by varying the chemical composition of the nanogels.
They are mostly spherical particles but the current advancement in synthetic strategies
allow for the fabrication of nanogels of different shapes [91, 92]. They can be also
designed to have either a core-shell or a core-shell-corona structure, with at least one of
the layers crosslinked for structural integrity. Being mostly hydrophilic in nature,
nanogels are highly biocompatible with a high loading capacity for guest molecules and
their unique physical properties offer them distinct advantages over other types of
nanomaterials for biomedical applications. Nanogels not only protect the cargo from
degradation and elimination but also participate actively in the delivery process due to
their characteristic properties like stimuli-responsive behavior, softness and swelling to
help achieve a controlled, triggered response at the target site [93-95]. The versatility of
their architecture allows for incorporation of a plethora of guest molecules ranging from
inorganic nanoparticles to biomacromolecules like proteins and DNA with suitable
modifications of the materials used for their construction, without compromising their
gel-like behavior [96-99]. This multifunctionality and stability is hard to find in other
types of nanoparticulate systems [100, 101]; especially the ability to incorporate entities
with very different physical properties within the same carrier. Inorganic nanomaterials
have distinct material properties like optical activity, electrical conductivity and magnetic
properties that make them suitable for in vivo diagnostic and imaging applications, but
they suffer from limitations of poor colloidal stability, low aqueous solubility and rapid
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elimination by the mononuclear phagocytic system (MPS). Polymeric nanogels can be
used as carriers for such imaging probes by imparting stability and increasing their utility.
This lead to the evolution of a new class of agents termed ‘nanohybrids’ which are
nanogels incorporating inorganic materials [102, 103]. Such nanohybrids can contain a
wide variety of diagnostic and imaging agents for different types of medical conditions.
Nanogels prevent biomolecules like enzymes and genetic material from degradation
while their own macromolecular properties help increase the circulation half-lives of
small molecules, and serve as a highly convenient platform for combination delivery of
therapeutic molecules. They can be targeted specifically to the site of interest by
conjugation with a targeting ligand or due to the passive targeting that is a characteristic
feature of their nanoscale size. Despite such diversity in their applications, nanogels are
not yet a part of clinical use. Many comprehensive and more specialized review articles
on synthesis and application of nanogels were recently published.
1.5.4.1.

Synthesis of nanogels

Nanogels can be synthesized by a number of techniques. Since an in-depth discussion
of all the available techniques is beyond the scope of this review, a brief overview of the
techniques is given, along with reference to more detailed sources. Traditionally,
nanogels have been classified based on the method of crosslinking as either physically or
chemically (covalently) crosslinked nanogels. Chemical crosslinking involves formation
of covalent bonds between the polymer chains during polymerization of low molecular
weight monomers or crosslinking of polymer precursors. The most extensively employed
methods for preparing chemically crosslinked nanogels utilize heterogeneous
polymerization reactions in the presence of either bifunctional or multifunctional
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crosslinkers [104, 105]. Conventional and controlled/living radical polymerization
techniques allow for preparation of nanogels with different composition, dimensions, and
architectures including core-shell and hollow nanogel particles [106, 107]. The use of
functional initiators and macroinitiators further allows the incorporation of functionalities
in the interior or on the surface of nanogels, which facilitate multivalent bioconjugation
[108]. A variety of other crosslinking approaches including click chemistry, Schiff-base
reactions, thiol-disulfide exchange, amide crosslinking, photo-induced crosslinking,
enzyme-mediated crosslinking etc., have been developed for the synthesis of nanogels
from the polymer precursors. In addition, the crosslinking reactions carried out on
preformed core-shell self-assemblies such as polymer micelles allow introducing a high
degree of spatial organization into the nanogels [109]. For a comprehensive look into
crosslinking strategies, the reader is directed to excellent review written by Haag and
colleagues [110]. Recent advances in nanoscale fabrication methods provided further
unique opportunities to fabricate well-defined nanogels with precise control over size,
shape, deformability and surface chemistry in a high-throughput manner [111-113].
Physically crosslinked systems though formed under the mild conditions, tend to be more
fragile than their covalently crosslinked counterparts since they are stabilized by
relatively weak interactions between polymer chains such as hydrogen bonding,
hydrophobic interactions or ionic interactions. The use of hydrophobically-modified
polymers and other associating polymers for preparing functional nanogels has recently
been reviewed by Sasaki and Akiyoshi [114]. One of the challenges in the formation of
nanogels by such polymers is a control over the particle size, which requires fine-tuning
of the polymer concentrations or environmental parameters such as temperature, pH, and
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ionic strength. A study by Nielsen and co-workers has demonstrated that these challenges
can be addressed by utilizing a microfluidics-based approach [115]. Overall, the advances
in polymer chemistry led to the exceptional diversity and control over the composition,
architecture and functionality of crosslinked nanogels, which in turn provide more
flexibility to tune their properties to comply with targeted biomedical applications.
1.5.4.2.

Stimuli-responsive behavior

Stimuli-responsive behavior of nanogels is a sequence of events initiated by an
external cue that comes either from the specific environment within the body like change
in pH, temperature, redox conditions or enzyme concentration, or a stimulus that can be
applied externally such as light, magnetic field, etc. This stimulus then causes a
conformational or structural change in the nanogel, which is mediated by various factors
including, but not limited to, transition in the temperature below or above its lower
critical solution temperature (LCST) or the ionization of acidic or basic functional groups
on the polymer chains. These changes also alter the hydrophilicity and/or hydrophobicity
of the nanogels or, in other words, the extent of interaction of the system with water
molecules [116-118] and is mostly manifested in the form of swelling or deswelling of
the nanogel network, which in turn causes responses like release of the entrapped cargo
[119, 120]. One of the considerable advantages of nanogels over the macroscopic gels is
their very rapid response to a change in environmental conditions [121]. The
responsiveness of nanogels to the external physical or chemical signals can be tightly
regulated by controlling the structure of the materials used for preparation of the nanogels
[93, 122]. For example, in the case of polyelectrolyte nanogels pH-dependent ionization
of functional groups results in an increase of osmotic pressure inside the nanogel due to
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entrapped counterions and ultimately results in the swelling of the nanogels [122-124]. It
is well recognized that a balance between the osmotic pressure and the polymer elasticity
sets the physical dimensions of a hydrogel particle [125]. Thus, the extent of swelling
also depends on structural characteristics of the nanogel like the chemical composition,
hydrophilicity of crosslinkers, and the degree of crosslinking of the nanogel network,
which controls the freedom of conformational mobility of the polymer chains [126, 127].
Tan et al. studied pH-responsive polyampholyte nanogels with different fractions of
methacrylic acid (MAA) and 2-diethylaminoethyl methacrylate (DEAM) units in the
crosslinked polymer cores that were sterically stabilized by poly(ethylene glycol), PEG,
shell [128] The MAA segment in this nanogel is a weak acid and DEAM is a weak base
(pKa = 5.4 for MAA and pKa = 7.3 for DEAM). The DEAM segments could be
protonated at low pH, imparting a positive charge to this segment, whereas the MAA
units are negatively charged at high pH. As a result, these nanogels exhibited marked
swelling at both high and low pH values, but shrunk in the vicinity of isoelectric point
due to overall charge neutralization. It was demonstrated that swelling-deswelling
transition can be tuned by varying the composition of MAA and DEAM in the nanogels.
The unique charge-switching properties of amphoteric nanogels based on poly(Nisopropylacrylamide) functionalized with aminophenylboronic acid (PBA) were explored
by Hoare and Pelton to regulate the release of preloaded insulin in glucose-dependent
manner [129]. The binding of glucose to the PBA residues shifts the boronic acid
ionization equilibrium, increases the anionic charge density on the gel and drives a gel
swelling response. These nanogels were designed to both swell and deswell in response
to glucose according to the pH of the medium, the concentration of PBA groups grafted
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to the nanogel, and the relative concentrations of the cationic and anionic functional
groups in the platform nanogel. Such PBA-nanogels had a high capacity for insulin
uptake and selectively released insulin under physiological conditions in an “on-off”
manner with fluctuating glucose level. Similar approach was adapted by Wu et al. for the
design of a nanogel-based glucose sensor, which comprised of a core of Ag nanoparticle
encapsulated within a glucose-recognizing crosslinked shell containing PBA residues.
The swelling of the gel in response to glucose binding causes a change in the refractive
index of the medium around Ag nanoparticle that leads to change in its fluorescence
properties. The response rate is reported to be on the order of 100 ns, and the detection
sensitivity for change in glucose concentration was reported to be ± 0.1 mM [130]. Thus,
both sensitivity and rate of response of the nanogels can be programmed and fine-tuned
by alterations in the structure of the building blocks [93, 122]. Accordingly, the cargo
(mostly drugs) can either be conjugated chemically to the nanogels or merely entrapped
physically into its core [15], depending on the stimulus that is most feasible for utilization
at the targeted site of disease. Often multifunctional nanogels, which respond to a
combination of more than one external signal, can also be fabricated for more sitespecific response [131-133]. These stimuli are frequently disease- or organ-specific, since
different pathological conditions are associated with changes in pH, temperature and
redox balance or expression levels of certain biomolecules as compared to the normal
physiological conditions [134]. The reversible crosslinks containing disulfide bonds that
are stable in extracellular milieu but are cleaved in the reductive intracellular
environments due to the differences in the reductive potential between the extracellular
and intracellular compartments, are successfully utilized in design of redox-responsive
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nanogels [132, 135, 136]. The nanogels with disulfide links are stable during circulation
in the blood but labile while internalized in cells, thus, facilitating the release of the drug.
Matyjaszewski et al. have prepared biodegradable nanogels with disulfide-functionalized
dimethacrylate crosslinkers that degraded into individual polymeric chains in the
presence of glutathione and enabled both the release of encapsulated cargos and the
removal of the carriers [137]. Thayumanavan and coworkers reported the preparation of
redox-sensitive nanogels based on random amphiphilic copolymer that contains
hydrophilic oligoethyleneglycol (OEG) and hydrophobic pyridyldisulfide (PDS) units as
side-chain functionalities [138]. Self-assembled nanostructures formed by this polymer
were crosslinked by initiating a thiol-disulfide exchange reaction among the PDS groups
using dithiothreitol (DTT). The size of the resulting nanogels can be tuned by varying the
copolymer molecular weight, composition and concentration, while the extent of
crosslinking can be controlled by the amount of added DTT. The release of the
encapsulated doxorubicin (DOX) was triggered by glutathione treatment and the release
rate can be tuned by adjusting the crosslinking density.
1.5.4.3.

Nanogels as a therapeutic drug carrier

Nanogels are highly swollen and can incorporate 30% wt. or more of biological
molecules and drugs through electrostatic, van der Waals and/or hydrophobic interactions
or covalent bonding with the polymer chains. These loading capacities are unusually high
and exceed those of liposomes and polymeric micelles. As a result of drug loading, the
nanogels collapse forming stable nanoparticles, in which biological agent becomes
entrapped. Introducing dispersing hydrophilic polymers (e.g., PEG) in a nanogel structure
can prevent their aggregation. During the collapse of the drug-nanogel complex
hydrophilic polymer chains become exposed at the surface and form a protective layer
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around the nanogel. The control and versatility of polymer chemistry allows designing a
broad range of drug formulations and inclusion of multiple therapeutic cargos within the
same nanogel carrier. Stimuli-responsive drug release via temperature or pH-induced
volume collapse can also be very attractive for drug delivery applications. The
functionalization of the nanogel surface can further facilitate their selective accumulation
in the target tissue or cells. Development of nanogels that can carry, protect, target and
release therapeutic agents in spatially and temporally controlled manner is actively
ongoing and their rational design can provide a platform for multiple applications. The
group of Wang took advantage of the activity of bacterial lipases, which are abundant in
microbial flora, to construct a nanogel for the on-demand release of antibiotics [134]. In
this approach, the triple-layered nanogel contains a hydrophobic lipase-sensitive poly(εcaprolactone) (PCL) interlayer between the crosslinked polyphosphoester core and the
PEG shell. Prior to reaching sites of bacterial infection, the antibiotics are protected
inside the polyphosphoester core and are not released due to the compacted PCL
molecular fence. However, rapid drug release was observed in the presence of lipase or
lipase-secreting bacteria.
1.5.4.3.1. Nanogels for small therapeutic molecule delivery
Over the past few years, significant progress has been achieved in application of
nanogels as a delivery carrier for small biologically active molecules. Nanogels can be a
versatile platform for the incorporation of various small drug molecules through the
combination of electrostatic and hydrophobic interactions as well as hydrogen-bond
formation [139]. The swelling of nanogels in an aqueous environment allows for easy
permeation of the cargos. The rational design of the nanogels might be an effective tool
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to tune the drug release rates, to affect carrier-cell interactions, and achieve desirable
therapeutic effect of the drugs. One of the most important features of weakly-crosslinked
polyelectrolyte nanogels is their ability to incorporate molecules of the opposite charge.
For example, cationic crosslinked PEG-polyethyleneimine (PEG-PEI) nanogels were
explored for immobilization of negatively charged biologically active compounds such as
retinoic acid, indomethacin or valproic acid [139, 140]. These drug formulations formed
stable colloidal dispersions at physiological pH and ionic strength, could be lyophilized
and then redispersed. Similar nanogels and complexation strategy has been successfully
utilized for incorporation of various nucleoside analog 5′-triphosphates [141, 142]. It was
reported that these drug-loaded nanogels could improve the delivery of the active
triphosphates of therapeutic nucleoside analogs into cancer cells and inhibited tumor
growth in the mammary carcinoma animal model [142]. Recently, the same group
demonstrated the significant advantage of active 5′-triphosphates of nucleoside reverse
transcriptase inhibitors encapsulated in cationic nanogels over free drugs in the antiviral
therapy of HIV-1 infection in the central nervous system (CNS) [143]. Our group utilized
a controlled template synthesis of nanogels by polyion complexation and crosslinking of
doubly hydrophilic block ionomers, such as PEG-b-poly(methacrylic acid) (PEG-bPMA) [123, 144]. The resulting nanogels have swollen cores of a crosslinked PMA
network surrounded by a shell composed of PEG chains. This synthetic approach allows
versatile control of the macroscopic properties of nanogels (size, degree of swelling, drug
loading) by changing the number and the chemical structure of the crosslinks [144].
Notably, in contrast to many nanoparticles these anionic nanogels exhibited very low
nonspecific adhesion to nontargeted surfaces, which can minimize their off target effect
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and facilitate target-specific delivery [145]. Such core-shell nanogels can incorporate
very large amounts (up to 50% wt.) of weakly basic drug DOX through electrostatic
coupling with carboxylic groups in the cores. DOX-loaded nanogels were stable for a
prolonged period of time, exhibited noticeable pH-sensitive behavior with accelerated
release of DOX in acidic environment due to the protonation and swelling of the nanogel
crosslinked cores, and demonstrated cytotoxic activities in cancer cell lines [146].
Introduction of reversible crosslinks with disulfide bonds in the PMA ionic cores
(cystamine was used as a biodegradable crosslinker) allowed developing nanogels that
are degradable in the presence of the reducing agent (glutathione, cysteine), which in turn
facilitated the release of the incorporated DOX [146]. This difference in the release
kinetics led to considerable increase of cytotoxicity: degradable DOX-loaded nanogels
displayed nearly six-fold higher cytotoxic activity than non-degradable nanogels. Shi et
al. used PEG-poly(L-glutamic acid-co-L-cystine) copolymers to prepare nanogels
stabilized by disulfide bridges and also demonstrated that DOX release was accelerated in
intracellular reductive and acidic conditions [147]. DOX was loaded into these
polypeptide-based nanogels, and an accelerated release was observed in glutathione
monoester pretreated HeLa cells. Anionic PEG-b-PMA nanogels were further used to
encapsulate hydrophilic drug cisplatin through coordination interactions with COOH
functionalities [123]. Cisplatin-loaded nanogels displayed pH-sensitive release of Pt
species in sustained manner that can be effectively controlled by adjusting the degree of
crosslinking of the crosslinked cores. The released platinum species retained their activity
and were able to form Pt adducts with nuclear DNA in the cancer cells [123]. It was
shown that loading of cisplatin into the nanogels greatly improved drug therapeutic index
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by improving PK, enhancing tumor delivery, increasing antitumor efficacy, and
mitigating the cisplatin-mediated nephrotoxicity in a mouse model of ovarian cancer
[148]. When the same cispaltin-loaded nanogels were also decorated with targeting
ligands (e.g. folate or LHRH peptide), tumor growth inhibition could be even further
enhanced [149, 150]. Peng et al. described dual pH- and temperature-responsive nanogels
based on N-isopropylacrylamide, MAA, and PEG methylether methacrylate (NIPAAmMAA-PEGMA) for the entrapment and release of cisplatin. It was shown that cisplatin
release can be accelerated at acidic pH, and could be additionally controlled by the
temperature change due to the deswelling behavior of these nanogels at the body
temperature [151]. Small molecules usually contain only limited number of ionic groups,
which are able to interact with oppositely charged nanogels, and complementary
hydrophobic, hydrogen or coordination bonding between drug molecules and nanogels
can further stabilize the electrostatic pairing [139]. Recently, our laboratory demonstrated
that microenvironment formed by the hydrophobic domains in the nanogel ionic cores
influences solubilization capacity and release characteristics of the nanogels [152].
Diblock copolymer, PEG-b-poly(L-glutamic acid), hydrophobically-modified with Lphenylalanine methyl ester moieties was used for the synthesis of nanogels with small
size (ca. 70nm in diameter) and narrow particle size distribution. Stable DOX-loaded
hybrid nanogels were prepared at high DOX capacity (30% wt.). It was shown that the
release rates of DOX from hydrophobically-modified carriers were substantially less
compared to nonmodified nanogels: a burst release of over 85% of the incorporated drug
within 8h for nonmodified nanogels was observed while only ~20% of the incorporated
DOX was released from hydrophobically-modified nanogels during the same period of
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time. These results suggested that intermolecular interactions in combination with more
compact crosslinked core could account for the delayed and controlled release of DOX
from hydrophobically-modified polyelectrolyte nanogels. It was also found that these
DOX-loaded nanogels exhibited an improved antitumor efficacy compared to free DOX
in an ovarian tumor xenograft mouse model.
Nanogels have also been explored as a carrier for poorly water-soluble drugs. Wang
et al. introduced thermoresponsive nanogels based on chitosan–poly(NIPAAm-coacrylamide) for the delivery of paclitaxel (PTX) [153]. Loading capacity of these
nanogels for PTX was around 9% wt. and drug-nanogel formulation showed very good
colloidal stability. This nanogel released PTX in a temperature-dependent manner
wherein significantly faster drug release was achieved at higher temperature. Moreover,
PTX-loaded nanogels demonstrated improved antitumor efficacy in mice bearing HT-29
colon carcinoma tumors after intravenous administration. In another study by Gref and
coworkers, hydrophobic molecule benzophenone (widely used as sunscreen agent) was
solubilized into nanogels formed spontaneously upon the association of a lauryl-modified
dextran and a β-cyclodextrin polymer in aqueous media [154]. The highest benzophenone
loadings (about 2.5 % wt.) were obtained by solubilizing it in both polymer solutions
before mixing them to form nanogels. Such nanogel-based formulations present a
compelling future opportunity for the application in the cosmetic field as sun screen
carriers prepared by a simple “green” technology. The use of nanogels for the
development of long-lasting formulations of local anesthetics has recently been reviewed
by Tan et al [155]. Eckmann and colleagues explored biocompatible physically
crosslinked hybrid nanogels consisting of a partially denaturated lysozyme cores and
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dextran shells for the local delivery of dexamethasone to alleviate acute pulmonary
inflammation [156]. To target the pulmonary vasculature, nanogels were coated with
antibodies directed to endothelial determinant, Intercellular Adhesion Molecule-1
(ICAM). The synthesized ICAM- targeted nanogels were loaded with dexamethasone at
5% wt. In vivo studies in animal model of LPS-induced lung injury showed that nanogels
targeted to lungs succeeded in delivering encapsulated dexamethasone, as was indicated
by drastic reduction in pulmonary vasculature inflammation to levels found in naïve
mice. In other work, similar dextran-lysozyme nanogels were utilized as scaffolds for the
in situ synthesis of silver nanoparticles [157, 158]. Such hybrid nanogels exhibited
bactericidal properties towards E. coli and bacteriostatic properties towards S. aureus, and
their antibacterial activity can be tuned by varying lysozyme content. The tunability of
the hybrid nanogels makes it possible to optimize release of the bactericidal agent for
specific clinical use and type of infection. Nagasaki’s group used the protonated
crosslinked poly(2-[N,N-diethylamino]ethyl methacrylate) (PEAMA) cores of the
stimuli-responsive PEGylated nanogels for the synthesis of gold nanoparticles without
any reducing agents (“gold nanogels”) [159]. It was shown that the tertiary amino groups
in the PEAMA gel core play a crucial role in the reduction of the Au(III) ions
(nanoreactor) as well as the immobilization of the resulting gold nanoparticles
(nanomatrix) to attain large payloads of gold nanoparticles. The resulting gold-containing
nanogels showed a remarkable photothermal efficacy in response to laser-irradiation
resulting in selective cytotoxicity in cancer cells. In other studies, a potential of the
similar constructs to enhance cancer cell radiosensitivity was reported [160].
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1.5.4.3.1.1.

Nanogels for combination drug delivery

Drug combinations directed simultaneously at multiple pharmacological targets have
the potential to dramatically improve the response to treatment and are already a standard
clinical practice in the treatment of cancer and infectious diseases [161].

However, the

difference in pharmacokinetic and pharmacodynamic profiles among diverse drug
molecules makes dosing and scheduling optimization very challenging. Combining drugs
in one delivery carrier is a well-suited strategy for controlling the pharmacokinetics and
co-delivery of the desired drug ratio in vivo, and a variety of nanoscale carriers, including
nanogels, have been investigated in terms of their ability to deliver multiple drugs [162,
163]. As highlighted in previous sections, the nanogel structure can be readily adjusted to
integrate features of different materials and, thus, offer advantages for combinatorial
encapsulation of drugs with varying physicochemical properties such as small molecules,
proteins and nucleic acids. Fahmy and coworkers developed liposomal nanogels of drugcomplexed cyclodextrins and cytokine-encapsulating biodegradable polymers that can
deliver small hydrophobic molecular TGF-β inhibitor and water-soluble protein cytokine
(IL-2) in a sustained fashion to the tumor microenvironment [164]. They demonstrated
that synergistic effects of simultaneously delivered IL-2 and TGF-β inhibitor on
activation of the innate arm of the immune system led to delayed tumor growth and
enhanced survival of melanoma tumor-bearing mice after systemic administration.
Akiyoshi and colleagues evaluated nanogels based on acrylate group–modified CHP for
co-delivery of prostaglandin E2 receptor–specific agonist EP4A (small molecule) in
combination with bone morphogenic proteins (BMP-2) for bone regeneration [165]. In
this study, EP4A-containing nanogels and BMP-2-containing nanogels were crosslinked
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with thiol-bearing PEG to obtain disc-like scaffolds for the implantation into large bone
defects. Combination treatment with EP4A and low-dose BMP-2 efficiently activated
bone cells to regenerate calvarial bone by forming both outer and inner cortical plates as
well as bone marrow tissue and resulted in the formation of enough bone to cover the
defects in calvarial bone. In another study, cationic physically-crosslinked nanogels
composed of a hexadecyl group-bearing cycloamylose and spermine-modified
cycloamylose to complex and co-deliver plasmid DNA along with phospholipaseA2
(PLA2) [166]. As a lipolytic enzyme, PLA2 catalyzes hydrolysis of a variety of different
phospholipids. Thus, being delivered into endosomes by nanogel it could disrupt the lipid
membrane and subsequently trigger the release of the co-encapsulated DNA into the
cytoplasm. Transfection experiments confirmed that DNA expression level was enhanced
when complexed with PLA2. Similarly, pDNA and proteins were successfully coencapsulated using pH- and temperature-sensitive carbohydrate-based nanogels [167].
The nanogels had a core-shell structure with a crosslinked hydrophobic core that could be
loaded with proteins and the shell contained carbohydrate residues that allowed for the
complexation of DNA. These nanogels were capable of loading larger-than-normal
amounts of cargo by using a heating and cooling cycle. Altogether, these studies may
open new avenues for the development of the carrier-mediated combination therapies.
1.6.

Conclusion

Combination chemotherapy is preferred over treatment with single agents to combat
most cancers as it targets multiple cell-survival pathways at the same time and delays the
onset of resistance. This helps in achieving long-term tumor remission and increases
median survival. Cisplatin (CDDP)-based therapy has been the standard treatment for
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ovarian cancer since its discovery. After paclitaxel (PTX) was shown to be effective in
ovarian cancer, multiple clinical trials studied the overall efficacy of CDDP and PTX and
found significant benefit over the pre-existing treatments. Since then, this combination
has been the treatment of choice for both early stage as well as advanced cases of ovarian
cancer. However, administration of two different agents comes with the inconvenience of
repeated or extended duration of drug infusion in patients. Moreover, the most
extensively used conventional formulation of paclitaxel, Taxol®, utilizes Cremophor EL
(polyethoxylated castor oil) that has been linked to significant toxicities including
allergic, hypersensitivity and anaphylactic reactions during infusion that require
premedication and prolonged peripheral neuropathy. Combining such drugs in one
delivery carrier is therefore a well-suited and convenient strategy for controlling the
pharmacokinetics and co-delivery of the desired drug ratio in vivo, to maximize the
therapeutic potency and minimize drug-associated toxicities.
Cross-linked nanogels have been found to be promising drug carriers to achieve this
goal. Being mostly hydrophilic in nature, nanogels are highly biocompatible with a high
loading capacity for guest molecules. The nanogel structure can be readily adjusted to
integrate features of different materials and, thus, offer advantages for combinatorial
encapsulation of drugs with varying physicochemical properties. One of the widespread
synthetic techniques for the synthesis of nanogels is the crosslinking of preformed coreshell self-assemblies such as polymer micelles that allows introducing a high degree of
spatial organization into the nanogels. Cross-linking is known to impart control over the
swelling behavior of the nanogels and thus helps in achieving controlled release of the
incorporated cargo, which is an added advantage over the structural integrity imparted to
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the carrier system upon in vivo administration. The enhanced stability also makes the
prolonged circulation of the nanogels possible, which in turn allows for increased drug
accumulation at the target site by enhanced permeability and retention effect (EPR). We
report a design of multi-compartment cross-linked nanogels based on hybrid triblock
copolymers,

poly(ethylene

glycol)-block-poly(L-glutamic

acid)-block-poly(L-

phenylalanine) (PEG-b-PGlu-b-PPhe) for simultaneous loading and delivery of binary
CDDP and PTX combination. Such nanogels have 1) a hydrophobic core formed by PPhe
chains, which serves as a reservoir for PTX solubilization, 2) an anionic layer, which
incorporates CDDP through coordination with the carboxylic groups of PGlu, and 3) an
outer PEG shell stabilized, which stabilizes micelles in aqueous dispersion. The
crosslinks incorporated into PGlu block layer ensure that the PEG-b-PGlu-b-PPhe
micelles remain stable until they encounter proteases, which degrade the micelles by
cleaving the polypeptide chains of the block copolymers. This work demonstrates that
such biodegradable hybrid micelles carrying CDDP and PTX drug combination exert
superior antitumor efficacy in treatment of ovarian cancer in xenograft mouse tumor
model. However, our system relied solely on the EPR effect to facilitate the delivery of
the drug combination to the tumor site. Regardless of the importance and popularity of
EPR effect-based drug delivery, this strategy has some limitations related to the inter- and
intra-tumor heterogeneity, variations in the density as well as permeability of the tumor
vasculature that can affect the accumulation of nanocarriers. One of the popular
approaches to circumvent these problems is by surface-functionalization of the drug
carrier with ligands that can target receptors with differential expression on the cancer
cell surface, which helps in increasing the mean residence time of the delivery system at
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the tumor site and improving target cell uptake. One such receptor of interest is the folate
receptor (FR). Malignant cells, due to their high rate of cell division, have an increased
requirement of folic acid (FA), since it is essential component of cell metabolism and
DNA synthesis and repair. To fulfill this higher need of FA, FR is known to be overexpressed in a large number of malignant tissues, including ovarian cancer, compared to
normal tissues with the exception of the kidney and choroid plexus. Furthermore, this
receptor becomes accessible via the plasma compartment only after the cells lose their
polarity owing to malignant transformation which makes it a differential target for cancer
tissue that is easily accessible for intravenously administered FA conjugated systems. Its
natural ligand, FA, comes with the advantages of high binding affinity, stability and a
simple chemical structure together with ease of availability, making it a suitable targeting
ligand for ovarian cancer therapy. FA can thus be successfully conjugated to
macromolecular systems without loss of binding affinity to its receptor. Many different
agents targeting the folate pathway are currently in clinical development. To date, FAtargeted agents showed significant promise in phase II clinical trials but it has not been
confirmed in phase III studies. Accordingly, there is a need for further identification of
new therapeutic combinations and refinement of patient selection. To this end, FAconjugated imaging agents could be used for pre-selection of patients based on the
expression of FR and several methods have been already developed for this purpose.
Our group has previously demonstrated a tumor-specific delivery and improved anticancer effect in vivo of CDDP-loaded nanogels decorated with FA targeting groups. In
our further study, we designed FA-linked nanogels incorporating platinum-taxane
combination, and examined whether FR-targeted concurrent delivery of synergistic
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combination of CDDP and PTX can lead to enhanced therapeutic efficacy compared to
nontargeted NG system.
1.7.
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CHAPTER II

BIODEGRADABLE HYBRID NANOGELS FOR COMBINATION DRUG
THERAPY IN OVARIAN CANCER1
2.1 Introduction.
Ovarian cancer is the most lethal gynecologic malignancy in women, which causes
nearly 15,000 deaths in the United States every year. Its high death rate is a result of the
fact that most patients (>75%) are diagnosed at an advanced stage of disease at which
point the 5-year survival rate is less than 30% [1, 2]. The vast majority of ovarian cancers
are epithelial in origin and characterized by the rapid growth and spread of solid
intraperitoneal tumors and formation of large volumes of ascitic fluid. The standard
treatment for patients with advanced ovarian cancer is maximal surgical cytoreduction
followed by systemic platinum-based chemotherapy [2]. Cytotoxic action of platinum
compounds such as cisplatin (cis-dichlorodiamminoplatinum (II), CDDP) is mediated
through the formation of platinum-DNA adducts, which in turn inhibits DNA replication
and/or transcription and results in apoptosis and necrosis [3, 4]. Despite its success, use
of CDDP is greatly limited by severe dose limiting side effects, rapid elimination, and
development of acquired drug resistance. No new small molecule platinum drug have
gained international marketing approval since 1999 indicating a shift in focus in the last
decade away from drug design and towards drug delivery [5]. Among drug delivery
systems, those based on self-assembled block copolymer micelles have great potential for
delivery of anticancer drugs [6]. The advantages of polymer micelles include their small
1
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size, long circulation times, and ability to circumvent renal excretion and extravasate at
sites of enhanced vascular permeability. However, disintegration of the polymer micelles
is a major drawback for their application in drug delivery. In order to overcome this
limitation, we have proposed hydrophilic polyelectrolyte micelles with core composed of
a network of cross-linked polyanion chains and PEG shell that can encapsulate CDDP
with high capacity (up to 35 w/w%) [7, 8]. We have demonstrated significant
improvement of drug safety and drug delivery using such CDDP-loaded cross-linked
micelles. However, single drug therapy agents directed to individual targets frequently
show limited efficacies. Hence, multi-component therapies and multi-targeted drug
combinations are key to most cancer treatments [9]. Combination chemotherapy using
sequential administration of paclitaxel (PTX) with a platinum-based regimen is currently
the standard first-line therapy for ovarian cancer resulting in increased success rates in
eradicating tumors and/or longer remission periods [10]. These clinical benefits of the
combination therapy can be possibly maximized by controlled delivery of the desired
drug ratio to the in vivo target. Combining drugs in one delivery carrier is well-suited
strategy for controlling the pharmacokinetics and co-delivery of the desired drug ratio in
vivo. The drug loading and structure of such carriers can be tuned to control the drug
release rates, maximize the therapeutic potency and minimize drug-associated toxicities.
Nanoscale delivery carriers such as liposomes, nanoparticles, polymeric micelles have
been explored for co-delivery of anticancer drugs [11-13]. However, co-incorporation of
drug molecules with different physicochemical properties, such as hydrophilic CDDP and
hydrophobic PTX, has been challenging. As an attempt to address this challenge, we
report a design of multi-compartment cross-linked micelles, also known as nanogels
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(NG) based on hybrid triblock copolymers, poly(ethylene glycol)-block-poly(L-glutamic
acid)-block-poly(L-phenylalanine) (PEG-b-PGlu-b-PPhe) for simultaneous loading and
delivery of binary CDDP and PTX combination. Such NGs have 1) a hydrophobic core
formed by PPhe chains, which serves as a reservoir for PTX solubilization, 2) an anionic
layer, which incorporates CDDP through coordination with the carboxylic groups of
PGlu, and 3) an outer PEG shell stabilized, which stabilizes NGs in aqueous dispersion.
The crosslinks incorporated into PGlu block layer ensure that the PEG-b-PGlu-b-PPhe
NGs remain stable until they encounter proteases, which degrade the NGs by cleaving the
polypeptide chains of the block copolymers. This work demonstrates that such
biodegradable hybrid NGs carrying CDDP and PTX drug combination exert superior
antitumor efficacy in treatment of ovarian cancer in xenograft mouse tumor model.
2.2 Material and Methods
2.2.1 Materials
PEG-b-PGlu-b-PPhe block copolymers with different ratios of glutamic acid and
phenylalanine units (90:7 and 90:25) were synthesized as described below. α-Amino-ωmethoxy poly(ethylene glycol) (mPEG-NH2 , Mw = 5,000 g mol-1, Mw / Mn = 1.05) was
purchased from Creative PEGWorks Inc., (NC, USA). CDDP was purchased from Acros
Organics. L-glutamic acid γ-benzyl ester (BGlu), L-phenylalanine (Phe), 1,2ethylenediamine, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC),
paclitaxel, and other chemicals were purchased from Sigma-Aldrich (St Louis, MO) and
were used without further purification. Fetal bovine serum (FBS), RPMI 1640 medium,
penicillin, streptomycin, Trypsin–ethylenediaminetetraacetic acid (EDTA) (0.5% trypsin,
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5.3 mM EDTA tetra-sodium) and other chemicals were purchased from Invitrogen
(Carlsbad, CA, USA).
2.2.2 N-carboxyanhydrides (NCA) of BGlu and Phe
BGlu (0.020 mole) or Phe (0.026 mole) and anhydrous tetrahydrofuran (THF) were
added into a dried glass reactor to form a suspension. Triphosgen (0.023mole) was
separately dissolved in fresh anhydrous THF and injected drop wise into reaction
mixture. Nitrogen was bubbled through the mixture during synthesis. The mixture was
heated at about 40oC with constant stirring till mixture became transparent. The solution
was precipitated in n-hexane and then stored at -20oC overnight in order to allow
complete precipitation of γ-benzyl L-glutamate-N-carboxyanhydride (BGlu-NCA) or Lphenulalanine –N-carboxyanhydride (Phe-NCA). The white solids obtained were
collected and purified further by repeated precipitation with n-hexane. The resulting NCA
monomers were dried under vacuum for 24 h and characterized by the proton nuclear
magnetic resonance (1H-NMR).
2.2.3 PEG-b-PGlu-b-PPhe block copolymer
Monoaminomethoxypoly(ethylene glycol) (mPEG-NH2) (0.02 mmol) was dissolved
under stirring in 10 mL of anhydrous dimethylformamide (DMF) in nitrogen atmosphere
at 40oC. BGlu-NCA (2 mmol, the feed molar ratio of mPEG-NH2 to BGlu-NCA was 1:
100) dissolved in 5 mL of anhydrous DMF was added dropwise and the solution was
stirred for 24 hrs. The aliquot of the reaction mixture was precipitated using excess of
diethyl ether, dried under vacuum, and the composition of PEG-PBGlu diblock
copolymer was determined by 1H-NMR from the peak intensity ratios of the methylene
protons of PEG and the phenyl protons of the γ-benzyl groups (400 MHz in CDCl3: δ =
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3.5 (s, 4H, -OCH2CH2-), 5.0 (m, 2H, benzyl), 7.3 (m, 5H, aryl)). The calculated amount
of the monomer for the third block, Phe-NCA, dissolved in anhydrous DMF was then
injected dropwise and mixture was stirred under a N2 atmosphere at 40 °C for additional
24 hrs. The product (PEG-b-PBGlu-b-PPhe) was precipitated by diethyl ether, purified by
repeated precipitation in diethyl ether and dried in a vacuum. The benzyl groups of PEGb-PBGA-b-PPhe were removed in the presence of NaOH to obtain PEG-b-PGlu-b-PPhe.
Polymer sample was dissolved in 10 mL of THF followed by addition of 5 mL of 1N
NaOH. After stirring for 10 hrs at 40oC THF was removed at reduced pressure, the
residual solution was neutralized by 1M HCl and dialyzed using a dialysis membrane
(MWCO 3,500 Da) against distilled water for 24 hrs. After dialysis the product was
dried, washed 2-3 times with ethanol followed by lyophilization. By varying the feed
molar ratio of mPEG-NH2 to Phe-NCA (1:10 and 1:30), two copolymers with targeted
compositions PEG-b-PBGlu(100)-b-PPhe(10) and PEG-b-PBGlu(100)-b-PPhe(30) were
synthesized. The concentration of carboxylate groups in the copolymer samples was
estimated by potentiometric titration. Self-assembly behavior of PEG-b-PGlu-b-PPhe
copolymers was examined using pyrene as a hydrophobic fluorescence probe [14].
2.2.4 Pyrene assay and fluorescence spectroscopy
Self-assembly studies of PEG-PGlu90-PPhe25 and PEG-PGlu90-PPhe7 using pyrene as
fluorescent probe were performed using a spectrofluorometer system (Flourlog®,
HORIBA Jobin Yvon Inc., NJ, USA). Known amounts of pyrene in acetone were added
to empty vials, followed by acetone evaporation. Subsequently, the pyrene film was
incubated with varying concentrations (ranging from 3.9 to 2000mg/L) of polymer
overnight on shaker at room temperature. The pyrene concentration in the final solution
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was 6 x 10-7 M (MW 202.25). Fluorescence spectra were recorded on a microplate
reader (SpectraMax M5, MDS, CA) with samples in a 1.0 cm quartz cuvette. Emission
spectra were recorded for PEG-PGlu90-PPhe25 and PEG-PGlu90-PPhe7 solutions in
water (1mg/mL) from 250 to 350 nm using an excitation wavelength λex=265 nm.
2.2.5 Preparation of NGs
NGs were prepared by directly dissolving PEG-b-PGlu-b-PPhe copolymer in aqueous
media at a concentration of about 1 mg/mL. EDC in water (0.2 eq with respect to the
amount of carboxylate groups) was added dropwise to this solution and allowed to stir for
additional 10 min at r.t.. An aqueous solution of cross-linker, 1,2-ethylenediamine (0.1
eq) was then added to the dispersion of micellar aggregate to achieve 20% of crosslinking degree. This degree represents the maximum theoretical amount of cross-linking
that could take place, rather than the precise extent of amidation. The reaction mixture
was allowed to stir overnight at r.t. Byproducts of the cross-linking reaction were
removed by exhaustive dialysis of the reaction mixtures against distilled water.
2.2.6 Physicochemical methods of characterization and in vitro degradation of
NGs
The 1H NMR spectra for the monomers and copolymers were acquired in CDCl3 or
D2O at 25 °C using a Bruker 400 MHz spectrometer. Effective hydrodynamic diameters
(Deff) and ζ-potential of NGs were determined by dynamic light scattering (DLS) using a
Zetasizer Nano ZS (Malvern Instruments Ltd., Malvern, UK). All measurements were
performed in automatic mode at 25°C. Software provided by the manufacturer was used
to calculate the size, polydispersity indices (PDI), and ζ-potential of NGs. All
measurements were performed at least in triplicate to calculate mean values ± SD.

59

Morphology of the NGs was characterized by transmission electron microscopy (TEM)
and atomic force microscopy (AFM) as previously described [24]. NGs (ca. 1 mg/mL)
were incubated with cathepsin B from human liver (10 units/mL) in phosphate buffered
saline (PBS, pH 6.5, 0.14 M NaCl) at 370C for various time points (0, 12, 24 hrs) and
analyzed by size exclusion chromatography (SEC) using an

KTA PLC (Amersham

Biosciences) system and Sepharose CL-6B column (300 mm × 10 mm; flow rate 0.5
mL/min; mobile phase PBS, r.t.). Detection was performed at 280 nm.
2.2.7 Drug loading
A solution of PTX in ethanol (2 mg/mL) was added dropwise into the aqueous
dispersion of NGs (1 mg/mL) and the mixture was stirred at r.t. overnight in an open-air
system to allow slow evaporation of ethanol [15]. The residual ethanol was then removed
at reduced pressure. The precipitate of unbound PTX was removed by centrifugation. The
aqueous dispersion of PTX-loaded NGs were mixed with an aqueous solution of CDDP
(1 mg/mL) at pH 9.0 at 0.5 molar ratio of CDDP to carboxylate groups followed by
incubation at 37°C for 48 h. Unbound CDDP was removed by Ultracon filter units
(MWCO 10,000 Da, Millipore). Pt content in NGs (Pt194/Pt195) was assayed on Nexion
ion coupled plasma-mass spectrometer (NexION 300Q, PerkinElmer) calibrated with Pt
(2-100 ng/ml) and Holmium as the internal standard. Samples were diluted in 0.1 N HCl.
PTX levels were determined by high-performance liquid chromatography (HPLC)
analysis under isocratic conditions using an Agilent 1200 HPLC system a diode array
detector set at 227 nm. As stationary phase a Nucleosil C18 column was used (250 mm 
4.6 mm), a mobile phase of acetonitrile/water mixture (55/45, v/v) was applied at a flow
rate of 1 mL/min.
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2.2.8 Release studies
Drug release from the NGs was examined in PBS (pH 7.4), acetate buffered saline
(ABS, pH 5.5, 0.14 M NaCl), and ABS in presence of cathepsin B (10 units/mL) by
dialysis method using a membrane with 3,500 Da cutoff. The concentrations of PTX and
Pt(II) released were determined by HPLC and inductively coupled plasma mass
spectrometry (ICP-MS), respectively, and expressed as a percentage of the total PTX or
Pt(II) available vs. time.
2.2.9 Cell culture and cytotoxicity assay
A2780 human ovarian carcinoma cells were provided by Dr. P. Rogers (Institute of
Cancer Research, University of Bristol, UK). Cells were maintained in RPMI 1640
medium with 2 mM glutamine supplemented with 10% (v/v) FBS in the presence of
penicillin and streptomycin (100 U/ml and 0.1 mg/ml, respectively) at 37°C in a
humidified atmosphere containing 5% CO2. Cells were harvested with trypsin-EDTA
(Life Technologies) after 80% confluence. Cells seeded in 96-well plates (5,000
cells/well) 24 h prior the experiment were exposed to various doses (0-10 μg/mL on
CDDP or PTX basis) of CDDP alone, polymeric NGs alone, CDDP-loaded NGs, PTXloaded NGs and (CDDP+PTX)-loaded NGs for 72 h at 37 °C, followed by washing with
PBS, and maintaining in RPMI 1640 medium with 10% FBS for additional 24 h.
Cytotoxicity of drug-loaded NGs was assessed by a standard MTT assay [16] and the
IC50 values were calculated using GraphPad Prism software. Combination index (CI)
analysis based on Chou and Talaly method [17] was performed using CompuSyn
software for CDDP and PTX combinations, determining synergistic, additive, or
antagonistic cytotoxic effects against A2780 breast cancer cells. Values of CI < 1
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demonstrate synergism while CI = 1 and CI > 1 values represent additive and
antagonistic effects of drug combination, respectively.
2.2.10 Animal studies
Upon arrival, animals were placed in a facility accredited by the Association for
Assessment and Accreditation of Laboratory Animal Care. Food and reverse osmosis
water were available ad libitum throughout the study. Treatments were administered by
tail vein injection. Drug amount was calculated based on the average animal body weight.
The University of Nebraska Medical Center Institutional Animal Care and Use
Committee approved all animal protocols. A xenograft human ovarian carcinoma model
was used as previously described [8, 18]. Briefly, A2780 cells (5 x 106 cells/site) were
subcutaneously transplanted into the flanks, one above each hind limb, of four-week-old
female athymic (Ncr-nu/nu) mice (National Cancer Institute). When the tumors reached a
size of about 200-400 mm3 (12-15 days after transplantation) animals were randomized
(5 treatment groups, n = 8) and treated with free CDDP or CDDP/NGs or PTX/NGs or
(CDDP+PTX)/NGs at an equivalent dose of 4 mg/kg CDDP, or 1mg/kg PTX or (4 mg/kg
CDDP+1 mg/kg PTX) or 5% dextrose solution. Treatments were administered via tail
vein injections at 4-day intervals. Animal body weight and tumor volume were monitored
every second day. Tumor volume (V = 0.5 x L x W2) was estimated by measuring two
orthogonal diameters (longer dimension: L, and smaller dimension: W) of the tumor
using electronic calipers. Animals were sacrificed when tumor volume exceeded 3000
mm3, greatest tumor dimension exceeded 20 mm, tumor became necrotic, or animal
exhibited a body weight loss of more than 20%. Euthanasia was performed by CO 2
asphyxiation. All other animals were sacrificed by day 45.
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2.2.11 Apoptosis and proliferation
Tumors from mice that received different treatments were excised at day 14 (2-3 mice
per group). The tumors were dissected and fixed in 10% neutral buffered formalin. Then,
the tissues were processed routinely into paraffin, sectioned at a thickness of 4 μm.
Proliferating and apoptotic cells were detected using an antibody against Ki-67 and
caspase-3, respectively. Visualization was done by incubation with DAB+ (brown, for
Ki-67) and Permanent red (for caspase-3) (DAKO) for 2 min. After being rinsed with
distilled water, the sections were counterstained with hematoxylin. For quantification of
Ki-67 and caspase-3 expression, the area of positive cells was determined (Image J) in 5
random high power fields (20X magnification) and divided by the total area of cells for
each field of slice.
2.2.12 Sample preparation and drug content measurement in tissue.
Known weights of thawed tissue, collected from the animals sacrificed at different
days during treatment, were decomposed by wet-ashing in screw-capped vials with six
volumes of concentrated nitric acid, overnight heating, and stirring at 65°C. An iridium
internal standard was added prior to digestion. Total platinum concentrations were
determined by ICP-MS using iridium correction. Calibration range for the assay was
platinum 2–100 ng/mL with extrapolation to platinum 1000 ng/mL. Necessary dilutions
were made when the platinum concentration exceeded the calibration range. Assay
sensitivity was 0.8 ng of Pt/mL, with inter- and intraday assay variability not exceeding
5%. For PTX measurements, tissue sample (200 mg) was spiked with 50 uL diazepam
(internal standard, I.S.) to achieve a final concentration about 25 ug/mL, then 2mL of
tert-butyl methyl ether (TBME) was added and tissue was homogenized. Homogenized

63

samples were centrifuged at 3000g for 10 min, 1mL of supernatant TBME layer was
collected and dried under air. Residue was reconstituted using 1mL of mobile phase and
20uL of it was injected into HPLC system. Samples of PTX was prepared by directly
dissolving PTX and I.S. in mobile phase and measured in HPLC system to calculate
recovery rate.
2.2.13 Blood chemistry and histopathology
Blood from the sacrificed animals was collected in EDTA tubes and analyzed for
blood cell count and liver enzymes using Vetscan VS (Abaxis). Fixed tissues were
processed, sectioned, inserted into tissue cassettes, dehydrated in 70% ethanol overnight,
and paraffin embedded (UNMC Tissue Sciences
sections

were

stained

with

either

acility, Omaha, NE). Serial 5 μm

hematoxylin

and

eosin

(H&E)

or

by

immunohistochemistry (IHC). For histopathological diagnosis, H&E-stained slides were
examined by light microscopy and photomicrographs were taken using a Nikon camera
mounted on a Nikon Eclipse 600 microscope (both Nikon Instruments, Melville, NY)
with Adobe Elements 3.0 software (Adobe Systems, San Jose, CA). For IHC detection of
NGs in tissues, rabbit monoclonal antibody to PEG (anti-PEG methoxy group; Epitomics,
Burlingame, CA) was used. Goat anti-rabbit secondary antibody conjugated with
fluorescence label AF 488 was used for the detection followed by counterstaining with
Mayer’s hematoxylin. Stained slides were visualized using confocal imaging (Carl Zeiss
LSM 510).
2.2.14 Statistical analysis
Statistical comparisons except animal studies were carried out using Student t-test.
For the antitumor study and toxicity studies, group means for tumor volume and body
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weights were evaluated using repeated measures analysis of variance with the Bonferroni
post test. Survival was estimated using Kaplan–Meier analysis and compared using logrank test. P values less than 0.05 were considered significant. Analysis of variance with
Bonferroni test and Kaplan–Meier analysis with log-rank test were performed using
GraphPad Prism 5 (GraphPad Software, Inc.).
2.3 Results and Discussion
2.3.1 Synthesis and characterization of PEG-b-PGlu-b-PPhe
The synthesis of the amphiphilic hybrid polypeptide-based triblock copolymers PEGb-PGlu-b-PPhe is illustrated in Scheme 2.1.

Figure 2.1. Scheme for the synthesis of PEG-b-PGlu-b-PPhe polymer via ring-opening
NCA-based polymerization.
The copolymers were synthesized via sequential ring-opening polymerization of BGluNCA and Phe-NCA monomers using amino-terminated PEG (Mw = 5,000 g mol-1) as
macroinitiator in three stages. At first, PEG-b-PBGlu diblock copolymer was prepared.
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The length of PBGlu block was set constant by using feed molar ratio of mPEG-NH2 to
BGlu-NCA at 1 : 100. The second step was polymerization of Phe-NCA initiated by
PEG-b-PBGlu copolymer. The length of PPhe block was varied by adjusting the feed
molar ratio of NCA monomers, BGlu-NCA : Phe-NCA (10:1 and 10:3). At the final step,
the deprotection of the glutamate residues was carried out by alkali hydrolysis to obtain
PEG-b-PGlu-b-PPhe. The chemical composition of two resulting triblock copolymers
was determined by 1H-NMR analysis (Fig. 2.2) and further confirmed by Fourier
transform infrared spectroscopy (FTIR) (data not shown).
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Figure 2.2. 1H NMR spectra for A) BGlu-NCA, B) Phe-NCA, C) PEG-PBGlu and D)
PEG-PBGlu-PPhe
Notes: peak assignments are as follows:
A) BGlu-NCA. 1H-NMR (CDCl3): δ ppm= 2.22 (2H, m, -CH2-), 2.60 (2H, t, -CH2-),
4.37 (1H, m, -CH-), 5.15 (2H, s, -CH2-), 7.33 (5H, m, C6H5), 9.10 (1H, s, -NH-),
B) Phe-NCA. 1H-NMR (CDCl3): δ ppm= 3.01 (2H, s, -CH2-), 4.90 (1H, m, -CH2-); 7.20
(5H, m, C6H5), 9.10 (1H, s, -NH-).
C) PEG-PBGlu 1H-NMR (DMSO-d6): δ ppm= 1.95 (2H, broad s, -CH2-) 2.25 (2H, broad
s, -CH2), 3.45 (4H, s, CH2CH2-), 5.06 (2H, m, -CH2-); 7.24 (5H, m, C6H5).
D) PEG-PBGlu-PPhe 1H-NMR (DMSO-d6): δ ppm = 1.95 (2H, broad s, -CH2-) 2.25 (2H,
broad s, -CH2-), 3.05 (2H, broad s, -CH2-), 3.45 (4H, s, CH2CH2-), 3.95 (1H, broad s, CH-), 5.06 (2H, m, -CH2-); 7.24 (10H, m, C6H5).

The polymerization degrees of PGlu and PPhe blocks are summarized in Table 2.1.
Table 2.1. Characteristics of the PEG-PGlu-PPhe triblock copolymer.
Polymer

Feed molar ratio (mmol)

PEG-PGlu92-PPhe7

PEG BGlu-NCA Phe-NCA
0.02
2
0.2

PEG-PGlu90-PPhe25

0.02

2

0.6

Repeating units ratio*
PEG
114
114

PGlu
92
90

Mw*
(g/mol)

Phe
7

19,700

25

22,400

1

*Calculated from H-NMR spectra.
Notably, PEG-b-PGlu-b-PPhe maintained the same degree of polymerization after
complete removal of the benzyl protecting groups. These copolymers had a constant PEG
block (114 repeating units), practically identical length of anionic PGlu block (about 90
repeating units), and differed in the length of PPhe blocks (7 and 25 repeating units).
They are further denoted as PEG-PGlu90-PPhe7 and PEG-PGlu90-PPhe25, respectively.
2.3.2 Synthesis and characterization of NGs
We anticipated that incorporation of hydrophobic PPhe block into triblock copolymer
confers amphiphilic properties and facilitate the formation of micellar aggregates in
aqueous medium. Indeed, formation of small (intensity-average diameter of
approximately 90 nm) particles with relatively narrow particle size distribution (PDI =
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0.16) and net negative charge (ξ-potential = -22 mV) was detected in aqueous solutions
of PEG-PGlu90-PPhe25 copolymer. In contrast, formation of large aggregates with a broad
size distribution was observed only in relatively concentrated PEG-PGlu90-PPhe7
solutions. Differences in association behavior of PEG-PGlu-PPhe block copolymers were
further confirmed by a fluorescence measurements using pyrene as a probe (Fig. 2.3).

Figure 2.3. Plot of fluorescence intensity I1 (from pyrene emission spectra) as a function
of PEG-PGlu90-PPhe25 (●) and PEG-PGlu90-PPhe7 (■) concentration.
Using this approach, we determined that the critical micelle concentration (cmc) for
PEG-PGlu90-PPhe25 was low (62.5 mg/L). In contrast the onset of aggregation of PEGPGlu90-PPhe7 chains was detected at concentrations higher than 1000 mg/L. These data
indicate that increase in the length of the hydrophobic PPhe block from 7 to 25 units is
accompanied by an order of magnitude decrease in the cmc value. A similar trend in the
dependency of cmc on the length of core-forming block was observed earlier for other
amphiphilic block copolymers [19]. In dilute solution, hydrophobic and π-π stacking
interactions of the phenylalanine residues play a major role in driving self-assembly of
Phe-based peptides like amyloid β peptide [20] or synthetic polypeptides [21]. A red shift
of the emission peak from the normal phenylalanine fluorescence maximum (around 280
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nm) has been previously observed upon assembly in amyloid system [20]. In the present
case, the fluorescence spectra obtained from 0.01% solutions of PEG-PGlu-PPhe
copolymers displayed a peak at 320 nm that is attributable to π-π stacking interactions of
phenyl units; though the intensity of the fluorescence was lower for PEG-PGlu90-PPhe7
copolymer (Fig. 2.4).

Figure 2.4. Emission spectra of A) PEG-PGlu90-PPhe25 (●) and B) PEG-PGlu90-PPhe7
(■) in water (1mg/mL, λex=265 nm).
Notably, the fluorescence spectrum for PEG-PGlu90-PPhe7 was recorded below the cmc.
It is possible that some loose pre-micelle aggregates of copolymer chains with short PPhe
blocks might exist below experimentally determined cmc and the observed fluorescence
characteristics may reflect the local association of aromatic units in such pre-aggregates.
Interestingly, it was previously reported that peptide-PEG amphiphiles containing the
hydrophobic sequence of four Phe residues conjugated to PEG of molar mass 5,000 g
mol-1 (PEG-PPhe4 using our nomenclature) exhibit self-assembly behavior despite its
relatively short peptide sequence with cmc value of 950 mg/L in water. It seems that
insertion of ionic PGlu block into PEG-b-PGlu-b-PPhe triblock copolymer provides for
additional negative contribution to micellization and increasing cmc. This may be
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explained, on the one hand, by stabilization of the single polymer chains in solution, and,
on the other hand, by destabilization of multimolecular NGs due to the strong
electrostatic repulsion of PGlu chains in the micelle corona. Overall, the optimal
hydrophilic-lipophilic balance (HLB) in terms of numbers of Phe groups with respect to
PEG and PGlu chains is essential for the formation of multilayer NGs with well-defined
and distinct domains: hydrophobic PPhe core, the intermediate ionic PGlu layer, and
hydrophilic nonionic PEG outer shell.
The PEG-PGlu90-PPhe25 micelles were further utilized as ‘‘core–shell’’ templates for
synthesis of NGs. The cross-linking was achieved via condensation reactions between the
carboxylic groups of PGlu chains in intermediate layer and the amine groups of
ethylenediamine in the presence of a water-soluble carbodiimide, EDC. The targeted
extent of cross-linking (20%) was controlled by the molar ratio of cross-linker to
carboxylic acid groups of the Glu residues. The NGs displayed an effective diameter of
about 90 nm (ξ-potential = - 20 mV) and were uniform (monomodal, narrow size
distribution) as determined by DLS. It is important to note that NGs had comparable sizes
with the precursor PEG-PGlu90-PPhe25 micelles (90 ± 1.2 nm) indicating that the micelles
retained their integrity and formation of cross-links was limited to intramicellar reactions.
It is likely that the outer PEG shell of the micelles prevented the undesirable intermicellar
reactions. The dimensions and morphology of NGs were further characterized by TEM
and tapping-mode AFM in air. Based on AFM and TEM images PEG-PGlu90-PPhe25
NGs had a spherical morphology. As expected the number-average particle height (Hav)
and diameter (Dav) values of dehydrated NGs were reduced compared to the
hydrodynamic diameters Deff determined by DLS (Table 2.2). Upon adsorption on mica
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surface NGs exhibited a high diameter versus height aspect ratios (D av/Hav) suggesting
substantial flattering of the particles. This observation was in agreement with the
expected flexible character of the PEG-PGlu shell of the NGs. The electrostatic
interactions of the negatively charged NGs with the positively charged amino-modified
mica surface may induce additional flattering of NGs.
Table 2.2. Summary of characterization data for NGs by TEM, AFM, and DLS.
Sample

TEMa

AFMb

Dav, nm Dav, nm
NG

DLSc

Hav, nm

Deff, nm

45 ± 3.3 47 ± 6.8 8.7 ± 3.7

90 ±1.2

a

Number-average diameter (Dav), n = 27. A drop of the sample solution was allowed to
settle on a Formvar precoated copper grid and the sample was allowed to air-dry.
b
Number-average height (Hav) and diameter (Dav), n = 55. NGs were deposited from
aqueous solutions at pH 6.5 onto APS mica surface and allowed to dry in vacuum.
c
Intensity-average hydrodynamic diameter( Deff) for DLS was determined at pH 7.4, n=
5.
Data are expressed as mean ± SD.
Interestingly, the hybrid PEG-PGlu90-PPhe25 NGs were characterized by a significantly
lower aspect ratio (ca. 6) compared to PEG-poly(methacrylic acid) (PEG-PMA) NGs
containing entirely hydrophilic cross-linked PMA cores [22]. For example, PEG-PMA133
and PEG-PMA75 NGs were characterized by dimension aspect ratios of 13.3 and 15.0,
respectively. The observed topological differences can be explained by the presence of
relatively rigid hydrophobic PPhe cores in the PEG-PGlu90-PPhe25 NGs that rendered
them more stiff and deceased their deformation at the substrate surface.
The pH-induced dimensional changes (nanogel-like behavior) of the NGs were
evident from an increase in the micelle size and net negative charge (Fig. 2.5A).
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A

B

Figure 2.5. Swelling behavior (A) and stability (B) of NGs. (A) The effective diameter,
Deff (●) and ζ-potential (■) of NGs as a function of pH. (B) Changes in Deff of NGs (●)
and non-crosslinked NGs (■) upon treatment with different concentrations of 8M urea.

Such behavior was indicative of ionization and swelling of the intermediate layer formed
by the cross-linked PGlu chains in the shell of the NGs. The kinetic stability of NGs was
further analyzed in the presence of urea (Fig. 2.5B). Urea, a small hydrophilic molecule,
is widely used as protein denaturant due to its ability to form stronger attractive
dispersion interactions with the protein side chains and backbone than does water.
Therefore, it was expected that urea is able to destabilize PEG-PGlu90-PPhe25 NGs by
weakening the hydrophobic interactions in PPhe core region as well as by disrupting
hydrogen-bonding interactions between polypeptide chains. Indeed, for non-cross-linked
NGs addition of 8 M urea led to significant increase in the size and PDI of the aggregates.
In the meantime, only little changes in the average size of NGs were detected in the
presence of urea (Fig. 2.4B). The observed limited swelling of PEG-PGlu90-PPhe25 NGs
can be thus directly related to a restricted mobility of the PGlu chains in the shell and
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provides additional evidence that the physical stability of NGs can be greatly enhanced
via covalent crosslinking. Importantly, the cross-linking did not prevent the degradation
of NGs by proteolytic enzymes. The enzymatic biodegradability of PEG-PGlu90-PPhe25
NGs was determined by incubating the NGs with cathepsin B followed by analysis of the
reaction mixture using size exclusion chromatography (SEC) (Fig. 2.6).

Normalized
uv absorbance

0.15

0.10

0.05

0.00
0

10

20

30

Volume, mL
Figure 2.6. Degradation of NGs upon treatment with cathepsin B at 37 0C wherein
aliquots were removed at 0 h (●), 12 h (■) and 24 h (▲) followed by its analysis using
FPLC.

A gradual decrease in the UV absorption of the micelle peak was observed in SEC
chromatograms over the incubation time, which almost disappeared after 24 hrs.
Furthermore, decrease in light scattering intensity along with the drastic increase of PDI
was detected by DLS of the NGs dispersions already after 12 hrs of incubation with
cathepsin B suggesting structural disintegration of such NGs (Table 2.3).
Table 2.3. Physicochemical characteristics of NGs after incubation with cathepsin B (10
units/mL).
Time (h)
0

NGs + cathepsin Ba
Deff, nm
PDI
125±1.5
0.223
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12

181±2.2

0.424

24
738±9.0
0.619
Effective diameter (Deff) and polydispersity index (PDI) were determined
in water (pH 6.1). Data are expressed as mean ± SD (n=3).
a

However, further studies will be necessary to characterize the degradation products and
determine whether drug incorporation can alter the degradation pattern of the NGs.
Overall, these results imply that the reinforcing cross-links within the shell of PEGPGlu90-PPhe25 NGs can permanently suppress their dissociation. Resulting NGs can
withstand environmental challenges and sink conditions encountered after systemic
administration and, consequently, provide means for temporal control over drug
disposition. On the other hand, enzymatic degradation of the polypeptide-based building
blocks of NGs reduces the risk of polymer accumulation inside cells and can also
facilitate specific intracellular drug release.
2.3.3 Drug loading and release from NGs.
PEG-PGlu90-PPhe25 NGs have a well-defined structure with a central hydrophobic
core formed by PPhe chains, swollen intermediate layer of a cross-linked PGlu network
and external PEG shell surrounding the core and intermediate layer. Each of these three
nanodomains contributes to the utility of NGs as drug nanocarriers. A PPhe core can
serve as a cargo for water-insoluble drugs. An ionic intermediate layer can incorporate
hydrophilic drug molecules through electrostatic or covalent bonding while PEG shell in
addition to stabilizing NGs in dispersion also allows minimizing interactions of the NGs
with blood components. Therefore, such NGs would provide unique opportunity to
simultaneously incorporate and deliver multiple chemotherapeutic drugs with very
different physical properties and modes of action inside a single polymeric carrier in
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order to achieve a synergistic effect and enhance the efficacy of treatment. In the present
study NGs with binary drug combination of hydrophilic CDDP and hydrophobic PTX
were prepared. At first, PTX was solubilized into the PPhe cores of the NGs using
micelle extraction method. According to this method, PTX dissolved in ethanol was
added to the aqueous dispersion of NGs upon agitation followed by evaporation of
organic solvent and removal of unbound PTX. Under these conditions PTX loading
capacity (the net amount of drug loaded into a carrier) was about 9 w/w% weight as was
quantified by HPLC. The size and ζ-potential of the PTX-loaded NGs were comparable
to those of empty NGs indicating that the PTX incorporation into PPhe cores did not
affect the macroscopic characteristics of the pre-formed NGs. As the next step, CDDP
was incubated with the aqueous dispersions of PTX-loaded NGs for 48 h at pH 9.0 [7].
Such conditions were chosen to maximize the swelling of PGlu cross-linked layer (Fig.
2.4A) and increase the accessibility of the bulk of the carboxylate groups to CDDP. As
expected, the net negative charge and particle size of NGs decreased upon CDDP loading
consistent with neutralization and condensation of PGlu segments by CDDP (Table 2.4).
Table 2.4. Physicochemical characteristics of NGs before and after drug loading.
Sample
NGs

0.14

-20.0 ± 1.2

-

105 ± 2.8 0.23

-19.1 ± 1.5

8.4

CDDP/NG

71 ± 3.3

0.19

-3.7 ± 1.0

22.4

(CDDP+PTX)/NG

76 ± 4.0

0.24

-5.7 ± 0.47

24.8c

PTX/NG

a

Deff (nm) PDI ζ-potential (mV) LC (w/w%)b
90 ± 1.2

Effective diameter (Deff), polydispersity index (PDI) and ζ-potential were determined in
water (pH 6.5).
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b

Pt and PTX content were deternined by ICP-MS and HPLC, respectively. Loading
capacity (LC) is expressed as mass of incorporated drug per mass of drug loaded NGs
(w/w).
C
Total LC for combination of CDDP (15.4%) and PTX (9.4%).
Data are expressed as mean ± SD (n = 3).

15 w/w% loading was achieved with respect to CDDP while total loading values for
binary drug combination was about 25% and corresponded to 10 : 1 molar ratio (CDDP :
PTX) of drugs in the NGs. (CDDP+PTX)/NG maintained their spherical morphology as
was confirmed by TEM (Fig. 2.7).

Figure 2.7. TEM image of (CDDP+PTX)/NG. Bar equals 100nm
Notably, (CDDP+PTX)-loaded NGs were stable in aqueous dispersions, exhibiting no
aggregation or precipitation with loading capacity preserved for as long as month (Table
2.5).
Table 2.5. Physicochemical characteristics of empty and drug-loaded NGs after one
month of storage in aqueous dispersion at 4oC.
Sample
Deff (nm) PDI ζ-potential (mV) LC (w/w%)b
NG
95 ± 0.8 0.16
-24.6 ± 3.2
(CDDP+PTX)/NG 77 ± 0.5 0.26
-7.7 ± 1.8
21.2C
a

Effective diameter (Deff), polydispersity index (PDI) and ζ-potential were determined in
water (pH 6.5).
b
Pt and PTX content were deternined by ICP-MS and HPLC, respectively.
C
Total LC for combination of CDDP (13.8%) and PTX (7.4%).

Interestingly, the loading capacity of NGs with respect to CDDP was decreased after
loading of PTX as compared to single CDDP/NG formulation (15% vs. 23%). This
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apparent difference in drug loading is not yet understood and needs to be investigated
further. We hypothesize that the presence of hydrophobic solute in the core of the micelle
affects the conformation of the polypeptide chains at the PPhe core - PGlu shell interface.
Specifically, in more hydrophobic environment PGlu chains can transition from random
coil to α-helical conformation leading to structural condensation in this region which may
restrict space for the loading CDDP molecules. Validation of this hypothesis is of
considerable interest and is ongoing in our laboratory.
The release of the drugs from NGs was studied by equilibrium dialysis at 37 °C at
either pH 7.4 (PBS) or pH 5.5 (ABS), which reflect conditions encountered in plasma and
in intracellular compartments (lysosomes), respectively. The kinetic profiles of drug
release from (CDDP+PTX)/NGs are presented in Fig. 2.8. As seen from these data
sustained but temporally distinct release of Pt(II) species and PTX was observed.
Notably, PTX release was much faster than that of Pt(II), which is expected since PTX is
physically entrapped into the PPhe core. In contrast, CDDP binds with PGlu chains
through electrostatic and coordination interactions and its release usually proceeds via
ligand exchange reactions with chloride or other biologically abundant anions, thus
delaying its liberation from the NGs. Pt(II) release from the NGs was also a pHdependent process. Indeed, Pt(II) species were liberated from the NGs faster at pH 5.5
than at pH 7.4 (Fig. 2.8B), probably, due to protonation of carboxylic groups of PGlu,
which weakens the drug and micelle electrostatic coupling. For example, during 24 hrs
(CDDP+PTX)/NGs released 16.7 ± 5.5% of loaded Pt(II) at pH 5.5 and only 8.8 ± 3.6%
at pH 7.4, respectively.
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Figure 2.8. In vitro drug release profiles for Pt (●) and PTX (■) from NGs in (A) PBS,
pH 7.4; (B) ABS, pH 5.5; and (C) ABS in presence of cathepsin B (10 units/mL) at 37 oC.
Data are expressed as mean ± SD (n=3).

Notably, pH changes practically did not affect the release of PTX. Also, noteworthy that
Pt (II) release from (CDDP+PTX)/NG at the acidic pH was further accelerated in
presence of cathepsin B in the media (Fig. 2.8C). Cathepsin B is a lysosomal thioldependent protease [23] and is also extracellularly present in pathological tissues such as
tumors and sites of inflammation [24, 25]. These results indicate that degradation of NGs
can further facilitate the drug release once located within targeted tissue and cells.
2.3.4 In vitro cytotoxicity of the drug-loaded NGs
The cytotoxicity of drug combination loaded into NGs was determined in human
ovarian carcinoma A2780 cells using MTT assay. Calculated IC50 values are summarized
in Table 2.6.
Table 2.6. Comparison of IC50 values for various drug-loaded NGs and free CDDP
against A2780 cells as determined by the MTT assay.
IC50 (µM)
Free CDDP
1.5
CDDP/NG
3.9
PTX/NG
0.17
(CDDP+PTX)/NG
0.14*
CDDP/NG + PTX/NG
6.3*
*Calculated with respect to CDDP.
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Importantly, NGs alone were nontoxic to the cells up to the concentration of 5 mg/mL.
CDDP/NG displayed lower cytotoxic activity than free CDDP. Since unloaded NGs did
not affect the cell survival in the entire range of concentrations the cytotoxic activity of
CDDP/NG was mediated by the Pt(II) species slowly released from the NGs. However,
we found that (CDDP+PTX)/NG were significantly more effective in killing A2780
ovarian cancer cells than CDDP/NG. The dose of CDDP in NGs was indeed reduced
nearly by 30-fold when used in combination with PTX (at 10 : 1 CDDP/PTX molar ratio)
to achieve the same cytotoxic effect produced by the CDDP loaded NGs. The CI value at
IC50 for this (CDDP+PTX)/NG combination was 0.078, indicating strong synergistic
cytotoxicity against A2780 ovarian cancer cells. Notably, the combination of two
separate micellar formulations (CDDP/NG +PTX/NG) applied at the same drug ratio
elicited cytotoxicity comparable to that of the CDDP/NG formulation (Table 4) and
displayed antagonistic CI value of 1.2 at IC50. These data suggest that synchronized
delivery of this drug combination in the same cl-micelle formulation may play an
essential role in the cytotoxic activity.
2.3.5 Antitumor activity
Motivated by the enhanced in vitro efficacy of (CDDP+PTX)/NG formulation, we
evaluated its antitumor efficacy in vivo in mice bearing A2780 human ovarian cancer
xenografts. Free CDDP and CDDP/NG were injected 4 times at 4-day intervals at an
equivalent dose of 4 mg-CDDP/kg determined as the maximum tolerated dose upon this
treatment schedule [18]. Animals injected with (CDDP+PTX)/NG received 4mg/kg
CDDP and 1 mg/kg PTX equivalents per dose. The changes in the relative tumor volume,
body weight and animal lifespan are shown in Fig. 2.9.
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Figure 2.9. In vivo antitumor efficacy of (CDDP+PTX)/NG in A2780 human ovarian
cancer xenograft-bearing female nude mice. Relative changes in (A) tumor volume and
(B) body weight were measured following intravenous administration of
(CDDP+PTX)/NG (●) or CDDP/NG (■) or PTX/NG (▲) or free CDDP (▼) or 5%
dextrose (♦). Drug formulations were injected in100 μL at a dose of 4 mg CDDP or 1mg
PTX equivalents/kg body weight 4 times at 4-day intervals as indicated by the arrows.
Values indicated are means ± SEM (n = 8). (C) Kaplan–Meier analysis of overall
survival in (CDDP+PTX)/NG group (1) or CDDP/cl-micelles group (2) or PTX/NG
group (4) or free CDDP group (3) or control group (5). Tumor volume and body weight
are normalized with respect to tumor volume or body weight at day 0. * P<0.05.
Tumor burden was significantly decreased by both free CDDP (P<0.05) and CDDP/NG
(P<0.05) treatments compared to control (Fig. 2.9A). However, tumors in the animals
treated with CDDP/NG remained relatively smaller than in animals treated with free
CDDP between days 0 and 18. As a result, increased survival of the animals was
observed in mice treated with CDDP/NG compared to CDDP alone (Fig. 2.9C). Notably,
treatment with PTX-loaded NG did not have any substantial effect on the tumor growth
and only minor increase in survival was observed over controls. In contrast, nearly
complete inhibition of tumor growth was observed for the mice treated with
(CDDP+PTX)/NG from day 0 to 14, which translated into significantly increased overall
survival of the animals treated with (CDDP+PTX)/NG compared to either CDDP/NG
(P<0.05) or CDDP alone (P<0.05) (Fig. 2.9A and C). On the second day post treatment
animals injected with either (CDDP+PTX)/NG or CDDP/NG displayed significantly
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higher levels of Pt in tumors compared to free CDDP treatment group (P<0.05) which
may be attributed to the enhanced permeability and retention (EPR) effect (Fig. 2.10A)
[26].
A

B

Figure 2.10. Tissue distribution of platinum in different treatment groups as determined
ICP- MS. (A) Mice were sacrificed at day 14 of the treatment with (CDDP+PTX)/NG or
CDDP/NG or free CDDP. (B) Significant reduction in the Pt levels in various organs of
mice treated with (CDDP+PTX)/NG was confirmed by comparing Pt levels at day 14 and
day 45. Values indicated are means ± SEM (n = 3), * P<0.05.
To elucidate the mechanism underlying the enhanced antitumor activity of
(CDDP+PTX)/NG, the tumors were excised post-treatment (on 2nd day after last
injection) and processed for Ki-67-Caspase-3 assay to examine the effect of each
treatment on induction of apoptosis (Fig. 2.11).
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Figure 2.11. Ki-67-caspase-3 apoptosis assay. Quantification of caspase-3 positive cells
in tumor tissue from mice from various groups. Data are presented as mean ± SD (n = 5
random microscopic fields for each tumor slice).
The number of caspase-3 positive cells were significantly higher in tumors from mice
that received (CDDP+PTX)/NG compared to tumors in CDDP/NG (P<0.05) or PTX/NG
(P<0.05) or free CDDP (P<0.05) (Fig. 2.11). This assay further corroborates the superior
antitumor efficacy of binary drug combination NG formulation over single drug-loaded
NGs or CDDP alone. Since the levels of Pt accumulation in tumors were comparable for
the treatments with both single and binary drug formulations, we rationalize that an
increase in therapeutic efficacy of (CDDP+PTX)/NG can be related to highly synergistic
interactions between CDDP and PTX simultaneously delivered to the tumors. Indeed, the
average weight ratio of the CDDP and PTX in the tumors of the animals treated with
(CDDP+PTX)/NG was determined to be 4 : 1, the same as the drug loading ratio in NG,
indicating the spatial-temporal synchronization of drug exposure. CDDP and PTX are
highly suited for combination chemotherapy because they have distinct mechanisms of
action. CDDP binds to DNA base pairs creating adducts, cross-links, and strand breaks
that inhibit DNA replication. Unrepairable DNA damage often results in activation of the
apoptotic pathway. Paclitaxel acts by binding to intracellular β-tubulin, which leads to
microtubule stabilization, G2–M arrest and apoptosis [27]. CDDP is thought to be
relatively non-cell cycle specific in terms of its cell-killing effects and tends to synergize
or have additive cytotoxicity with agents that alter mitosis (PTX) [28, 29]. Apart from the
mechanism basis, synergistic effect greatly depends on drug dosages, combination ratios,
cell lines and intervention schedules. Indeed, synergy between CDDP and PTX was
reported to be highly schedule dependent [30, 31]. Profound synergistic effects were
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observed when PTX was administered prior to CDDP [28, 30] while the sequence of
CDDP before PTX had less antitumor activity in vitro [31], and induced more profound
neutropenia in vivo [32]. One can speculate that the ability of (CDDP+PTX)/NG to
supply drugs in a temporally controlled fashion by releasing PTX significantly faster than
CDDP may contribute into observed improvement of antitumor efficacy of drug
combination.
It should be emphasized that PTX and CDDP may also interact synergistically with
respect to toxicity to the normal tissues as well. However, this was not the case in our
studies. Fig. 2.9B shows that either single or binary drug loaded NG did not induce body
weight loss while the same dose of the free CDDP produced a considerable body weight
loss (P < 0.05), which indicated systemic toxicity of free CDDP. In the kidney, the
primary target organ of CDDP toxicity [33, 34], single or binary drug loaded NGs
showed significantly lower Pt levels than the free CDDP (Fig. 2.12A). Reduced Pt
accumulation in kidney after (CDDP+PTX)/NG or CDDP/NG treatment ameliorated
CDDP-induced nephrotoxicity as confirmed by tissue histopathology analysis.
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Figure 2.12. Light microscopy images (original magnification 100×) of hematoxylin and
eosin-stained kidney sections of mice. Tissue samples were collected at day 14.
Light microscopic examination of H&E stained kidney sections from sacrificed animals
indicated focal tubular basophilia with regeneration in kidneys from all animals treated
with free CDDP, while no histopathological changes were observed in kidney from
animals in the (CDDP+PTX)/NG-treated or CDDP/NG-treated groups compared with the
control (Fig. 2.12). Reduced nephrotoxicity of (CDDP+PTX)/NG or CDDP/NG is likely
due to its macromolecular size coupled with slow release of the drug, which leads to a
lower renal tubular drug exposure. This is a significant result considering renal toxicity is
the most severe, dose-limiting toxicity with CDDP treatment [35]. (CDDP+PTX)/NG
showed very high Pt accumulation in spleen and liver (Fig. 2.10A), but this amount
reduced significantly (P<0.01) with time (Fig. 2.10B). Despite much higher exposure of
liver and spleen to CDDP in the (CDDP+PTX)/NG or CDDP/NG treatment, there was no
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significant change in hepatic toxicity markers of blood chemistry (Table 2.7), indicating
no obvious toxicity to the liver.
Table 2.7. Clinical chemistry parameters at day 14 of the treatment.
ALP ALT
Control
<5
43 ± 8
Free CDDP
<5
58 ± 2
CDDP/NG
<5
45 ± 9
PTX/NG
<5 66 ± 17
(CDDP+PTX)/NG <5
41 ± 9
Data were expressed as mean ± SD (n=3)
Values of ALP and ALT are expressed as U/L
Abbreviations: Alkaline phosphatase; ALP, alanine aminotransferase; ALT.
There was no evidence of liver or splenic toxicity by histopathology (data not shown). In
spleen, the NGs (either free or localized inside macrophages) were detected
predominantly in the red pulp with little to no staining in the lymphoid region (Fig. 2.13).
Free CDDP treatment has previously been reported to have a remarkable effect on
immunological function due to its ability to reduce lymphocytes in the thymus and the
spleen with changes in splenic white pulp being the most significant [36].

Figure 2.13. Confocal image of spleen section stained for NGs (green) and macrophages
(red). Spleen shows accumulation of NGs only in the red pulp region.
Absence of (CDDP+PTX)/NG in lymphoid regions of white pulp may thus limit freedrug exposure to these follicles. Collectively, these results demonstrate that
biodegradable PEG-polypeptide hybrid NGs carrying CDDP and PTX drug combination
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exerted superior antitumor efficacy, both in terms of tumor inhibition and survival, which
could be attributed to the preferential simultaneous accumulation, and increased potency.
2.4 Conclusions
In the present investigation, NGs based on biodegradable and biocompatible
amphiphilic PEG-b-PGlu-b-PPhe triblock copolymers were evaluated as potential carriers
for co-delivery of chemotherapeutic drugs with various physicochemical properties and
modes of action. These nanostructures were designed to have multicompartment
morphology for drug loading and were cross-linked at an intermediate layer within the
polymeric NGs to ensure their prolong stability upon systemic administration.
Hydrophilic CDDP and hydrophobic PTX were loaded in such NGs with high efficiency,
exhibited differential release profiles and synergistic cytotoxic effect against ovarian
cancer cells. The binary drug combination simultaneously delivered using NGs exhibited
superior antitumor efficacy over single drug cl-micelle analogues in vivo in synergistic
manner. Altogether, this study demonstrates a fundamental possibility for simultaneous
delivery of chemotherapeutics and molecular targeting agents via single well-defined and
structurally tunable polymeric nanocarrier.
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CHAPTER III

TARGETED DELIVERY OF PLATINUM-TAXANE COMBINATION THERAPY
IN OVARIAN CANCER
3.1. Introduction
Combination chemotherapy is preferred over treatment with single agents to combat most
cancers as it targets multiple cell-survival pathways at the same time and delays the onset
of resistance. This helps in achieving long-term tumor remission and increases median
survival [1]. Cisplatin (CDDP)-based therapy has been the standard treatment for ovarian
cancer since its discovery. After paclitaxel (PTX) was shown to be effective in ovarian
cancer, multiple clinical trials studied the overall efficacy of CDDP and PTX and found
significant benefit over the pre-existing treatments. Since then, this combination has been
the treatment of choice for both early stage as well as advanced cases of ovarian cancer
[2, 3]. However, administration of two different agents comes with the inconvenience of
repeated or extended duration of drug infusion in patients. Moreover, the most
extensively used conventional formulation of paclitaxel, Taxol®, utilizes Cremophor EL
(polyethoxylated castor oil) that has been linked to significant toxicities including
allergic, hypersensitivity and anaphylactic reactions during infusion that require
premedication and prolonged peripheral neuropathy. Combining such drugs in one
delivery carrier is therefore a well-suited and convenient strategy for controlling the
pharmacokinetics and co-delivery of the desired drug ratio in vivo, to maximize the
therapeutic potency and minimize drug-associated toxicities.
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Cross-linked nanogels have been found to be promising drug carriers to achieve this
goal. Being mostly hydrophilic in nature, nanogels are highly biocompatible with a high
loading capacity for guest molecules [4]. The nanogel structure can be readily adjusted to
integrate features of different materials and, thus, offer advantages for combinatorial
encapsulation of drugs with varying physicochemical properties. One of the widespread
synthetic techniques for the synthesis of nanogels is the crosslinking of preformed coreshell self-assemblies such as polymer micelles that allows introducing a high degree of
spatial organization into the nanogels [4, 5]. Cross-linking is known to impart control
over the swelling behavior of the nanogels and thus helps in achieving controlled release
of the incorporated cargo, which is an added advantage over the structural integrity
imparted to the carrier system upon in vivo administration [4, 6]. The enhanced stability
also makes the prolonged circulation of the nanogels possible, which in turn allows for
increased drug accumulation at the target site [5-9].
We have previously described a biodegradable hybrid nanogel carrier system (NG)
for the combination of CDDP and PTX for ovarian cancer therapy, which not only
mitigated the toxicities associated with the use of free drugs but also improved treatment
outcome [10]. However, our system relied solely on the enhanced permeation and
retention (EPR) effect to facilitate the delivery of the drug combination to the tumor site
[11]. Regardless of the importance and popularity of EPR effect-based drug delivery,
this strategy has some limitations related to the inter- and intra-tumor heterogeneity,
variations in the density as well as permeability of the tumor vasculature that can affect
the accumulation of nanocarriers. One of the popular approaches to circumvent these
problems is by surface-functionalization of the drug carrier with ligands that can target
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receptors with differential expression on the cancer cell surface, which helps in
increasing the mean residence time of the delivery system at the tumor site and improving
target cell uptake [12-15]. One such receptor of interest is the folate receptor (FR).
Malignant cells, due to their high rate of cell division, have an increased requirement of
folic acid (FA), since it is essential component of cell metabolism and DNA synthesis
and repair. To fulfill this higher need of FA, FR is known to be over-expressed in a large
number of malignant tissues, including ovarian cancer, compared to normal tissues with
the exception of the kidney and choroid plexus [16, 17]. Furthermore, this receptor
becomes accessible via the plasma compartment only after the cells lose their polarity
owing to malignant transformation which makes it a differential target for cancer tissue
that is easily accessible for intravenously administered FA conjugated systems. Its natural
ligand, FA, comes with the advantages of high binding affinity, stability and a simple
chemical structure together with ease of availability, making it a suitable targeting ligand
for ovarian cancer therapy. FA can thus be successfully conjugated to macromolecular
systems without loss of binding affinity to its receptor [18]. Many different agents
targeting the folate pathway are currently in clinical development [19]. To date, FAtargeted agents showed significant promise in phase II clinical trials but it has not been
confirmed in phase III studies [20-22]. Accordingly, there is a need for further
identification of new therapeutic combinations and refinement of patient selection. To
this end, FA-conjugated imaging agents could be used for pre-selection of patients based
on the expression of FR [23] and several methods have been already developed for this
purpose [24, 25].
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Our group has previously demonstrated a tumor-specific delivery and improved anticancer effect in vivo of CDDP-loaded NGs decorated with FA targeting groups [26]. In
the current study, we designed FA-linked NGs incorporating platinum-taxane
combination, and examined whether FR-targeted concurrent delivery of synergistic
combination of CDDP and PTX can lead to enhanced therapeutic efficacy compared to
nontargeted NG system.
3.2. Materials and Methods
3.2.1. Materials
α-Amino-ω-methoxy poly(ethylene glycol) (mPEG-NH2, Mw = 5000 g mol−1 , Mw/Mn =
1.05) was purchased from Creative PEGWorks Inc., (NC, USA). Fmoc-NH-PEG-NH2
(Mw = 7500 g mol-1, Mw/Mn = 1.04) was purchased from JenKem technology (TX,
USA). CDDP was purchased from Acros Organics (NJ, USA). L-Glutamic acid γ-benzyl
ester

(BGlu),

L-phenylalanine

(Phe),

1,2-ethylenediamine

(ED),

1-(3-

dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC), paclitaxel, folic acid
and other chemicals were purchased from Sigma-Aldrich (MO, USA) and were used
without further purification. Fetal bovine serum (FBS), RPMI 1640 medium, penicillin,
streptomycin, Trypsin–ethylenediaminetetraacetic acid (EDTA) (0.5% trypsin, 5.3 mM
EDTA tetra-sodium) and other chemicals were purchased from Invitrogen (CA, USA).
3.2.2. Preparation of polymeric NGs
Poly(ethylene glycol)-b-poly(L-glutamic acid)-b-poly(L-phenylalanine) block copolymer
with 90:25 ratio of glutamic acid and phenylalanine units (PEG-PGlu90-PPhe25) was
synthesized as previously described [10]. Details of the procedures used for polymer
synthesis and characterization are described in the Chapter 2. NGs were prepared by
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using previously described method [10] using PEG-PGlu90-PPhe25 micelles as templates
for further cross-linking by ED and EDC ([EDC]/[ED] = 2; [COOH]/[EDC] = 5) at r.t.,
overnight. Byproducts of the cross-linking reaction were removed by exhaustive dialysis
of the reaction mixtures against distilled water. To synthesize fluorescence (Alexa 594)labeled NGs, solution of Alexa luor 594 hydrazide (0.25 μmol, equivalent to 1% of
carboxylate groups in NGs) in DMF was added to aqueous dispersion of NGs and the
mixture was incubated for 2 h in dark. Unbound dye was removed by filtration on
Ultracon filter units (MWCO 10,000 Da, Millipore) at 3000 rpm for 15 min (3 washes)
and then additionally purified using NAP-10 column (GE healthcare). Notably, the same
stock of Alexa 594-labeled NGs was used to prepare FA-decorated NGs.
3.2.3. Synthesis of FA-decorated NGs and drug loading
FA targeting moieties were conjugated to drug-loaded NGs via PEG spacer having Fmoc
protection group (Fmoc-NH-PEG-NH2). Firstly, Fmoc-NH-PEG-NH2 (0.013 mmol, 0.05
eq with respect to the amount of carboxylate groups and 1.5 eq with respect to required
FA) was conjugated to the free carboxyl groups (0.25 mmol) of NGs via EDC (0.023
mmol) chemistry. Fmoc group was then removed by adding 5 µL of 30%
piperidine/DMF (1.1 eq piperidine, 0.014 mmol) and incubating the reaction mixture for
10 min. Resulting constructs were purified using repeated ultrafiltration (MWCO 30,000,
Millipore) at 3000 rpm for 15 min (3 washes). Size exclusion chromatography ( KTA
Fast Protein Liquid Chromatography system) was used to determine the presence of
residual PEG. PEG-NGs conjugates were analyzed by proton nuclear magnetic resonance
spectroscopy (1H NMR) using Varian INOVA 500 NMR spectrometer (Varian, Palo
Alto, CA) operating at 500 MHz (1 mg/mL, D2O, pH 7.0, 25 °C). The dispersion of PEG-
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conjugated NGs was mixed with an aqueous solution of CDDP (1mg/mL) at pH 9.0 at a
0.5 molar ratio of CDDP (0.12 mmol) to carboxylate groups (0.24 mmol) of the NGs
followed by incubation at 37 °C for 48 h. Unbound CDDP was removed by Ultracon
filter units (MWCO 10,000 Da, Millipore) at 3000 rpm for 15 min. FA (0.025 mmol)
dissolved in water was subsequently reacted with 1.5 eq EDC (0.037 mmol) at pH 7 for 2
h. This EDC-activated FA was then conjugated to amine terminus of the PEG linker.
Amount of FA was selected based on the previously reported optimal density of FA on
NGs (0.1-0.2 µmol/mg of polymer) to maintain good loading, stability and cell uptake
[26]. The amount of conjugated FA was determined by UV spectrometry (ϵ363=6500 M1

cm-1) using non-modified PEG-conjugated NGs reference. Finally, PTX (0.01 mmol)

was solubilized into the hydrophobic PPhe core of CDDP-loaded FA-modified NGs
using an extraction method [27]. According to this method, a thin film of PTX (prepared
by evaporation of a methanol solution of PTX) was incubated with aqueous dispersion of
NGs (24 h, r.t.). Unincorporated PTX was removed by filtration with 0.8 µm syringe
filters (Thermo Scientific). Similar procedures were used to prepare single drug NGs
formulations. Pt content in NGs (Pt194/Pt195) was measured by the inductively coupled
plasma-mass

spectrometer

(ICP-MS,

NexION

300Q,

ICP-MS

spectrometer,

PerkinElmer) calibrated with Pt (2-100 ng/ml) and Holmium as the internal standard.
Samples were diluted in 1% HNO3. PTX levels were determined by HPLC analysis under
isocratic conditions using an Agilent 1200 HPLC system with a diode array detector set
at 227 nm. As stationary phase a Nucleosil C18 column was used (250 mm × 4.6 mm), a
mobile phase of acetonitrile/water mixture (55/45, v/v) was applied at a flow rate of 1
mL/min.
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3.2.4. Physicochemical characterization of the NGs and drug release study
Intensity-mean Z-averaged particle diameter (Deff) and ζ-potential of NGs were
determined using a Zetasizer NanoZS (Malvern Instruments Ltd.). All measurements
were performed in automatic mode at 250C. Software provided by the manufacturer was
used to calculate size, polydispersity indices and ζ-potential of NGs. All measurements
were performed at least in triplicate to calculate the mean values ± SD. Drug release from
NGs was examined in PBS (pH 7.4, 0.14M NaCl) by dialysis method using a membrane
with 3500 Da cutoff. The concentrations of Pt and PTX released were determined by
ICP-MS and HPLC, respectively, and expressed as a percentage of the total Pt or PTX
available vs. time.
3.2.5. Cell culture
A2780 human ovarian carcinoma cells were provided by Dr. P. Rogers (Institute of
Cancer Research, University of Bristol, UK). A2780 cells were transfected using F-LucG P Lentivirus (Capital Biosciences, Rockville, MD) according to manufacturer’s
protocol to obtain A2780/Luc cell line. Cells were cultured in folate-depleted RPMI 1640
medium (FD-RPMI) with 2 mM glutamine, 10% (v/v) FBS, 100 U/ml penicillin and 0.1
mg/mL streptomycin at 370C, 5% CO2. This medium contains nearly physiological level
of FA.
3.2.6. Flow cytometry
Cells (50,000 cells/well) grown in FD-RPMI media in 24-well plates for 2 days were
exposed to Alexa 594-labeled NGs or FA-NG (0.20 µmol FA/mg of polymer) at 370C for
up to 2 h, washed three times with PBS, trypsinized, centrifuged (1500 rpm, 5 min) and
re-suspended in PBS (pH 7.4). The % gated cells were analyzed using Becton Dickinson

96

FACStarPlus flow cytometer and FACSDiva software (Version 8.0, Becton Dickinson,
San Jose, CA). At least 5,000 events were acquired in linear mode, gated to exclude
debris and dead cells, and visualized in logarithmic mode. For the competition assay,
cells were co-incubated with Alexa 594-labeled FA-NGs in presence of free FA (25mM),
and the experiment was carried out as described above.
3.2.7. In vitro cytotoxicity
A2780 cells seeded in 96-well plates (10,000 cells/well) 24 h before the experiment were
exposed to various doses (0 -10 µg/ml on CDDP basis) of (CDDP+PTX)/NG or FA(CDDP+PTX)/NG for 24 or 48 h in FD-RPMI at 370C followed by washing with PBS,
and maintaining in FD-RPMI medium with 10% FBS for additional 24 h. Cytotoxicity
was determined by standard colorimetric MTT assay [28] and the IC50 values were
calculated using GraphPad Prism Software. Ratio of CDDP to PTX was c.a. 10:1
(mol/mol).
3.2.8. Animals and bioluminescence imaging procedure
Female six-week old nude mice (athymic nude-nu) were obtained from Charles River
Laboratories and housed in AAALAC accredited facility. Food and reverse osmosis
water were available ad libitum throughout the study. Animals were quarantined for 7
days prior to study initiation. All animal studies were conducted in accordance with the
protocol approved by the University of Nebraska Medical Center Institutional Animal
Care and Use Committee. Imaging was conducted with the in vivo imaging system IVIS200 (Xenogen Corporation, Alameda, CA) composed of a cooled charge-coupled device
camera connected to a light-tight black chamber. Animals were maintained on a FA
deficient diet (Harlan diet TD.00434) for a week before tumor inoculation and during the
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period of studies to achieve plasma folate levels in the physiologic range normally seen
for humans [29]. Before in vivo imaging, animals were anesthetized with isoflurane
(Henry Schein, Dublin, OH) and injected IP with D-luciferin (Perkin-Elmer, Waltham,
MA) at the dose of 150 mg/kg (reconstituted in sterile PBS). Whole-body Imaging was
performed 5 min after injection. Total bioluminescence signal in the regions of interest
(ROIs) drawn around the whole abdomen region was quantified using Living Image
software (version 2.50; Xenogen) and expressed as photons/s/cm2/sr.
3.2.9. Animal studies
Peritoneal carcinomatosis was generated by IP injection of A2780/Luc cells (~1.75 × 106
cells). After development of tumors (3 days after injection) animals were randomized (8
treatment groups, n = 8) and treated with 5% dextrose (control) or free CDDP or
(CDDP+PTX)/NG or combination of CDDP/NG and PTX/NG at the same drug ratio or
FA-(CDDP)/NG or combination of FA-(CDDP)/NG and FA-(PTX)/NG or FA(CDDP+PTX)/NG or FA + FA-(CDDP+PTX)/NG at an equivalent dose of 4 mg/kg
CDDP, or (4 mg/kg CDDP + 1 mg/kg PTX). Treatments were administered via tail vein
injections at 4-day intervals. We used one additional group which received IP injection of
FA-(CDDP+PTX)/NG. The treatment groups and the doses of each drug are presented in
Table 3.1.
Table 3.1 Treatment groups and drug doses used and the doses used in antitumor
actificay studies.
CDDP
Route of
PTX
Free FA
Treatment group
(mg/k
administration
(mg/kg)
(mg/kg)
g)
Control
IV
Free CDDP

IV

4

-

-

(CDDP+PTX)/NG

IV

4

1

-

FA-(CDDP)/NG

IV

4

-

-
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FA-(CDDP)/NG + FA-(PTX)/NG

IV

4

1

-

FA-(CDDP+PTX)/NG

IV

4

1

-

FA + FA-(CDDP+PTX)/NG

IV

4

1

1

FA-(CDDP+PTX)/NG

IP

4

1

-

Animal body weight and tumor progression, as assessed by BLI, were monitored every
fourth day. All images were acquired using identical BLI system settings. Tumors were
allowed to grow until ascites developed or the mice showed signs of pain and/or distress,
then the mice were euthanized via CO2 asphyxiation. At necropsy, the abdominal cavity
was carefully checked and the extent of tumor was determined.
3.2.10. Sample preparation and CDDP measurement in tissue
Known weights of thawed tissues (tumor, kidney, spleen, liver and lung), collected from
the animals sacrificed at day 14 (2-3 mice per group) during treatment, were decomposed
by wet-ashing in screw-capped vials with six volumes of concentrated nitric acid,
overnight heating, and stirring at 650C. An iridium internal standard was added prior to
digestion. Total platinum concentrations were determined by ICP-MS using iridium
correction. Calibration range for the assay was platinum 2–100 ng/mL with extrapolation
to platinum 1000 ng/mL. Necessary dilutions were made when the platinum
concentration exceeded the calibration range. Assay sensitivity was 0.8 ng of Pt/mL, with
inter- and intraday assay variability not exceeding 5%.
3.2.11. Cancer antigen (CA)-125 assay and histopathology
Serum from the blood of sacrificed animals was collected and analyzed for CA-125
levels using CA-125 ELISA kit (Abcam, MA) according to the manufacturer’s
instructions. Formalin-fixed tissues were processed, sectioned, inserted into tissue
cassettes, dehydrated in 70% ethanol overnight, and paraffin embedded (UNMC Tissue
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Sciences acility, Omaha, NE). Serial 5 μm sections were stained with hematoxylin and
eosin (H&E). For histopathological diagnosis, H&E-stained slides were examined by
light microscopy and photomicrographs were taken using a Nikon camera mounted on a
Nikon Eclipse 600 microscope (both Nikon Instruments, Melville, NY) with Adobe
Elements 3.0 software (Adobe Systems, San Jose, CA).
3.2.12. Statistical analysis
Statistical comparisons for in vitro studies were carried out using Students t-test. In
animal studies, group means BL signal intensity and body weights were analyzed using
one-way analysis of variance [30]. Survival was estimated using Kaplan–Meier analysis
and compared using log-rank test. P values less than 0.05 were considered significant.
Analysis of variance and Kaplan–Meier analysis tests were performed using GraphPad
Prism 5 (GraphPad Software, Inc.).
3.3. Results and Discussion
3.3.1. Preparation and characterization of folate-targeted NGs
Triblock copolymer PEG-PGlu90-PPhe25 was utilized for the synthesis of multicompartment biodegradable NG. We have previously demonstrated that the incorporation
of Phe moieties into PEG-PGlu block copolymers facilitated self-assembly of block
copolymers in an aqueous medium, which was ascribed to hydrophobic and π-π stacking
interactions of the phenylalanine units, and was essential for solubilization of various
hydrophobic compounds [10, 27]. As it was reported, the incorporation of aromatic units
in the polymer chains forming the hydrophobic micellar core can considerably improve
the stability, loading capacity and drug retention of taxane-loaded polymeric micelles
[31-34]. These favorable properties were attributed to π-π stacking and hydrophobic
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interactions between aromatic groups in the micelle’s core, and those of the drug.
Therefore, we believe that PPhe domains in our NG system may provide a suitable
environment for encapsulation of PTX. NGs were prepared as previously described by
template-assisted method involving self-assembly of these amphiphilic block copolymers
into micelles, followed by chemical cross-linking of the polyion chains [10]. The crosslinking was achieved via condensation reactions between the carboxylic groups of PGlu
segments and the amine groups of ethylenediamine in the presence of a water-soluble
carbodiimide. The resulting NGs displayed an average diameter of about 90 nm (ζpotential = −20 mV) and were uniform (monomodal, narrow size distribution) as
determined by dynamic light scattering (DLS). Such NGs have 1) a hydrophobic core
formed by PPhe chains, which serves as a reservoir for PTX solubilization, 2) an anionic
intermediate layer, which can incorporates CDDP through coordination with the
carboxylic groups of PGlu, and 3) an outer PEG shell, which stabilizes NGs in aqueous
dispersion. The crosslinks incorporated into PGlu block layer ensure that NGs remain
stable until they encounter proteases, which degrade them by cleaving the polypeptide
chains of the block copolymers [10]. NGs were further modified by FA via a PEG linker
for delivering drug combination to FR-positive ovarian tumors.
preparation of FA-targeted nanogels is presented in Figure 3.1.

Scheme for the
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Figure 3.1. Scheme for the preparation of FA-decorated NGs.
To this end, EDC activated NGs were first reacted with Fmoc-NH-PEG-NH2 (we chose
PEG with a longer chain length, Mw = 7.5 kDa, to reduce steric interference with
receptor binding) followed by deprotection of Fmoc groups. The deprotection was
confirmed by disappearance of Fmoc signals in PEG-NGs 1H NMR spectrum (Fig. 3.2).

Figure 3.2. Confirmation of Fmoc deprotection by 1H-NMR
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The hydrodynamic diameter of PEGylated NGs was 94 ± 3 nm, which is only slightly
larger than that of precursor NGs (88 ± 2 nm). However, the ζ-potential of the PEGmodified NGs significantly increased to -11.1 ± 2.5 mV compared to -20.0 ± 1.2 mV for
the unmodified NGs (Table 3.2), which can be indicative of consumption of the PGlu
carboxylate groups that reacted with the PEG linkers as well as additional shielding of
surface charge by tethered PEG chains. Finally, EDC-activated FA was reacted to amino
groups on NG-attached PEG linkers. Conjugation using carbodiimide chemistry is known
to produce inactive α- and active γ-isomers of folate. However, since multiple folate
residues were linked to each nanogel, the resulting FA-NGs contained sufficient amounts
of the active γ-derivative as shown in the cell association studies described below. After
thorough purification, little to no residual PEG or FA was present in the final FA-NGs as
was

confirmed

by

size

exclusion

chromatography

(Fig.

3.3).

Figure 3.3. Estimation of residual content in FA-NG after its purification using FPLC.
The particle size and ζ-potential of FA-NGs remained practically the same as those of the
PEGylated NGs (Table 3.2).
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Table 3.2. Physicochemical characteristics of empty NGs.
Sample
NG
PEG-NG
FA-NG

Deff (nm)a PDIa ζ-potential (mV)a
88 ± 2
0.14
-20.0 ± 1.2
94 ± 3
0.19
-11.5 ± 2.5
98 ± 4
0.20
-10.9 ± 1.3

a

Effective diameter (Deff), polydispersity index (PDI) and ζ-potential were determined in
water (pH 6.5). Data are expressed as mean ± SD (n = 3).

We have previously shown that the attachment of the FA groups should be carried out
after NGs loading with CDDP to avoid inactivation of folate through CDDP binding with
its carboxylic groups [26]. Therefore, in this study to prepare targeted NGs with binary
drug combination (further abbreviated as FA-(CDDP+PTX)/NGs), CDDP was first
loaded into PEGylated NGs followed by conjugation of FA ligands to PEG linkers. At
the next step, PTX was solubilized into targeted CDDP/NGs using an extraction method.
FA-(CDDP+PTX)/NG were small particles (D eff of approximately 95 nm) with unimodal
particle size distribution (PDI = 0.24) and contained 0.2 μmol A per mg of polymer. As
expected, the net negative charge of drug-loaded NGs was further decreased (ζ-potential
= −5 mV) as a result of neutralization of PGlu segments upon CDDP binding. The
average weight ratio of the CDDP and PTX incorporated into NGs was about 4 : 1, which
has been previously shown to provide strong synergistic cytotoxic effects [10]. A similar
procedure was used to prepare nontargeted (CDDP+PTX)/NGs from PEGylated NG
precursors. Notably, the drug content and physicochemical characteristics of targeted FA(CDDP+PTX)/NGs were quite similar to nontargeted NGs (Table 3.3). Moreover, FA(CDDP+PTX)/NG were stable in aqueous dispersions, exhibiting no aggregation or
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precipitation for a prolonged period of time (weeks) (Table 3.3). We have previously
showed that such NG system can retain drug cargo for longer period of time (weeks) [10]
Table 3.3. Physicochemical characteristics of drug-loaded NGs.
Sample
(CDDP+PTX)/NG
FA-(CDDP+PTX)/NG

Deff (nm)a PDIa ζ-potential (mV)a CDDP:PTX (wt/wt)
86 ± 2
0.26
-7.0 ± 0.7
3.84:1
95 ± 3

0.24

-5.5 ± 1.0

3.78:1

FA-(CDDP+PTX)/NG b
96 ± 4
0.25
-5.7 ± 2.7
a
Effective diameter (Deff), polydispersity index (PDI) and ζ-potential were determined in
water (pH 6.5). Data are expressed as mean ± SD (n = 3).
b
Effective diameter, polydispersity index and ζ-potential after one month of storage in
aqueous dispersion at 40C.

For both drugs there was very little difference in the release profiles between targeted
FA-(CDDP+PTX)/NG and nontargted (CDDP+PTX)/NG, which indicates that the
modification of nanogels with targeting groups had no influence on drug retention (Fig.
3.4). As it seen in Fig. 4, sustained but temporally distinct release of Pt [35] species and
PTX was observed. Notably, PTX release was much faster than that of Pt [35], which is
expected since PTX is physically entrapped into the PPhe core.

Figure 3.4. Drug release profiles from FA-(CDDP+PTX)/NG (solid line) and
(CDDP+PTX)/NG (dotted line) for Pt (●) and PTX (■) in PBS buffer, pH 7.4. The data
represent averaged values and standard deviations calculated based on three independent
experiments.
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3.3.2. Cellular association and in vitro cytotoxicity of FA-NGs
To demonstrate effect of attachment of FA on cellular association of NGs, we used FR+
human ovarian carcinoma A2780 cells and FR- A549 lung carcinoma cells [26]. Cultured
cells were treated with fluorescence Alexa 594-labeled FA-NGs or NGs for 30 min at
37°C. Particle association with cells was determined by flow cytometry. As expected, the
cellular association of FA-NGs with FR+ cells significantly (P < 0.01) exceeded that of
the nontargeted NG (Fig. 3.5). On the other hand, no difference in association of targeted
and nontargeted NGs was observed with A549 cells (Fig. 3.5).

Figure 3.5. A) Cellular association of Alexa fluor 594-labeled NG, FA-NG and FA-NG
in presence of free FA in FR+ A2780 and FR- A549 cell lines at 30 min. B) Inhibitory
effect of free FA on the cellular association of FA-NG in FR+ A2780 as analyzed by flow
cytometry. FA-NG = 0.5 mg/mL and 0.2 μmol A/mg polymer. [ A-NG] = 0.5 mg/mL
and 0.2 μmol folate/mg polymer. ** indicate significantly higher uptake of FA-NG vs.
NG and FA-NG in presence of free FA. ** P < 0.01 and NS - not significant. Data are
mean ± SD (n = 3).

To further elucidate whether the enhanced cellular association of FA-NGs depends on
specific binding to FR on the cell surface, A2780 cells were treated with FA-NGs in the
presence of excess free FA (25 mM). Flow cytometry analysis revealed that the cellular
association of FA-NGs was suppressed to the level of the nontargeted NGs (Fig. 3.5).
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This inhibition was also significant (P < 0.05) after 1 h of treatment in the FR+ A2780
cells (Fig. 3.6). These results validate that the conjugation of FA to the surface of NGs
resulted in efficient and specific association with FR+ cells.

Figure 3.6. Cellular association of Alexa 594-labeled NG, FA-NG and FA-NG in
presence of free FA with A) FR-positive A2780 and B) FR-negative A549 cell lines at
different time points. [FA-NG] = 0.5 mg/mL and 0.2 μmol A/mg polymer. * and **
indicate significantly higher cellular association of FA-NG vs. NG and FA-NG in
presence of free FA. ** P < 0.01 and ** P < 0.05. Data are mean ± SD (n = 3).
It is worth noting that after two hours of treatment there was no significance between FRtargeted and nontargeted NGs uptake, which internalized efficiently (approx. 90% gated
cells) in both cell types (Fig. 6), indicating that a long incubation time could enhance
non-specific uptake of NGs. These differences in cellular association translated into
cytotoxicity (Table 3.4). The cytotoxicity of FA-(CDDP+PTX)/NG against FR+ A2780
cells was increased by two fold compared to (CDDP+PTX)/NG (IC50 expressed in CDDP
equivalents: 1.4 ± 0.75 μM vs 3 ± 1.3 μM) at 24 h. Notably, the difference between
targeted and nontargeted formulations was only apparent at lower time point and it
becomes negligible at 48 h.

Table 3.4. Comparison of IC50 values for targeted and nontargeted drug-loaded NGs
against A2780 cells as determined by the MTT assay.
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(CDDP+PTX)/NG
a

FA-[(CDDP+PTX)/NG]
Calculated with respect to CDDP.

IC50 (µM)a
24 h
48 h
3.0 ±1.3
0.4 ± 0.1
1.4 ± 0.7

0.3 ± 0.1

3.3.3. Antitumor activity in intrapertoneal xenograft model
Our previous studies have shown effective tumor inhibition by platinum-taxane-loaded
NG system in subcutaneously growing ovarian tumor model. Herein, we tested the
efficacy and the toxicity of FR-targeted combination therapy in peritoneal xenograft
model that mimics the clinical manifestations in the advanced stage of the human ovarian
carcinomatosis. The A2780/luc cells, injected into the peritoneum of female nude mice,
grew rapidly in vivo and were able to trigger formation of tumor nodules throughout the
abdominal peritoneum that were detectable by BLI as early as 3 days post inoculation. If
mice were left untreated, the bioluminescene signal rapidly increased and mice ultimately
developed ascites in 2-3 weeks. Treatments were initiated on 4th day post A2780/luc
inoculation. IV administrations of each formulation were given 4 times at 4-day intervals
at 4mg/kg CDDP and 1 mg/kg PTX equivalents per dose. CDDP (4 mg/kg) was also used
as a control-free drug with the same dosing schedule. As shown in Fig. 4, all treatments
were effective in delaying tumor progression in comparison with control group. Tumor
growth inhibition ratio between treated versus control groups (T/C value) was calculated
on day 16 after treatment initiation according to the formula: T/C = (R t - Ro) treated tumor/ (Rt
- Ro)

control tumor,

where Rt and Ro represent the mean bioluminescence intensity on the

evaluation day and at the start of the treatment, respectively (Table 3.5). Consistent with
our previous observations [10], platinum-taxane combination administered as single NG
formulation, (CDDP+PTX)/NG, was found to be significantly more effective (T/C= 0.26)
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than CDDP alone (T/C = 0.56, P < 0.05, Fig. 3.7). In contrast, the mice treated with a
cocktail of single drug NG formulations (CDDP/NG + PTX/NG) at the same drug ratio
had a similar impact on the tumor progression as free CDDP (Fig. 3.7). These data
reinforce our hypothesis that synchronized delivery of platinum-taxane combination
chemotherapy using NGs plays an essential role in its cytotoxic activity.
Table 3.5. In vivo antitumor efficacy of various formulations in ovarian cancer xenograftbearing female nude mice.
Treatment group

T/C

Control

-

Median survival
(days)
19

Free CDDP

0.56

23

(CDDP+PTX)/NG

0.26

31

FA-(CDDP)/NG + FA-(PTX)/NG

0.31

30

FA-(CDDP+PTX)/NG

0.09

41

FA-(CDDP+PTX)/NG IP

0.05

43

FA + FA-(CDDP+PTX)/NG
0.29
27
Note: T/C = (Rt - Ro) treated tumor/ (Rt - Ro) control tumor, where Rt and Ro represent
the mean bioluminescence intensity on the evaluation day and at the start of the
treatment, respectively.

Figure 3.7. In vivo antitumor efficacy of (CDDP+PTX)/NG] vs. CDDP/NG + PTX/NG
in A2780/Luc human ovarian cancer xenograft-bearing female nude mice. (A)
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Bioluminescence images of each 3 mice representative for 8 mice per experimental arm
at the end of treatment (day 16). The colored scale bar indicates the intensities of
bioluminescence in photons/s/cm2/sr. (B) Comparison of tumor growth inhibition
following IV administration of (CDDP+PTX)/NG (▲) or CDDP/NG + PTX/NG (Ж) or
free CDDP (■) or control (●). Drug formulations were injected in100 μL at a dose of 4
mg CDDP or 1mg PTX equivalents/kg body weight 4 times at 4-day intervals as
indicated by the arrows. Data presented in terms of relative bioluminescence units (R t/Ro)
to the day when treatment was initiated for individual animal. Values indicated are means
± SD
(n = 8), *P < 0.05.
(C) Kaplan–Meier analysis of overall survival in
(CDDP+PTX)/NG (1) or CDDP/NG + PTX/NG group (2) or free CDDP (3) or control
group (4). * P<0.05.

Tumor growth in the mice treated with (CDDP+PTX)/NG was further suppressed
when the same drug combination was administered in FA-decorated NGs. FA(CDDP+PTX)/NG showed significant tumor reduction as measured by BLI (T/C = 0.09)
compared to nontargeted (CDDP+PTX)/NG group (T/C = 0.26, P < 0.05) (Fig 3.8A and
3.8B). As a result, combination therapy with FA-(CDDP+PTX)/NG significantly
increased the probability of survival compared to its nontargeted counterpart (Fig. 3.8C).
The median survival times (post-tumor inoculation) for the FA-(CDDP+PTX)/NG and
(CDDP+PTX)/NG groups were 41 and 31 days, respectively (P < 0.01) (Table 3.5).
Notably, the enhanced antitumor effect of FA-(CDDP+PTX)/NG was inhibited when it
was administered with free FA (Fig 3.8A and 3.8B) suggesting that FA-decorated
(CDDP+PTX)/NG display folate specificity and exhibit elevated activity through a
mechanism involving in vivo FR. The peritoneal cavity is the principal site of disease in
ovarian cancer. The concept of direct IP administration of chemotherapy, especially to
treat microscopic residual disease after debulking surgery, has been evaluated in many
clinical trials and has demonstrated an improvement in overall and disease-free survival
[2, 36, 37]. A randomized phase III clinical trial showed IP administration of CDDP and
PTX plus IV PTX improves survival when compared to standard of care with IV
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combination of CDDP and PTX [2]. However, IP chemotherapy also led to significantly
higher toxicities due to exposure of both cancer and healthy tissues to high concentrations
of drugs. We, therefore, utilized our FA-(CDDP+PTX)/NG formulation to determine
whether there are therapeutic advantages in providing targeted IP chemotherapy in
ovarian cancer. As seen in Fig. 8B the BLI data shows a trend towards enhanced
therapeutic efficacy of FA-(CDDP+PTX)/NG when administered IP (T/C = 0.05)
compared to IV regimen (T/C = 0.09). Kaplan-Mayer survival analysis also demonstrated
that mice given IP FA-(CDDP+PTX)/NG appear to have the best outcomes. However,
the differences between groups were not statistically significant.

Figure 3.8. In vivo antitumor efficacy of FA-(CDDP+PTX)/NG in A2780/Luc human
ovarian cancer xenograft-bearing female nude mice. (A) Bioluminescence images of each
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3 mice representative for 8 mice per experimental arm after treatment (day 16). The
colored scale bar indicates the intensities of bioluminescence in photons/s/cm2/sr. (B)
Comparison of tumor growth inhibition following IV administration of FA(CDDP+PTX)/NG (♦) or (CDDP+PTX)/NG (▲) or mixture of 1 mg/kg FA and FA(CDDP+PTX)/NG (ϕ) or free CDDP (■) or 5% dextrose (control) (●). We used one
additional group which received IP injection of FA-(CDDP+PTX)/NG (▼). Drug
formulations were injected in100 μL at a dose of 4 mg CDDP or 1mg PTX
equivalents/kg body weight 4 times at 4-day intervals as indicated by the arrows. Data
presented in terms of relative bioluminescence units (Rt/Ro) to the day when treatment
was initiated for individual animal. Values indicated are means ± SD (n = 8), *P < 0.05.
(C) Kaplan–Meier analysis of overall survival in FA-(CDDP+PTX)/NG IP group (1) or
FA-(CDDP+PTX)/NG IV group (2) or (CDDP+PTX)/NG (3) or FA + FA(CDDP+PTX)/NG (4) or free CDDP (5) or control group (6). Log-rank test was used to
determine statistical difference between (CDDP+PTX)/NG and free CDDP groups, *P <
0.05, and between FA-(CDDP+PTX)/NG and (CDDP+PTX)/NG groups, **P < 0.01.
CA-125 also known as MUC16 is a protein that in humans is encoded by the MUC16
gene [38]. Around 90% of women with advanced ovarian cancer have elevated levels of
CA-125 in their blood serum, making CA-125 a useful tool for detecting ovarian cancer
after the onset of symptoms [39]. Monitoring CA-125 blood serum levels is also useful
for determining how ovarian cancer is responding to treatment and for predicting a
patient’s prognosis after treatment [40]. It has frequently been used as an indicator of
tumor progression in various ovarian cancer mouse xenograft models [41-43]. To further
characterize tumor response to the treatments, we analyzed the serum CA-125 levels in
mice on day 14 (second day after last injection). As shown in Fig. 3.9, levels of CA-125
were significantly low in the mice that received (CDDP+PTX)/NG compared to either
control group (P < 0.01) or free CDDP group (P < 0.05). CA-125 levels were lowest in
the mice that received FA-(CDDP+PTX)/NG either IV or IP. Notably, compared to
nontargeted (CDDP+PTX)/NG group, IP treatment with FA-(CDDP+PTX)/NG resulted
in significant decrease in serum CA-125 levels (P< 0.05) indicating its better therapeutic
potential.
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Figure 3.9. CA-125 ELISA assay. Quantification of serum CA-125 levels in mice from
various treatment groups. Data are presented as mean ± SD (n = 3).

To compare the ability of the NGs-based carriers to deliver a cytotoxic payload to the
tumor sites, we sacrificed 2-3 mice on day 14 and excised the tumors for CDDP content
estimation. Both targeted and nontargeted drug-loaded NGs displayed enhanced tumor
accumulation relative to administration of free drug supporting the well-known
characteristic of nanoparticles to improve tumor drug delivery by the EPR effect (Fig.
3.10). However, FA-(CDDP+PTX)/NG induced a significantly higher Pt accumulation in
the target site compared to nontargeted (CDDP+PTX)/NG (P < 0.05). This increase
appeared to be due to FR-specific interaction of folated NGs with cancer cells because it
was completely reversed by co-administration of free folate. We have previously showed
that the average weight ratio of the CDDP and PTX in the tumors of the animals was
same as the drug loading ratio in (CDDP+PTX)/NG, indicating the spatial–temporal
synchronization of drug exposure. We expect the similar synchronized delivery of CDDP
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and PTX is occurred using our current NG systems as well. Notably, while all drugloaded NGs displayed considerable accumulation of Pt in the highly perfused organs such
as liver and spleen, tumor was the only tissue where Pt content was significantly higher
for FA-(CDDP+PTX)/NG (Fig. 3.10). FA-(CDDP+PTX)/NG treatment which was
administered IP led to the maximum Pt retention in the tumors which may be a result of
regional exposure to high drug concentrations at the tumor sites. This might be the reason
for the observed enhanced tumor responsiveness with IP FA-(CDDP+PTX)/NG
treatment. The binding of FA-(CDDP+PTX)/NG to and/or their uptake by FR+ cancer
cells can retain them within the tumor for a longer period of time, prevent their rapid reentering into systemic circulation and, thus, provide some benefits over passively
targeted formulations. The introduction of FA moieties can also have an effect on
pharmacokinetics and biodistribution of NGs and influence tumor uptake. Further
detailed pharmacokinetic study may help to elucidate the relationship between the
therapeutic effect of the FR-targeted NGs and distribution at the tumor and the whole
body.
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Figure 3.10. Tissue distribution of platinum in different treatment groups as determined
by ICP-MS. Mice were sacrificed at day 14 of the treatment with FA-(CDDP+PTX)/NG
IP or FA-(CDDP+PTX)/NG or FA+ FA-(CDDP+PTX)/NG or (CDDP+PTX)/NG or free
CDDP. Data are presented as mean ± SD (n = 3). * P < 0.05.

To further determine whether concurrent targeted delivery of drug combination will have
therapeutic benefits, we also compared the inhibition of tumor progression and survival
between FA-(CDDP+PTX)/NG and a combination of targeted single drug formulations
(FA-(CDDP)/NG + FA-(PTX)/NG) administered at the same drug ratio (Fig. 3.11 and
3.12). Our data showed significantly better tumor growth inhibition and survival for FA(CDDP+PTX)/NG than FA-(CDDP)/NG + FA-(PTX)/NG. This confirms an advantage
of delivering a platinum-taxane drug combination via single carrier to the same targeted
cells simultaneously. We have not tested this strategy with other drug combinations. So at
time we are not claiming that the same phenomena will hold true for other drug
combinations.
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Figure 3.11. Bioluminescence images of each 3 mice representative for 8 mice per
experimental arm at the end of treatment (day 16). The colored scale bar indicates the
intensities of bioluminescence in photons/s/cm2/sr.

Figure 3.12. In vivo antitumor efficacy of FA-(CDDP+PTX)/NG vs. FA-(CDDP)/NG +
FA-(PTX)/NG co-administration against A2780/Luc human ovarian cancer xenografts.
(A) Comparison of tumor growth inhibition as indicated by relative radiance units over
time following IV administration of FA-(CDDP+PTX)/NG (♦) or FA-CDDP/NG + FAPTX/NG or FA-(CDDP)/NG (Ж) or control (●). Drug formulations were injected in 100
μL at a dose of 4 mg CDDP or 1 mg PTX equivalents/kg body weight 4 times at 4-day
intervals as indicated by the arrows. Values indicated are means ± SD (n=8). (C) Kaplan–
Meier analysis of overall survival in FA-(CDDP+PTX)/NG (1) or FA-(CDDP)/NG + FA(PTX)/NG group (2) or FA-(CDDP)/NG (3) or control group (4). * P < 0.05. Log-rank
test was used to determine statistical difference between FA-(CDDP+PTX)/NG and FA(CDDP)/NG + FA-(PTX)/NG groups, *P < 0.05.

Importantly, the introduction of targeting FA moieties on the surface of NGs did not
alter the favorable toxicity profile of (CDDP+PTX)/NG formulation. Neither targeted nor
nontargeted NG-based binary drug combination caused a significant change in body
weight, indicating that the treatments were well tolerated (Fig. 3.13). In contrast, the
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same dose of free CDDP produced a considerable body weight loss (> 15%, P < 0.05),
which indicated systemic toxicity of free CDDP (Fig. 3.13).

Figure 3.13. Relative changes in body weight were measured following intravenous
administration of FA-(CDDP+PTX)/NG (♦) or (CDDP+PTX)/NG (▲) or A + FA(CDDP+PTX)/NG (ϕ) or free CDDP (■) or control (●).Values indicated are means ± SD
(n=3). * P<0.05. Values indicated are means ± SD. * P<0.05.
In the kidney, the primary target organ of CDDP toxicity [44, 45], both targeted or
nontargeted drug-loaded NGs showed significantly lower Pt levels than free CDDP (Fig.
10) which ameliorated CDDP-induced nephrotoxicity as confirmed by tissue
histopathology analysis. Light microscopic examination of H&E stained kidney sections
from sacrificed animals indicated focal tubular degeneration and regeneration in kidneys
from all animals treated with free CDDP, while no histopathological changes were
observed

in

kidney

from

animals

in

the

FA-(CDDP+PTX)/NG-treated

or

(CDDP+PTX)/NG-treated groups compared with the control (Fig. 14). This is a
significant result since a higher expression of FR in this organ may raise a concern of
toxicity to this tissue [46]. We also observed focal acute inflammation in the lungs of
animals treated with free CDDP while no such changes were detected in any of the NGs
formulation (Fig. 3.14). Despite relatively higher exposure of liver and spleen to CDDP
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in the FA-(CDDP+PTX)/NG or (CDDP+PTX)/NG treatment, there was no evidence of
liver or splenic toxicity by histopathology (Fig. 3.15).

Figure 3.14. Light microscopy images (20X) of hematoxylin and eosin-stained kidney
and lung sections of mice. Tissue samples were collected at day 14.

Figure 3.15. Light microscopy images (20X) of hematoxylin and eosin-stained kidney
and lung sections of mice. Tissue samples were collected at day 14. Liver and spleen
appear normal.
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Mice which received FA-(CDDP+PTX)/NG IP also did not show any evidence of
toxicity in any of the investigated organs. Indeed, the local delivery of FA(CDDP+PTX)/NG into intraperitoneal cavity reduced nonspecific drug accumulation in
normal tissues (spleen, liver, and kidney) (Fig. 3.10). Blood cell counting analysis on day
14 was conducted and normal cell counts were observed for red blood cells and platelets
for all groups (Table 3.6) while there was significant reduction in the count of white
blood cells (below normal range) in the mice which were treated with free CDDP.

Table 3.6. Blood cell counting analysis at day 14 (second day post-treatment).
Sample
Control
Free CDDP
(CDDP+PTX)/NG
FA-(CDDP+PTX)/NG
FA-(CDDP+PTX)/NG IP

RBC (1012/L)
6.03 ± 0.23
4.66 ± 0.10
4.13 ± 0.31
4.01 ± 0.19
3.60 ± 0.14

PLT (109/L)
312 ± 32
368 ± 26
273 ± 19
350 ± 42
360 ± 70

Figure 3.16. Blood cell counting analysis for WBC at day 14.

In contrast, mice treated with drugs loaded in NGs did not have any changes in white
blood cells compared to control (Fig. 3.16).
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Collectively, these in vivo data support the efficacy of this targeted platinum-taxane
combination therapy in FR-expressing ovarian cancer model without toxicity-related
consequences.
3.4. Conclusion
In this study, we demonstrated that folate-decorated NGs carrying CDDP and PTX
drug combination exerted enhanced antitumor efficacy, both in terms of tumor growth
inhibition and survival, compared to its nontargeted counterpart in rapidly growing
murine model of FR-positive ovarian cancer. This better efficacy was only observed
when CDDP and PTX are concurrently delivered to the tumor sites. Our data also
indicate that IP administration of FA-(CDDP+PTX)/NG can be more effective in the
context of targeted combination therapy without extending its cytotoxicity to the normal
tissues. Localized chemotherapy has demonstrated survival advantages in advanced
ovarian cancer patients and our NG-based drug delivery system can be a suitable
candidate for further optimization and pre-clinical evaluation of intraperitoneal
chemotherapy for ovarian cancer.
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CHAPTER IV

HSP90-INHIBITION ENHANCES THE LYSOSOMAL TARGETING AND
EFFICACY OF ErbB2-TARGETED DRUG DELIVERY
4.1. Introduction
Overexpression of surface receptors on cancer cells presents opportunities to achieve
targeted delivery of cytotoxic agents linked directly to targeting ligands/antibodies or
encapsulated within nanometer-sized drug delivery vehicles decorated with targeting
ligands/antibodies [1]. The receptor tyrosine kinase family members, EGFR and ErbB2
are overexpressed in many types of cancers and have served as popular models for the
development of targeted drug delivery modalities, including Antibody-Drug-Conjugates
(ADCs) and nanoparticulate drug delivery systems. Trastuzumab-DM1 (Kadcyla,
Genentech, San Francisco) is an example of an ADC developed against ErbB2overexpressing cancers in which the cytotoxic drug (Emtansine) is chemically conjugated
to Trastuzumab (the humanized anti-ErbB2 monoclonal antibody) [2]. The success of
these strategies is predictably dependent on robust endocytosis of the receptor-bound
cargo and trafficking from early endosomes to the lysosomes, where the conjugate
undergoes disintegration, resulting in the release of the cytotoxic drug into the cytosol. In
normal cells, endocytosis and receptor trafficking is a highly regulated process mediated
by several cellular factors. Receptors may be endocytosed via clathrin- or caveolinmediated pathways, or via macropinocytosis. Following endocytosis, the receptors are
either routed to the lysosomes or recycled back to the cell-surface, process regulated
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among other factors by receptor ubiquitination (mediated by E3 ubiquitin ligases such as
Cbl) or de-ubiquitination (mediated by AMSH or USP8) [3-8]. Ubiquitin-dependent
sorting proteins, known as ESCRT (Endosomal Sorting Complex Required for Transport)
proteins recognize the ubiquitinated receptor cargo and help sort them into inner vesicles
of multivesicular bodies for transport to lysosomes [4, 5, 9, 10]. Various Rab-family
GTPases, functioning at distinct vesicular trafficking stages, also play a critical role in
directing the sorting of endocytosed cargo between recycling and lysosomal pathways.
Cancer cell-specific alterations (mutations, overexpression) in receptors themselves or in
the trafficking regulators can alter the balance between receptor-recycling and lysosomal
trafficking [3, 11]. While the focus has been more in designing receptor-targeted drug
delivery systems, the consequence of alterations in regulatory factors that affect the
recycling vs. lysosomal trafficking behavior of targeted receptors and consequently the
efficiency of drug delivery have received little attention. In this study, we illustrate the
importance of receptor dynamics on targeted drug delivery, using ErbB2-overexpressing
breast tumor targeting through anti-ErbB2 humanized monoclonal antibody Trastuzumab
as a model.
The oncogenic receptor tyrosine kinase ErbB2, overexpressed in over 20% of
breast cancers, has served as a major target for the development of targeted drug delivery
strategies [12-15]. However, ErbB2 is thought to be either impaired in endocytosis or to
rapidly recycle back to the cell-surface [16, 17], which can significantly dampen the
efficacy of ErbB2-targeted drug delivery. Such altered trafficking dynamics is believed to
be due to its constitutive association with HSP90 [18], [17-22] which can be anticipated
to significantly dampen the efficacy of ErbB2-targeted drug delivery. We therefore
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hypothesized that HSP90-inhibition will enhance ErbB2-targeted drug delivery by
promoting the endocytic uptake of ErbB2-bound nanoencapsulated cargo and facilitating
its re-routing from a recycling pathway to the lysosomes. Using Trastuzumab-conjugated
nanogels (Trast-NG) encapsulating the DNA-damaging drug Doxorubicin (DOX) as a
model chemotherapeutic, we demonstrate through both in vitro and in vivo studies that
HSP90-inhibition can indeed lead to an enhancement of targeted delivery of DOX
specifically into ErbB2-overexpressing breast cancer cells. As a consequence, a subtherapeutic and non-toxic dose of the HSP90 inhibitor 17AAG markedly improves the
efficacy of ErbB2-targetd nanogels in vivo.
4.2. Materials and methods:
4.2.1. Materials.
Trastuzumab was obtained from UNMC pharmacy. PEG-b-PMA diblock copolymer
(Mw/Mn = 1.45) was purchased from Polymer Source Inc., Canada. The block lengths
were 170 and 180 repeating units for PEG and PMA respectively. The concentration of
carboxylate groups in the copolymer samples was estimated by potentiometric titration.
FMOC-PEG-NHS was purchased from Creative PEGWorks, NC. Calcium chloride,
Ethylenediamine, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC)
and Ethylenediaminetetraacetic acid (EDTA) were obtained from Sigma-Aldrich (St
Louis, MO). Doxorubicin hydrochloride was kindly provided by Dong-A Pharmaceutical
Company, South Korea. Fetal bovine serum (FBS) (both dialyzed and heat inactivated),
DMEM and RPMI 1640 media and LysotrackerTM (green) were purchased from
Invitrogen Inc (Carlsbad, CA). Bovine serum albumin (BSA) and NUNC TM chambered
glass coverslips for live cell imaging were purchased from Fisher Scientific (Waltham,
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MA). MTT reagent (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) was
purchased from Research Products International (Prospect, IL). All other chemicals were
of reagent grade and used without further purification. The following primary antibodies
were used in this study: anti-human-ErbB2 mouse monoclonal (ErbB2) raised against the
C-terminal amino acid residues (1242-1255), used for Western blotting studies, were
purchased from BD Pharmingen™ (San Diego, CA); for flow cytometry and
immunofluorescence studies, the goat anti-human-ErbB2 polyclonal antibody (AF1129)
was from R&D Systems (Minneapolis, MN); the mouse monoclonal antiphosphotyrosine (anti-pY; 4G10) was kindly provided by Dr. Brian Druker (Oregon
Health & Science University, Portland, OR); the mouse monoclonal anti-Hsc70 antibody
were from Santa Cruz Biotechnology Inc. (Santa Cruz, CA).
4.2.2. Synthesis of the NGs.
The general procedure for the synthesis of NGs has been described earlier [23, 24].
Briefly, PEG-b-PMA/Ca2+ complexes were prepared by mixing an aqueous solution of
PEG-b-PMA with a solution of CaCl2 at a molar ratio of [Ca2+] / [COO−] = 1.3. The
chains were cross-linked overnight at room temperature (r.t.) using 1,2-ethylenediamine
and EDC ([EDC]/[1,2-ethylenediamine] = 2; [COOH]/[EDC] = 5). The NGs were
dialyzed (MWCO 3.5 kDa) extensively against a) 0.5% aqueous ammonia in the presence
of EDTA and b) bi-distilled water.
4.2.3. Synthesis and characterization of mAb-modified DOX-loaded NGs.
MAb (Trast and mouse IgG) were attached to the NGs via streptavidin-biotin complex
(Fig. 1). Details of conjugation procedure are as follows.
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PEGylation of streptavidin. Streptavidin was diluated with 50 mM sodium bicarbonate
buffer till concentration becomes 1 mg/mL (total volume: 6 mL). Separately, Fmoc-PEGNHS (Mw = 10 kDa, 1.5 mg, 1.5 eq with respect to streptavidin) was also diluted with
same buffer. Solution of streptavidin was added dropwise to Fmoc-PEG-NHS solution.
The mixture was incubated for 2 h followed by Fmoc group deprotection. Fmoc groups
were removed by adding 0.5 µL of 20% piperidine/DMF (5 eq piperidine) and incubating
the reaction mixture for 10 min. Resulting construct (NH2-PEG-streptavidin) was purified
using repeated ultrafiltration (MWCO 30,000, Millipore) at 3000 rpm for 15 min (3
washes) to remove unreacted PEG. Absence of free PEG was confirmed by size
exclusion chromatography (SEC) using an ÄKTA FPLC (Amersham Biosciences)
equipped with Sepharose CL-6B-based column.
Insertion of NH2-PEG-streptavidin into NGs. Carboxylate groups of NG were activated
with EDC (0.3 mg, 10 eq with respect to the amount of NH2-PEG-streptavidin) followed
by insertion of NH2-PEG-streptavidin into NGs through the reaction between free NH2
groups of PEG with EDC-activated carboxyl acid core of NGs. Mixture was allowed to
react for 2 h followed by purification of streptavidin-NG conjugate using repeated
ultrafiltration (MWCO 100,000, Millipore) at 4500 rpm for 30 min (3 washes) to remove
unreacted PEG-Streptavidin. Absence of free PEG-Streptavidin was confirmed by SEC.
Amount of streptavidin present in the streptavidin-NG conjugate was measured by
Bradford method using BioRad assay kit (BioRad, Richmond, CA, USA) and bovine
serum albumin as the standard.
Preparation of mAb-NG via streptavidin biotin complex and drug loading. StreptavidinNGs were further mixed with biotinylated mAb (ratio of streptavidin to biotin was 1:2).
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The mixture was incubated for 2 h at r.t.. The mAb-NG was purified SEC. This
purification procedure allowed removing all unbound mAb, while the unmodified NG
and mAb-NGs were not separated. Amount of mAb present in the mAb-NG conjugate
was measured by Bradford method using streptavidin-NG as control. mAb-NG/DOX was
prepared by adding DOX to an aqueous dispersion of NGs at the feeding ratio of R=
[DOX]/[COO-] = 0.25, for 24 h at pH 7.0. Unbound DOX was separated by repeated
ultrafiltration (MWCO 30,000, Millipore) at 3000 rpm for 15 min (3 washes).
4.2.4. Determination of particle size and zeta-potential.
Intensity-mean Z-averaged particle diameter (Deff) and -potential of NG were determined
using a Malvern Zetasizer (Malvern Instruments Ltd., Malvern, UK). All measurements
were performed in automatic mode, at 25C. Software provided by the manufacturer was
used to calculate size, polydispersity indices and -potential of NGs. The values were
calculated from the measurements performed at least in triplicate.
4.2.5. Cell culture conditions.
The ErbB2-overexpressing cell lines used in this study were SKBr-3, 21MT1 and BT474. MCF-7 cells were used as a representative ErbB2-low cell line for comparison. All
cell lines were maintained as previously described [19, 70]. The ErbB2-overexpressing
breast cancer cell line 21MT-1 was established by Band et al [71] and has been
previously described. BT-474 and MCF-7 cell lines were purchased from ATCC.
4.2.6. Confocal microscopy.
Cellular uptake and localization studies of Trast-NG were conducted using confocal
microscope (Carl Zeiss LSM 510 Meta, Peabody, MA). SKBr-3 breast cancer cells
(1×106) were plated on glass coverslips. Trast-NG (without drug) were incubated with
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ErbB2-overexpressing SKBr-3 cells for 1h. 17-AAG (100 nM) was added for the
different times (2, 4 and 8h), after which the slides were washed and fixed in 4%
parafolmaldehyde. Nanogels were visualized by staining the Fc-portion of the conjugated
Trast on the NG using FITC-conjugated anti-Human antibody (green). ErbB2 was stained
either using the goat anti-ErbB2 polyclonal antibody (AF1129) directed against the Nterminal extracellular domains of ErbB2 or a mouse monoclonal antibody directed
against the C-terminal tail of ErbB2 (BD Pharmingen) followed by Alexa594-conjugated
secondary antibody (anti-goat or anti-mouse respectively). The lysosomal marker LAMP1 was stained using mouse anti-human LAMP-1 mAb, followed by Alexa-594conjugated anti-mouse secondary.
4.2.7. Cell cycle analysis.
We evaluated the ability of 17-AAG to enhance the delivery of DOX encapsulated within
the NG in 21MT-1 and MCF-7 cells by a cell cycle analysis [70]. Briefly, cells were
seeded in 6-well plates and allowed to adhere for 24 h prior to drug treatment. Cells were
then exposed to various concentrations of Trast-NG/DOX (1.7 – 13.3 μM Dox) for 6
hours, following which cells were either left alone (control) or treated with 100 nM 17AAG for 18 hours. Cell cycle distribution was then evaluated by using standard protocol
for FACS analysis of propidium iodide (PI)-stained cells.
4.2.8. Animal Studies.
All animal studies were conducted in accordance with an approved protocol by the
University of Nebraska Medical Center Institutional Animal Care and Use Committee
(IACUC). 107 BT-474 cells (an ErbB2 overexpressing human breast cancer cell line)
reconstituted in 50% Matrigel (BD Biosciences, California) in media were injected

131

directly into the mammary fat pad of 4-6 week old female Athymic NCr-nu/nu mice
(NCI, Fredrick National Lab, Fredrick, MD). 17--Estradiol pellets (0.72mg/pellet; 60
day release; Innovative Research of America, Sarasota, Fl) were implanted
subcutaneously on the lateral side of the neck of the mice, three days prior to the injection
of the tumor cells. The mice were stratified into treatment groups 14 days after tumor
inoculation, when the average tumor size reached 100-200 mm3.

Treatment groups

included: 1) 5 % dextrose (Control); 2) Trast alone (3 mg/kg); 3) IgG-NG/DOX (6
mg/kg); 4) IgG-NG/DOX (6 mg/kg) + free 17AAG (1 mg/kg); 5) Trast-NG/DOX (6
mg/kg); 7) Trast-NG/DOX (6 mg/kg) + free 17AAG (1 mg/kg). Treatments were
administered via tail vein injections at 4-day intervals. 17-AAG doses were given 2 h
after NG formulation administration. Animal body weight and tumor volume were
monitored every second day. Tumor volume (V = 0.5 x L x W2) was estimated by
measuring two orthogonal diameters (longer dimension: L, and smaller dimension: W) of
the tumor using electronic calipers. Animals were sacrificed when tumor volume
exceeded 3000 mm3, greatest tumor dimension exceeded 20 mm, tumor became necrotic,
or animal exhibited a body weight loss of more than 20%. All other animals were
sacrificed by day 78.
4.2.9. Apoptosis and proliferation.
Tumors from mice that received different treatments were excised at day 14 (2–3 mice
per group). The tumors were dissected and fixed in 10% neutral buffered formalin. Then,
the tissues were processed routinely into paraffin, sectioned at a thickness of 4 μm.
Proliferating and apoptotic cells were detected using an antibody against Ki-67 and
caspase-3, respectively. Visualization was done by incubation with DAB + (brown, for
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Ki-67) and Permanent red (for caspase-3) (DAKO) for 2 min. After rinsing with distilled
water, the sections were counterstained with hematoxylin. For quantification of Ki-67
and caspase-3 expression, the area of positive cells was determined (Image J) in 5
random high power fields (20× magnification) and divided by the total area of cells for
each field of slice.
4.2.10. Histopathology analysis.
Specific tissues (liver, spleen, heart kidney and lung) were fixed in buffered formalin and
were sectioned, inserted into tissue cassettes, dehydrated in 70% ethanol overnight, and
paraffin embedded (UNMC Tissue Sciences acility, Omaha, NE). Serial 5 μm sections
were stained with hematoxylin and eosin (H&E). For histopathological diagnosis, H&Estained slides were examined by light microscopy.
4.2.11. Statistical analysis.
Statistical comparisons for evaluating biological effects for the various treatment groups
were carried out using Student t-test using a type I error (α) = 0.05 . or the antitumor
study and toxicity studies, in vivo, group means for tumor volume and body weights were
evaluated using repeated measures analysis of variance. Survival was estimated using
Kaplan–Meier analysis and compared using log-rank test. P values less than 0.05 were
considered significant. Analysis of variance and Kaplan–Meier analysis with log-rank
test were performed using GraphPad Prism 5 (GraphPad Software, Inc.). Median survival
time for the various groups and the associated Confidence Interval limits were derived by
running PROC LIFETEST in SAS (Statistical Analysis System) software.
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4.3. Results:
4.3.1. Preparation and characterization of Trast-NG.
Core-shell NG studied here were synthesized as previously described [23, 24] via selfassembly of doubly hydrophilic poly(ethylene glycol)-b-poly(methacrylic acid) (PEG-bPMA) block copolymers in the presence of the condensing agent (CaCl2) followed by
chemical crosslinking of the polyion chains and removal of the condensing agent. The

Figure 4.1. Scheme for the synthesis of Trast-NG conjugate via streptavidine-biotin
complex.
resulting
NGs were of ca. 110 nm in diameter and had a net negative charge (ζ-potential

= -22 mV). The core of such NGs comprised a swollen network of the cross-linked
polyion chains bearing carboxylic groups and is surrounded by the shell of hydrophilic
PEG chains. These (PEG-b-PMA)-based NGs can incorporate very large amounts (~30%
wt.) of water-soluble drugs such as DOX through combination of electrostatic and Van
der Waals interactions [24], The preparation of Trast-NG is depicted in Fig. 4.1 and
detailed in the methods section. NGs were first functionalized with streptavidin by
inserting an NH2-PEG-streptavidin linker. Since 7.5 kDa PEG chains comprise NGs
shells, we chose PEG with a longer chain length, M w = 10 kDa, to reduce potential steric
interference with receptor binding. The average particle size of streptavidin-conjugated
NGs was 137 ± 4 nm (polydispersity Index = 0.09, ζ-potential = -19.0 ± 2.3 mV), which
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is only slightly larger than that of precursor NGs. Biotinylated Trast or control IgG was
then coupled with streptavidin-modified NGs. Final product was purified using fast
protein liquid chromatography (FPLC) (Fig. 4.2). FPLC chromatogram confirmed very
high yield of reaction with little residual Trast or IgG (Fig. 4.2).

Figure 4.2. Purification of Trast-NG by FPLC
Purified Trast-NG had an average particle size of 173 ± 3 nm (polydispersity Index =
0.08, ζ-potential = -20.2 ± 3.1 mV), whereas the control IgG-NG had a size of 177 ± 2
nm (polydispersity Index = 0.07, ζ-potential = -19 ± 2.2 mV). After DOX loading, the
average particle size of Trast-NG decreased to 154 ± 4 nm (polydispersity Index – 0.19,
ζ-potential = -4.1 ± 0.9 mV), whereas the particle size of IgG-NG was 157 ± 8
(polydispersity Index = 0.24, ζ-potential = -2.7 ± 1.3 mV). Reduction in particle size and
net negative charge of NGs after DOX loading was consistent with neutralization and
condensation of PMA segments by DOX.
The conjugation of Trast to NG did not compromise its ability to specifically bind to
ErbB2 receptors overexpressed on human breast adenocarcinoma SKBr-3 cells was
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confirmed by flow cytometry (FACS) (Fig. 4.3A) and confocal immunofluorescence
microscopy (Fig. 4.3B). By using two-color imaging, the latter analyses showed complete
colocalization of ErbB2 staining with Trast (stained in red) with signals form the bound
Trast-NG (stained in green) (Fig. 4.3B), demonstrating ErbB2-specific binding of the
NG.

Figure 4.3. Trast-NG retains its ability to specifically bind to ErB2. A. ErbB2overexpressing breast cancer cell line. SKBr-3 was left untreated or treated with
biotinylated Trast or Trast-NG on ice. The bound Trast or Trast-NG was detected using a
Cy5-labeled anti-human secondary Ab alone. Samples were subjected to FACS analysis.
Untreated cells stained with the Cy5-labeled secondary Ab served as a negative control,
whereas biotinylated Trast served as a positive control. B. Binding of Trast-NG to
ErbB2-overexpressing breast cancer cells was confirmed by confocal microscopy.
ErbB2-was visualized using a mouse monoclonal antibody directed against the Cterminal antigenic region of ErbB2 (BD Pharmingen), followed by Alexa594-conjugated
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anti-mouse secondary antibody. The Trast-NG bound to the ErbB2 was detected using a
FITC-conjugated goat anti-human secondary antibody to detect the Fc portion of the
Trast-conjugated to the NG.
To further explore the specificity of Trast-NG towards ErbB2-overexpressing breast
cancer cells, we compared the cancer cell growth inhibition induced by DOX
encapsulated within untargeted NG vs. Trast-NG (Table 4.1). The ErbB2overexpressing BT-474 and the ErbB2-low MCF-7 breast cancer cell lines were
used as models for comparison of targeting specificity. The biological effects were
assessed using MTT dye incorporation assay.
Table 4.1 . Comparison of IC50 values for targeted Vs non-targeted DOX-loaded
nanogels ErbB2 high and ErbB2 low cells as determined by the MTT assay.

The IC50

IC50 (µM)
BT-474
MCF-7
(ErbB2 +)
(ErbB2 -)
NG/DOX
0.43 ± 0.13
0.29 ± 0.1
Trast-NG/DOX
0.07 ± 0.08
0.19 ± 0.07
value of DOX against ErbB2-overexpressing BT-474 cells was 6-fold lower

using DOX-loaded Trast-NG (Trast-NG/DOX) compared to DOX-loaded NG
(NG/DOX). On the other hand, no appreciable difference in the IC 50 against ErbB2low MCF-7 cells was seen between Trast-NG/DOX and NG/DOX (Table 4.1). These
experiments confirmed the ability of Trast-NG to deliver chemotherapeutic payloads
to ErbB2-overexpressing breast cancer cells with high specificity.
4.3.2. Kinetics of endocytic uptake of Trast-NG into ErbB2-overexpressing breast
cancer cells.
Next, we compared the kinetics of the endocytic uptake of Trast-NG into ErbB2overexpressing cell line SKBr-3, using confocal immunofluorescence analysis in absence
or presence of an HSP90 inhibitor. For this set of experiments, we used the empty Trast-
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NG. Cells seeded on glass-coverslips were either left untreated or treated with 10 µg/mL
of free Trast or the equivalent protein concentration of Trast-NG for 2, 4 or 8 hours in
absence or presence of the HSP90 inhibitor 17-AAG (100 nM) followed by confocal
imaging (Fig. 4.4). In the absence of 17AAG, Trast-NG (stained in green) was found at
the cell surface throughout the 8h time course, with relatively little internalized pool,
comparable to that seen with free Trast (Fig. 4.4, second vs. first column). In contrast,
cells incubated with Trast-NG in the presence of 17-AAG demonstrated the rapid
internalization of ErbB2 (stained in red) with notable internal staining at 2 h and nearly
complete intracellular staining at 4h; as expected, ErbB2 levels decreased by 8h,
reflecting the destabilization due to HSP90 inhibition (Fig. 4.4, last column).
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Figure 4.4. The HSP90 inhibitor 17AAG promotes the internalization and lysosomal
degradation of Trast-NG. ErbB2-overexpressing SKBr3 cells were plated on glass
coverslips and incubated with Trast-NG without any encapsulated drug for 1h to allow
binding to the cell surface. 17-AAG (100 nM) was then added for the indicated time
points, after which the slides were washed and fixed, stained as described in the legend
for Fig. 4.3. The slides were analyzed by confocal immunofluorescence microscopy. The
inset within panel C shows Trast-NG accumulating in punctate intracellular vesicles
following 17-AAG treatment.
The loss of the green signal from Trast was concomitant with the loss of red signal from
ErbB2 (due to lysosomal degradation of both ErbB2 and Trast), suggesting that the
targeted NG cargo follows the endocytic itinerary of the ErbB2 receptor upon HSP90
inhibition [17-22]. To confirm if HSP90 inhibition indeed promoted the NG cargo
trafficking into the lysosomal compartment, which is desirable to facilitate the NG
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disintegration and release of encapsulated drugs [17-22], we examined the colocalization
of internalized NG (stained in green) with the lysosomal marker LAMP-1 (stained in red)
in SKBr-3 cells. Confocal Immunofluorescence analysis (Fig 4.5) confirmed that the NG
was indeed targeted to found in LAMP-1-positive compartments in the presence of
17AAG. These analyses demonstrate the strong positive impact of HSP90 inhibition to
promote the internalization and lysosomal targeting of Trast-NG.

Figure. 4.5. SKBR-3 cells grown on glass coverslips were treated with Trast-NG
followed by 17-AAG as described in the legend for Fig 3 A. The internalized Trast-NG
(seen in green) was visualized as described in the legend for Fig 2. The lysosomal marker
LAMP-1 (seen in red) was stained using mouse anti-human LAMP-1 mAb, followed by
Alexa-594-conjugated anti-mouse secondary. Co-localization of Trast-NG with LAMP-1
can be seen as regions in yellow/orange.

4.3.3. In vitro analysis of HSP90 inhibitor-facilitated delivery of DOX into ErbB2overexpressing breast cancer cells.
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Having verified our central hypothesis that HSP90-inhibition facilitates the routing of
Trast-NG (without drugs) into lysosomes, we evaluated the ability of 17-AAG to enhance
the delivery of NG-encapsulated DOX. The ErbB2-overexpressing 21MT-1 cell or the
ErbB2-low MCF7 cells (specificity control) were incubated with increasing
concentrations of Trast-NG/DOX for 6 h, after which the cells were either left alone
(control) or treated with 100 nM 17-AAG for 18 h to trigger the internalization and
lysosomal routing of the targeted NG cargo. Biological effects were assessed by
evaluating DOX-induced G2/M arrest using a FACS-based assay.

Figure 4.6. HSP90 inhibition potentiates the effect of Trast-NG/DOX on ErbB2expressing breast cancer cells. The ErbB2-overexpressing 21MT-1 or ErbB2-low MCF-7
cells were plated in 6-well plates and triplicate wells were treated with the indicated
concentrations of Trast-NG/DOX for 6h. Unbound Trast-NG/DOX was washed out and
cells were cultured further in DOX-free media without or with 17-AAG (100 nM) for 18
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h followed by the incubation with nanogel-free media. Cell cycle analysis was performed
after 48 h of treatment. Shown are the fold increase in the % of cells in G2/M phase of
the cell cycle for each treatment condition over DMSO control (the color coding is
indicated inside the histogram). The number of asterisks indicates increasing significance
(*, p<0.05; **, p<0.005; ***, p<0.0005); NS, not significant.
While Trast-NG/DOX treatment showed a dose-dependent increase in the % cells in
G2M in ErbB2-overexpressing 21-MT1 cells, little effect was seen on ErbB2-low
MCF7 cells, especially at lower concentrations (Fig. 4.6). Inclusion of 17AAG had no
impact on the effect of lower concentrations of Trast-NG/DOX on the % of MCF7 cells
in G2/M, but a statistically significant increase was noted in 21-MT1 cells treated with
identical concentrations of Trast-NG/DOX (Fig. 4.6). Thus, inclusion of 17AAG
markedly increased the biological impact of Trast-NG/DOX, relatively selectively
against the ErbB2-overexpressing cell line.
4.3.4. Potentiation of the antitumor efficacy of Trast-NG/DOX by 17 AAG in an
ErbB2-overexpressing breast cancer cell xenograft model in mice.
To examine if HSP90 inhibition potentiates the antitumor efficacy of Trast-NG/DOX
in vivo, we treated mice bearing ErbB2-overexpressing breast cancer cell line (BT-474)
xenografts with Trast-NGs carrying DOX with or without sequential treatment with
17AAG. In vivo experiments with BT-474 xenografts were conducted twice (with n=
10 mice/group). In the first set only tumor volume changes were measured, while in the
second, the mice were also followed for survival analyses. For comparison, we also
examined the impact of these treatments on xenografts of the ErbB2-low cell line MCF7. Control treatments included: 1) 5 % dextrose solution (negative control); 2) Trast
alone (positive control); 3) IgG-NG/DOX (non-targeted NG) and; 4) IgG-NG/DOX
plus 17-AAG. A total of four treatments (intravenous injections) were given at 4-day
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intervals at a NG dose equivalent to 6 mg of DOX/kg (determined as the maximum
tolerated dose for this treatment schedule). The NG doses administered were equivalent
to 6 mg/kg DOX and 3 mg/kg Trast per injection. In cohorts that included the 17-AAG
treatment, this drug was administered at 1 mg/kg, 2 h after the Trast-NG/DOX or IgGNG/DOX injection.
The changes in the relative tumor volume for mice bearing BT-474 (ErbB2-high)
tumors are shown in Fig. 4.7A (data combines results from two independent
experiments). To confirm the in vivo selectivity of the targeted NG to deliver DOX to
ErbB2-overexpressing tumors, we also evaluated the effect of treatments with TrastNG/DOX in comparison to the untargeted IgG-NG/DOX, on mice with MCF-7
(ErbB2-low) xenografts ( ig 4.8). Student’s t-test was run on the tumor relative volume
change data at day 16, comparing each treatment groups against 5% Dextrose control.

Figure 4.7. In vivo antitumor efficacy of Trast-NG/DOX and enhancement by concurrent
administration of 17-AAG against ErbB2-overexpressing breast cancer xenografts. BT474 xenografts were established by orthotopic injection of cells in mammary glands of
female Nude mice, and the following treatments intravenous administered after tumors
had grown between 200 and 300 mm3 in volume: Trast-NG/DOX + 17-AAG (■) or
Trast-NG/DOX (●) or IgG-NG/DOX + 17-AAG (▼) or IgG-NG/DOX (▲) or Trast
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alone (♦) or Control.. Drug formulations were injected in100 μL at a dose of 6 mg DOX
or 3 mg Trast equivalents/kg body weight 4 times at 4-day intervals as indicated by the
arrows. 17-AAG at a dose of 1mg/kg was given 2 h after NG formulation administration.
Changes in tumor volume (A) are presented as a fold-ratio compared baseline for each
animal on day 0 of treatment. Values represent mean ± SEM. Kaplan–Meier analysis of
the overall survival is shown (B). * and ** indicates a statistically significant difference
between the indicated groups. *** indicates a statistically significant difference between
Trast-NG/DOX and Trast alone.
In mice carrying BT-474 xenografts, treatment with Trast-NG/DOX alone led to a
statistically significant (p < 0.05) tumor growth inhibition when compared to the
control groups (p-value = 0.0159) (Fig. 4.7A). Sequential treatment with 17AAG led to
further enhancement of anti-tumor activity of the targeted nanoformulation, as
compared to the Trast-NG/DOX alone group. Statistical analysis confirmed that the
potentiation of the tumor inhibitory effect of Trast-NG/DOX by 17AAG was highly
significant (p = 0.0005). Remarkably, the Trast-NG/DOX + 17AAG treatment led to an
actual reduction in tumor volume (shrinkage) compared to the tumor volume at the
beginning of the treatment and is clearly observed at later time points (Fig. 4.7A).
However, the p-values (p = 0.293) between the Trast-NG/Dox vs. Trast-NG/DOX + 17AAG did not appear to reflect statistically significant differences at the given time
point.
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Figure 4.8. Relative changes in tumor volume after administration of ErbB2-targeted
Trast-NG/DOX in ErbB2 - breast cancer mice model. Trast-NG/DOX (●) or IgGNG/DOX (▲) or Control (Ø).
Compared to our results with the BT-474 xenograft model, mice bearing MCF-7
xenografts exhibited a small albeit statistically significant reduction in tumor volume
upon treatment with Trast-NG/DOX (p = 0.03 vs. control); however, the difference in
tumor volume between the IgG-NG/DOX and Trast-NG/DOX groups was not
significant (p-value = 0.397) (Fig. 4.8). Comparative analysis of BT-474 vs. MCF-7
xenografts establish the advantage of Trast-based targeting against an ErbB2+ tumor,
and clearly demonstrate the enhancement of the Trast-NG/DOX efficacy by sequential
post-treatment with a small dose (which by itself has no measurable effect on tumor
growth; not shown) of the HSP90 inhibitor 17AAG.
Kaplan-Meier analysis of survival was carried out among various treatment groups
to assess the potential survival advantage of the treatment regimen combining
17AAG and DOX-loaded NGs in the BT-474 xenograft model. The median
survival (in days), the associated Confidence Intervals and the p-values are shown
in Table 4.2.
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Table 4.2: Comparison of Median survival (in days), the associated Confidence Intervals
and the p-values (with respect to 5% Dextrose control).
Treatment
Group

Median
Survival

Confidence
Interval (days)

(days)

(Lower limit –
Upper limit)

p-values
(vs. 5%
Dextrose
control

% Survival at
censoring date
(76 days)

Saline

40

26 - NE

0

Trast

48

36 - NE

0.1794

0

IgG-NG/Dox

52

26 - NE

0.3221

0

IgG-NG/Dox +
17-AAG

40

32 - NE

0.2827

0

Trast-NG/Dox

NE

68 - NE

0.0032

56.8

Trast-NG/Dox
+ 17-AAG

NE

NE - NE

<0.0001

88.8

NE - Estimate not reached
This analysis clearly shows that, at the end of the experiment (76 days; censoring
date), the mice treated with Trast-NG/DOX + 17-AAG had a substantially longer
survival (>88%) compared to the Trast-NG/DOX group (56.8%) (Fig. 4.7 B). No mice
survived until the censoring date (0% survival) in all other treatment groups (5 %
dextrose, Trast alone, IgG-NG/DOX and IgG-NG/DOX + 17-AAG) (Fig. 4.7 B). The
data clearly indicates the superiority of Trast-NG/DOX treatment and suggests that
combined treatment with HSP90 inhibitors can vastly improve survival times.
Measurement of animal body weight during treatment with various regimens indicated
that the treatment-related toxicities associated with the administration of TrastNG/DOX or Trast-NG/DOX + 17-AAG were generally mild (<10%). In contrast, the

146

same dose of DOX or the free drug combination (DOX + 17-AAG) produced a
considerable body weight loss (18-20%, p< 0.05) (Fig. 4.9).

Figure. 4.9. Changes in body weight are presented as a fold-ratio compared baseline for
each animal on day 0 of treatment. Values represent mean ± SEM.
.Light microscopic examination of the H&E-stained tissue sections of liver, lung,
kidney, spleen and heart among the mice euthanized at the end of the experiment
showed no histopathological changes in the organs of Trast-NG/DOX or TrastNG/DOX + 17AAG treatment groups compared to the 5% dextrose control (data not
shown), confirming the relatively low toxicities of the targeted NGs.
As further evidence of enhanced antitumor activity of Trast-NG/DOX or TrastNG/DOX

administered

in

combination

with

17-AAG,

we

performed

histopathological analyses of the tumors excised post-treatment (on 2nd day after
last injection), using Ki-67 and Caspase-3 as markers for proliferation and apoptosis
respectively.
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Figure 4.10. Administration of Trast-NG/DOX reduces the cell proliferation and
promotes the apoptosis in BT-474 xenograft tumors and its activity is enhanced by
17AAG. Post-treatment tumor sections were stained for Ki-67 and caspase-3 and % Ki67-positive (A) and % caspase-3-positive (B) cells in were calculated based on
enumeration of at least 1000 cells. Tumors from three mice per group were analyzed.
Data are presented as mean ± SD (n = 5 random microscopic fields for each tumor). The
treatment groups are indicated.
As expected, treatment with Trast alone caused a significant reduction in Ki67+
cells (p = 0.0033) but little increase in caspase-3+ cells, consistent with the primarily
cytostatic effects of Trast [25, 26](Fig. 4.10). Treatment with untargeted NG (IgGNG/DOX) also reduced the percentage of Ki67+ cells (p = 0.0105) but with little
impact on caspase-3+ cells (Fig. 4.10), consistent with a cytostatic mechanism of
action of DOX [27, 28]. Notably, Trast-NG/DOX treatment led to a significant
reduction in Ki67+ cells (p = 0.0023) and an increase in caspase-3+ cells (p =
0.0059), and combined treatment with 17AAG further increased the impact on both
parameters (p = 0.0011 for Ki67+ cells and p = 0.0012 for caspase-3+ cells) (Fig.
4.10), indicating that the combination is superior and promotes substantial
cytotoxicity in addition to a pronounced cytostatic effect. 17AAG also improved the
pro-apoptotic efficacy of IgG-Trast/DOX but its impact on the anticancer activity of
Trast-NG/DOX was substantially more pronounced, especially on caspase-3 activity
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in tumors (Fig. 4.10). To mechanistically link the enhanced anti-tumor response of
Trast-NG/DOX + 17-AAG combination with the effects of 17-AAG on ErbB2, we
performed immunohistochemistry (IHC) and Western blot analyses of ErbB2 levels
in tumors of mice treated with various regimens. Indeed, lower ErbB2 levels were
seen in tumors of Trast-NG/DOX + 17-AAG treated mice (Fig. 4.11), correlating with
the superior antitumor efficacy of a combination of HSP90 inhibitor and ErbB2targeted drug-loaded NG strategy.
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Figure 4.11. ErbB2 levels analyzed in the tumor sections using A) western blot and
B) ErbB2-IHCs.
4.4. Discussion
Introduction of targeted cancer nanomedicines into clinical practice has provided
substantial momentum for the development of similar approaches against a variety of
cancers. Most nanosized therapeutic agents require internalization and traffic into acidic
endocytic compartments to ensure the delivery of drug cargo into the appropriate
subcellular target [29, 30]. While much consideration has been given to the polymer
design and the nature of drug to ensure successful delivery, the importance of the
endocytic traffic routes of cell surface receptors that provide the basis for targeting of
nanocarriers has received little attention. Here, we develop a proof-of-principle strategy,
using ErbB2 as a targeting receptor, to help facilitate the entry of a model nanogelencapsulated therapeutic agent Doxorubicin into the lysosomes of breast cancer cells by
tampering with the biological mechanism that retards the delivery of ErbB2 into
lysosomes. Our studies demonstrate the feasibility of this novel approach in achieving
superior in vitro targeting and in vivo anti-tumor efficacy in a xenograft breast cancer
model. We suggest that this approach could significantly potentiate the efficacy of
existing ErbB2-targeted nano-therapeutic agents against breast cancer. Furthermore,
adaptation of this approach to facilitate the lysosomal delivery of other receptors
currently used or considered for targeting cancer could substantially improve the efficacy
of targeted cancer nanomedicines in general.
Our choice of ErbB2 receptor for our proof-of-principle studies was based on
several key considerations: ErbB2 is the driver oncogene for over 20% of breast cancers
and smaller subsets of many other malignancies [31-33]; ErbB2 is the target of an
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clinically-approved Trastuzumab-emtansine conjugate, Kadcyla, whose conjugated
drug must be released to allow access to its cytosolic target [34]; ErbB2 is a prototype
receptor that is biologically impaired in lysosomal entry [17, 18, 33]; studies by us and
others have demonstrated that tampering with the function of a major biological partner
of ErbB2 and key to its inability to enter the lysosome, the molecular chaperone HSP90,
promotes rapid lysosomal sorting and eventual degradation of ErbB2 [17, 18, 33]. ErbB2
is constitutively associated with HSP90, and multiple lines of investigation have
demonstrated that HSP90 function is required for ErbB2 stability and ErbB2-driven
oncogenesis [35-37]. Availability of specific HSP90 inhibitors has allowed a dissection
of the mechanisms of ErbB2 instability upon HSP90 inhibition, and have revealed roles
for lysosomal degradation [17-22]. Careful cell biological studies have however revealed
the lysosomal targeting of ErbB2 upon HSP90 inhibition to be a relatively early event,
and one likely to be important for the rapid downregulation of ErbB2 from the surface of
HSP90 inhibitor-treated cancer cells [17-22]. In contrast, lysosomal delivery of ErbB2
upon the treatment of ErbB2+ cancer cell lines with Trast is distinctly slower and
incomplete [17, 19], apparently due to the maintenance of a recycling itinerary of Trastbound ErbB2 [38]. Our previous studies demonstrated that low concentrations of an
HSP90 inhibitor, 17AAG, could however promote Trast-induced lysosomal delivery of
ErbB2 and produce synergistic anti-tumor killing in vitro [19]. Indeed, Trast + 17AAG
exhibit enhanced antitumor activity in vivo [19]. However, 17AAG and other HSP90
inhibitors have been slower to be adopted clinically as they produce significant
toxicity[39-44]. The focus of such studies has been on the using of maximally-tolerated
doses of HSP90 inhibitors, even when these are combined with other therapeutic
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agents[40-43, 45-49]. Our studies help establish a new paradigm in which HSP90
inhibitors at sub-therapeutic doses can substantially improve the efficacy of a
nanoformulated therapeutic agent without significant added toxicity.
Our studies provide support for a potentially novel use of HSP90 inhibitors to
facilitate the endolysosomal delivery of ADCs or antibody-conjugated drug nanocarriers
(ANPs) that rely on targeting receptors that are HSP90 clients. A number of such targets
have been identified, including the mutant EGFR in non-small cell lung cancer [50-53], a
receptor we have shown to constitutively enter the endocytic recycling pathway [3, 53].
Similarly, glioblastoma-associated EGFR-vIII which lacks the normal EG R’s ability to
undergo ligand-triggered lysosomal traffic [54]. Recent studies also suggest that
overexpressed EGFR in gastric cancer cells is efficiently targeted by HSP90 inhibitors for
degradation [55]. Thus, our approach using low doses of an HSP90 inhibitor is likely to
be applicable to other malignancies as ADCs or ANPs against other HSP90-dependent
receptors are developed for clinical use. While our studies relied on 17AAG as an HSP90
inhibitor, a number of other HSP90 inhibitors are being evaluated in clinical trials,
including ones with oral bioavailability [42, 45, 46], and testing of such drugs in the
context of ANPs is highly desirable. Since HSP90 inhibition eventually promotes the
degradation of receptors such as ErbB2 [19, 35, 56, 57], the scheduling of the ANP and
HSP90 inhibitor is likely to be of key importance. In our studies, we considered this issue
upfront and demonstrated the ability of HSP90 inhibition to facilitate the internalization
and lysosomal targeting of Trast-NG in vitro (Fig 3). Accordingly, our preclinical therapy
was designed to administer the HSP90 inhibitor 17AAG 2h hours after the nano-therapy,
allowing time for the latter to reach its target. It remains possible that further studies to
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optimize the scheduling of the HSP90 inhibitor relative to the ANP will help improve the
efficacy of regimens targeting ErbB2 or other HSP90 client receptors.
Our studies also provide evidence that sub-therapeutic doses of an HSP90
inhibitor (1 mg/Kg 17AAG in our studies, which has little efficacy against BT-474
xenografts; unpublished data), dramatically enhances tumor killing by DOX-loaded
ErbB2-targeted NGs (Fig. 5A). Such a combination led to not just inhibition of xenograft
tumor growth but in fact a significant shrinkage of tumor masses from their pre-treatment
volume (Fig 5A). This was associated with a significant shift from a merely cytostatic to
a significantly cytotoxic effect on tumors as demonstrated by Ki67 and caspase-3 staining
of tumors among surviving mice at the end of therapy. Not surprisingly, combination
with low dose 17AAG markedly improved the survival of tumor-bearing mice (Fig. 5B).
We must point out that DOX was used in our proof-of-principle studies as the polymer
design we have previously established allows efficient loading of this clinically-used
chemotherapeutic agent [23]. However, DOX enhances cardiotoxicity associated with
ErbB2-targeted antibody therapeutics, including Trastuzumab [58-60], and as such the
approach will need modifications to incorporate more appropriate agents for ErbB2+
cancers. Such studies are currently ongoing in our laboratories. The current nanocarrier
design should however be applicable to other tumors where a targeting antibody or other
moiety is available.
Based on our studies, we suggest that the endocytic traffic itinerary of receptors
selected for targeting of ADCs and ANPs should receive careful consideration. An
understanding of mechanisms that may impair the endolysomal traffic of a targeted
receptor (as with ErbB2) may help overcome an efficacy barrier on newer agents in
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development and potentially improve the efficacy of agents already in the clinic. In this
regard, the potential combination of HSP90 inhibitors that are already in clinical trials
together with the ErbB2-targeted TDM-1 will be of considerable interest and is under
study in our group. A recently FDA-approved ADC, Brentuximab-Vedotin, targets CD30
receptor in Hodgkin’s lymphomas [61, 62] which requires lysosomal traffic for its
efficacy [63], although the mechanisms of lysosomal trafficking of CD30-bound ADC
remains unknown.
It is of interest that HSP90 is also thought to regulate the activity of Rab GTPasedependent endocytic recycling by its association with a Rab Guanine Nucleotide
Displacement Inhibitor (GDI) [64, 65], and HSP90 inhibitors could potentially help
attenuate Rab-dependent recycling of transmembrane receptors that are not direct HSP90
clients to enhance ADC or ANP delivery inside the tumor cell. Other factors that may
control trafficking of oncogenic cell-surface receptors such as the non-receptor tyrosine
kinase c-Src, endocytic adaptor proteins, E3 ubiquitin ligases, deubiquitinating enzymes,
RAB GTPases, ESCRT proteins and EHD family proteins [66, 67],[68, 69] may offer
future opportunities to develop facilitators of ADC and ANP traffic to endolysomal
compartments as approaches of therapeutic potentiation.
4.5. Conclusion. Our study demonstrates the potential of therapeutically exploiting the
vulnerabilities in cancer cell-specific trafficking behavior of receptors used to selectively
deliver nanoencapsulated therapeutic agents, and highlights the importance of identifying
such vulnerabilities in targeting receptors in order to fully realize the potential of ADCs
and targeted nanomedicines in cancer and other diseases.

154

Acknowledgements. The Core facilities used here were supported by the Nebraska
Research Initiative and the NCI Cancer Center Core Support Grant 5 P30 CA036727-24
to UNMC-Eppley Cancer Center. We thank members of the Band and Bronich
Laboratories for useful discussions.
4.6. References
1. Mehra NK, Mishra V, Jain NK. Receptor-based targeting of therapeutics. Ther Deliv
2013;4(3):369-94.
2. Mathew J, Perez EA. Trastuzumab emtansine in human epidermal growth factor
receptor 2- positive breast cancer: a review. Curr Opin Oncol 2011;23(6):594-600.
3. Chung BM, Tom E, Zutshi N, Bielecki TA, Band V, Band H. Nexus of signaling and
endocytosis in oncogenesis driven by non-small cell lung cancer-associated epidermal
growth factor receptor mutants. World J Clin Oncol 2014;5(5):806.
4. Molfetta R, Quatrini L, Gasparrini F, Zitti B, Santoni A, Paolini R. Regulation of Fc
receptor endocytic trafficking by ubiquitination. Front Immunol 2014;5.
5. Piper RC, Lehner PJ. Endosomal transport via ubiquitination. Trends Cell Biol
2011;21(11):647-55.
6. Sorkin A, Goh LK. Endocytosis and intracellular trafficking of ErbBs. Exp Cell Res
2009;315(4):683-96.
7. Marmor MD, Yarden Y. Role of protein ubiquitylation in regulating endocytosis of
receptor tyrosine kinases. Oncogene 2004;23(11):2057-70.
8. Wright MH, Berlin I, Nash PD. Regulation of endocytic sorting by ESCRT–DUBmediated deubiquitination. Cell Biochem Biophys 2011;60(1-2):39-46.
9. Tu C, Ahmad G, Mohapatra B, Bhattacharyya S, Ortega-Cava C, Chung BM, et al.
ESCRT proteins: Double-edged regulators of cellular signaling. Bioarchitecture
2011;1(1):45-48.
10. Raiborg C, Stenmark H. The ESCRT machinery in endosomal sorting of
ubiquitylated membrane proteins. Nature 2009;458(7237):445-52.
11. Mellman I, Yarden Y. Endocytosis and cancer. Cold Spring Harb Perspect Biol
2013;5(12):a016949.
12. Hendriks BS, Klinz SG, Reynolds JG, Espelin CW, Gaddy DF, Wickham TJ. Impact
of tumor HER2/ERBB2 expression level on HER2-targeted liposomal doxorubicinmediated drug delivery: multiple low-affinity interactions lead to a threshold effect. Mol
Cancer Ther 2013;12(9):1816-28.
13. Yousefpour P, Atyabi F, Farahani EV, Sakhtianchi R, Dinarvand R. Polyanionic
carbohydrate doxorubicin-dextran nanocomplex as a delivery system for anticancer
drugs: in vitro analysis and evaluations. Int J Nanomedicine 2011;6:1487-96.
14. Inoue S, Ding H, Portilla-Arias J, Hu J, Konda B, Fujita M, et al. Polymalic Acid–
Based Nanobiopolymer Provides Efficient Systemic Breast Cancer Treatment by
Inhibiting both
HER2/neu Receptor Synthesis and Activity. Cancer Res
2011;71(4):1454-64.

155

15. Miyano T, Wijagkanalan W, Kawakami S, Yamashita F, Hashida M. Anionic Amino
Acid Dendrimer− Trastuzumab Conjugates for Specific Internalization in HER2-Positive
Cancer Cells. Mol Pharm 2010;7(4):1318-27.
16. Baulida J, Kraus MH, Alimandi M, Di Fiore PP, Carpenter G. All ErbB receptors
other than the epidermal growth factor receptor are endocytosis impaired. J Biol Chem
1996;271(9):5251-57.
17. Austin CD, De Mazière AM, Pisacane PI, van Dijk SM, Eigenbrot C, Sliwkowski
MX, et al. Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics
trastuzumab and geldanamycin. Mol Biol Cell 2004;15(12):5268-82.
18. Cortese K, Howes MT, Lundmark R, Tagliatti E, Bagnato P, Petrelli A, et al. The
HSP90 inhibitor geldanamycin perturbs endosomal structure and drives recycling ErbB2
and transferrin to modified MVBs/lysosomal compartments. Mol Biol Cell
2013;24(2):129-44.
19. Raja SM, Clubb RJ, Bhattacharyya M, Dimri M, Cheng H, Pan W, et al. A
combination of trastuzumab and 17-AAG induces enhanced ubiquitinylation and
lysosomal pathway-dependent ErbB2 degradation and cytotoxicity in ErbB2overexpressing breast cancer cells. Cancer Biol Ther 2008;7(10):1630-40.
20. Marx C, Held JM, Gibson BW, Benz CC. ErbB2 trafficking and degradation
associated with K48 and K63 polyubiquitination. Cancer Res 2010;70(9):3709-17.
21. Bailey TA, Luan H, Tom E, Bielecki TA, Mohapatra B, Ahmad G, et al. A kinase
inhibitor screen reveals protein kinase c-dependent endocytic recycling of erbb2 in breast
cancer cells. J Biol Chem 2014;289(44):30443-58.
22. Lerdrup M, Hommelgaard AM, Grandal M, van Deurs B. Geldanamycin stimulates
internalization of ErbB2 in a proteasome-dependent way. J Cell Sci 2006;119(1):85-95.
23. Kim JO, Nukolova NV, Oberoi HS, Kabanov AV, Bronich TK. Block ionomer
complex micelles with cross-linked cores for drug delivery. Polym Sci Ser A
2009;51(6):708-18.
24. Kim JO, Kabanov AV, Bronich TK. Polymer micelles with cross-linked polyanion
core for delivery of a cationic drug doxorubicin. J Control Release 2009;138(3):197-204.
25. Raja SM, Clubb RJ, Ortega-Cava C, Williams SH, Bailey TA, Duan L, et al.
Anticancer activity of Celastrol in combination with ErbB2-targeted therapeutics for
treatment of ErbB2-overexpressing breast cancers. Cancer Biol Ther 2011;11(2):263-76.
26. Band V, Zajchowski D, Swisshelm K, Trask D, Kulesa V, Cohen C, et al. Tumor
progression in four mammary epithelial cell lines derived from the same patient. Cancer
Res 1990;50(22):7351-57.
27. Baselga J, Albanell J, Molina MA, Arribas J. Mechanism of action of trastuzumab
and scientific update. Semin Oncol 2001. Elsevier. p 4-11.
28. Albanell J, Codony J, Rovira A, Mellado B, Gascón P. Mechanism of action of antiHER2 monoclonal antibodies: scientific update on trastuzumab and 2C4. New Trends in
Cancer for the 21st Century: Springer; 2003. p 253-68.
29. Fornari FA, Jarvis WD, Grant S, Orr MS, Randolph JK, White FK, et al. Growth
arrest and non-apoptotic cell death associated with the suppression of c-myc expression
in MCF-7 breast tumor cells following acute exposure to doxorubicin. Biochem
Pharmacol 1996;51(7):931-40.
30. Konopa J. G 2 block induced by DNA crosslinking agents and its possible
consequences. Biochem Pharmacol 1988;37(12):2303-09.

156

31. Sahay G, Alakhova DY, Kabanov AV. Endocytosis of nanomedicines. J Control
Release 2010;145(3):182-95.
32. Sahay G, Querbes W, Alabi C, Eltoukhy A, Sarkar S, Zurenko C, et al. Efficiency of
siRNA delivery by lipid nanoparticles is limited by endocytic recycling. Nat Biotechnol
2013;31(7):653-58.
33. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular
portraits of human breast tumours. Nature 2000;406(6797):747-52.
34. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene
expression patterns of breast carcinomas distinguish tumor subclasses with clinical
implications. Proc Natl Acad Sci USA 2001;98(19):10869-74.
35. Roepstorff K, Grøvdal L, Grandal M, Lerdrup M, van Deurs B. Endocytic
downregulation of ErbB receptors: mechanisms and relevance in cancer. Histochem Cell
Biol 2008;129(5):563-78.
36. Phillips GDL, Li G, Dugger DL, Crocker LM, Parsons KL, Mai E, et al. Targeting
HER2-positive breast cancer with trastuzumab-DM1, an antibody–cytotoxic drug
conjugate. Cancer Res 2008;68(22):9280-90.
37. Zhou P, Fernandes N, Dodge IL, Reddi AL, Rao N, Safran H, et al. ErbB2
degradation mediated by the co-chaperone protein CHIP. J Biol Chem
2003;278(16):13829-37.
38. Xu W, Mimnaugh EG, Kim J-S, Trepel JB, Neckers LM. Hsp90, not Grp94, regulates
the intracellular trafficking and stability of nascent ErbB2. Cell Stress Chaperones
2002;7(1):91.
39. Citri A, Kochupurakkal BS, Yarden Y. The achilles heel of ErbB-2/HER2: regulation
by the Hsp90 chaperone machine and potential for pharmacological intervention. Cell
Cycle 2004;3(1):50-59.
40. LoRusso PM, Weiss D, Guardino E, Girish S, Sliwkowski MX. Trastuzumab
emtansine: a unique antibody-drug conjugate in development for human epidermal
growth factor receptor 2–positive cancer. Clin Cancer Res 2011;17(20):6437-47.
41. Arteaga CL. Why is this effective HSP90 inhibitor not being developed in HER2+
breast cancer? Clin Cancer Res 2011;17(15):4919-21.
42. Modi S, Stopeck A, Linden H, Solit D, Chandarlapaty S, Rosen N, et al. HSP90
inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus
trastuzumab in patients with HER2-positive metastatic breast cancer progressing on
trastuzumab. Clinl Cancer Res 2011;17(15):5132-39.
43. Johnson ML, Helena AY, Hart EM, Weitner BB, Rademaker AW, Patel JD, et al.
Phase I/II Study of HSP90 Inhibitor AUY922 and Erlotinib for EGFR-Mutant Lung
Cancer With Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase
Inhibitors. J Clin Oncol 2015:JCO. 2014.59. 7328.
44. Spreafico A, Delord J, De Mattos-Arruda L, Berge Y, Rodon J, Cottura E, et al. A
first-in-human phase I, dose-escalation, multicentre study of HSP990 administered orally
in adult patients with advanced solid malignancies. Br J Cancer 2015.
45. Modi S, Saura C, Henderson C, Lin NU, Mahtani R, Goddard J, et al. A multicenter
trial evaluating retaspimycin HCL (IPI-504) plus trastuzumab in patients with advanced
or metastatic HER2-positive breast cancer. Breast Cancer Res Treat 2013;139(1):107-13.
46. Pacey S, Banerj U, Judson I, Workman P. Hsp90 inhibitors in the clinic. Molecular
Chaperones in Health and Disease: Springer; 2006. p 331-58.

157

47. Infante JR, Weiss GJ, Jones S, Tibes R, Bauer TM, Bendell JC, et al. Phase I doseescalation studies of SNX-5422, an orally bioavailable heat shock protein 90 inhibitor, in
patients with refractory solid tumours. Eur J Cancer 2014;50(17):2897-904.
48. Saif MW, Takimoto C, Mita M, Banerji U, Lamanna N, Castro J, et al. A phase 1,
dose-escalation, pharmacokinetic and pharmacodynamic study of BIIB021 administered
orally in patients with advanced solid tumors. Clin Cancer Res 2014;20(2):445-55.
49.
Nowakowski GS, McCollum AK, Ames MM, Mandrekar SJ, Reid JM, Adjei AA,
et al. A phase I trial of twice-weekly 17-allylamino-demethoxy-geldanamycin in patients
with advanced cancer. Clin Cancer Res 2006;12(20):6087-93.
50. Heath EI, Hillman DW, Vaishampayan U, Sheng S, Sarkar F, Harper F, et al. A phase
II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory
metastatic prostate cancer. Clin Cancer Res 2008;14(23):7940-46.
51. Oh WK, Galsky MD, Stadler WM, Srinivas S, Chu F, Bubley G, et al. Multicenter
phase II trial of the heat shock protein 90 inhibitor, retaspimycin hydrochloride (IPI-504),
in patients with castration-resistant prostate cancer. Urology 2011;78(3):626-30.
52. Garon EB, Finn RS, Hamidi H, Dering J, Pitts S, Kamranpour N, et al. The HSP90
inhibitor NVP-AUY922 potently inhibits non–small cell lung cancer growth. Mol Cancer
Ther 2013;12(6):890-900.
53. Shimamura T, Lowell AM, Engelman JA, Shapiro GI. Epidermal growth factor
receptors harboring kinase domain mutations associate with the heat shock protein 90
chaperone and are destabilized following exposure to geldanamycins. Cancer Res
2005;65(14):6401-08.
54. Yang J, Mani SA, Weinberg RA. Exploring a new twist on tumor metastasis. Cancer
Res 2006;66(9):4549-52.
55. Chung BM, Raja SM, Clubb RJ, Tu C, George M, Band V, et al. Aberrant trafficking
of NSCLC-associated EGFR mutants through the endocytic recycling pathway promotes
interaction with Src@. BMC Cell Biol 2009;10(1):84.
56. Grandal MV, Zandi R, Pedersen MW, Willumsen BM, van Deurs B, Poulsen HS.
EGFRvIII escapes down-regulation due to impaired internalization and sorting to
lysosomes. Carcinogenesis 2007;28(7):1408-17.
57. Liu H, Lu J, Hua Y, Zhang P, Liang Z, Ruan L, et al. Targeting heat-shock protein 90
with ganetespib for molecularly targeted therapy of gastric cancer. Cell Death Dis
2015;6(1):e1595.
58. Solit DB, Zheng FF, Drobnjak M, Münster PN, Higgins B, Verbel D, et al. 17Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor
and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin Cancer Res
2002;8(5):986-93.
59. Tikhomirov O, Carpenter G. Geldanamycin induces ErbB-2 degradation by
proteolytic fragmentation. J Biol Chem 2000;275(34):26625-31.
60. Gianni L, Salvatorelli E, Minotti G. Anthracycline cardiotoxicity in breast cancer
patients: synergism with trastuzumab and taxanes. Cardiovasc Toxicol 2007;7(2):67-71.
61. Feldman AM, Lorell BH, Reis SE. Trastuzumab in the Treatment of Metastatic
Breast Cancer Anticancer Therapy Versus Cardiotoxicity. Circulation 2000;102(3):27274.

158

62. Seidman A, Hudis C, Pierri MK, Shak S, Paton V, Ashby M, et al. Cardiac
dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002;20(5):121521.
63. van de Donk NW, Dhimolea E. Brentuximab vedotin. 2012. Taylor & Francis. p 45865.
64. Muta H, Podack ER. CD30: from basic research to cancer therapy. Immunol Res
2013;57(1-3):151-58.
65. Sutherland MSK, Sanderson RJ, Gordon KA, Andreyka J, Cerveny CG, Yu C, et al.
Lysosomal trafficking and cysteine protease metabolism confer target-specific
cytotoxicity by peptide-linked anti-CD30-auristatin conjugates. J Biol Chem
2006;281(15):10540-47.
66. Sakisaka T, Meerlo T, Matteson J, Plutner H, Balch WE. Rab‐αGDI activity is
regulated by a Hsp90 chaperone complex. EMBO J 2002;21(22):6125-35.
67. Chen CY, Sakisaka T, Balch WE. Use of Hsp90 Inhibitors to Disrupt GDI‐Dependent
Rab Recycling. Methods Enzymol 2005;403:339-47.
68. Sandilands E, Frame MC. Endosomal trafficking of Src tyrosine kinase. Trends Cell
Biol 2008;18(7):322-29.
69. Reiter E, Lefkowitz RJ. GRKs and β-arrestins: roles in receptor silencing, trafficking
and signaling. Trends Endocrinol Metab 2006;17(4):159-65.
70. George M, Ying G, Rainey MA, Solomon A, Parikh PT, Gao Q, et al. Shared as well
as distinct roles of EHD proteins revealed by biochemical and functional comparisons in
mammalian cells and C. elegans. BMC Cell Biol 2007;8(1):3.
71. Naslavsky N, Caplan S. EHD proteins: key conductors of endocytic transport. Trends
Cell Biol 2011;21(2):122-31.

159

CHAPTER V

POLYPEPTIDE-BASED NANOGELS CO-ENCAPSULATING A SYNERGISTIC
COMBINATION OF DOXORUBICIN WITH 17-AAG SHOW POTENT ANTITUMOR ACTIVITY IN ErbB2-DRIVEN BREAST CANCER MODELS2
5.1. Introduction:
The receptor tyrosine kinase ErbB2 (also known as Her2/Neu) is overexpressed in
20-25 % of breast cancer patients [1-5]. Oncogenic ErbB2 signaling results in
hyperproliferation of the cells, increases cell survival and promotes invasion and
metastasis [6, 7]. The anti-ErbB2 monoclonal antibody, Trastuzumab (Herceptin™)[8], in
combination with chemotherapy is currently used for treatment of ErbB2-overexpressing
breast cancers, following surgical removal of the primary tumor [5, 8, 9]. However, many
patients either do not respond to Trastuzumab-based therapies or relapse during the
course of the treatment, necessitating the development of newer therapeutics [8]. ErbB2
depends on heat shock protein 90 (HSP90) association for stability and, among client
proteins of the chaperone, ErbB2 is perhaps the most sensitive to HSP90 inhibition [10].
HSP90 inhibitors (such as the ansamycin antibiotic, Geldanamycin and related molecules
like 17-AAG) have shown significant promise in pre-clinical models of ErbB2-driven
breast cancer as well as initial phase I/II clinical trials [11-13]. The mechanism involves
attenuation of oncogenic signaling via degradation of ErbB2 as well as other critical
downstream signaling mediators in the pathway, which include phospho-Akt and c-Raf.
2

Reproduced with permission from Desale SS, et al. "Polypeptide-based nanogels co-encapsulating a
synergistic combination of doxorubicin with 17-AAG show potent anti-tumor activity in ErbB2-driven
breast cancer models." J Control Release 208 (2015): 59-66.Copyright 2015 Elsevier B.V.
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In a cancer cell, these signaling molecules are strongly dependent on HSP90 to maintain
their stability [14-16]. Since numerous oncoproteins have been identified as HSP90
clients,

inhibition of Hsp90

functions

affects

multiple

oncogenic

substrates

simultaneously and represents an appealing molecular target for combination drug
therapy [17]. In a recently completed phase II study of 17-AAG and trastuzumab, an
overall clinical benefit (including stable disease) was seen in 57% of the patients with
ErbB2-positive metastatic breast cancer progressing on trastuzumab [13]. It has also
been reported that inhibition of Hsp90 with 17-AAG sensitizes different cancer cell lines
to DNA damage response mediated cellular senescence [18]. It was shown that the
17AAG pre-treatment followed by doxorubicin (DOX) treatment exhibited senescencelike characteristics such as increased nucleus to cytoplasm ratio and cell cycle arrest in
the pre-clinical evaluation [18-20]. These data suggest that combination chemotherapy
using co-administration of 17-AAG with a DOX-based regimen can be a potential
therapy for cancer especially ErbB2-positive breast cancer [18].
Combining drugs in one delivery carrier is a well-suited strategy for controlling
the pharmacokinetics and co-delivery of the desired drug ratio in vivo [21, 22]. The drug
loading and structure of such carriers can be tuned to control the drug release rates,
maximize the therapeutic potency and minimize drug-associated toxicities. However, coincorporation of drug molecules with different physicochemical properties, such as
hydrophilic DOX and hydrophobic 17-AAG, has been challenging. We have recently
described biodegradable polymeric nanogels (NGs) based on poly(ethylene glycol)-bpoly(L-glutamic acid) (PEG-b-PGlu) with pendant phenylalnine functionalities [23].
Such NGs have multiple hydrophobic domains formed by phenylalanine moieties within
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the cross-linked PGlu polyion cores surrounded by a hydrophilic PEG shell. Herein, we
explored these novel NGs for co-encapsulation of 17-AAG and DOX. The potency of this
co-delivery system was evaluated in a panel of human breast cancer lines and in an
ErbB2-driven orthotopic xenograft model. We demonstrate that NGs-based co-delivery
of synergistic combination of 17-AAG and DOX exhibited superior antitumor efficacy
compared to a combination of free drugs. The implications of our results may support a
new platform for delivery of combinations of HSP90 inhibitors with cytotoxic agents for
treatment of various types of cancers.
5.2. Materials and Methods
5.2.1 Materials
Poly(ethylene glycol)-b-poly(L-glutamic acid) (PEG-b-PGlu) diblock copolymer (Mw/Mn
= 1.38, MW 27,500) was purchased from Alamanda Polymers, Inc (Madison, AL, USA).
The block lengths were 114 and 150 repeating units for PEG and PGlu, respectively. Lphenylalanine

methyl

ester

(PME),

dimethylaminopropyl)-3-ethylcarbodiimide

calcium

chloride,

hydrochloride

cystamine,

1-(3-

(EDC)

and

ethylenediaminetetraacetic acid (EDTA) were obtained from Sigma-Aldrich (St Louis,
MO). Doxorubicin hydrochloride was kindly provided by Dong-A Pharmaceutical
Company, South Korea. Fetal bovine serum (FBS) (both dialyzed and heat inactivated),
DMEM and RPMI 1640 media and LysotrackerTM (green) were purchased from
Invitrogen Inc (Carlsbad, CA). Bovine serum albumin (BSA) and NUNC TM chambered
glass coverslips for live cell imaging were purchased from Fisher Scientific (Waltham,
MA). MTT reagent (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) was
purchased from Research Products International (Prospect, IL). All other chemicals were
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of reagent grade and used without further purification. The following primary antibodies
were used in this study: anti-human-ErbB2 mouse monoclonal (ErbB2) raised against the
C-terminal amino acid residues (1242-1255), used for Western blotting studies, were
purchased from BD Pharmingen™ (San Diego, CA); for flow cytometry and
immunofluorescence studies, the goat anti-human-ErbB2 polyclonal antibody (AF1129)
was from R&D Systems (Minneapolis, MN); the mouse monoclonal antiphosphotyrosine (anti-pY; 4G10) was kindly provided by Dr. Brian Druker (Oregon
Health & Science University, Portland, OR); the mouse monoclonal anti-Hsc70 antibody
was from Santa Cruz Biotechnology Inc. (Santa Cruz, CA).
5.2.2 Synthesis of nanogels
The hydrophobic phenylalanine functionalities were introduced in PEG-b-PGA
copolymer by polymer-analogous modification of the PGA segment with PME using
carbodiimide chemistry as we previously described [23]. The degree of PME grafting in
resulting PEG-b-PPGlu copolymer was 30% as determined by 1H-NMR analysis.
Nanogels were prepared as described earlier [23] by using block ionomer complex PEGb-PPGA/Ca2+ at a molar ratio of [Ca2+]/[COO−] = 1.5 with further cross-linking by
cystamine and EDC ([EDC]/[cystamine] = 2; [COOH]/[EDC] = 5) at r.t., overnight.
Byproducts of the cross-linking reaction and metal ions were removed by exhaustive
dialysis of the reaction mixtures, first against 0.5% aqueous ammonia with EDTA and
then against distilled water.
5.2.3 Drug loading
Dox-encapsulated nanogels (DOX/NG) were prepared by adding Dox to an aqueous
dispersion of NGs at the feeding ratio of R= [DOX]/[COO-] = 0.25, for 24h at pH 7.0.
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Unbound Dox was separated by centrifugal filtration on drug-pretreated Amicon YM-30
filters. 17-AAG was solubilized into the hydrophobic domains of NGs using an
extraction method [24]. According to this method, a thin film of 17-AAG (prepared by
evaporation of a methanol solution of 17-AAG) was incubated with aqueous dispersion
of NGs or DOX/NG (24 h, r.t.). Unincorporated 17-AAG was removed by filtration. Dox
was assayed by UV spectrophotometry (ε488 = 11,500 M-1 cm-1 in water) [25]. The
amount of 17-AAG incorporated into NGs was quantified via reverse-phase HPLC using
an Agilent Eclipse XDB C18 5 μm column (250 mm × 4.6mm) and Agilent 1200 HPLC
system. Mobile phase was composed of 10 mM ammonium acetate containing 0.1% (v/v)
acetic acid (pH 4.8) and 50% acetonitrile and was applied at a flow rate of 1 mL/min.
Detection wavelength was 334 nm. Drug loading capacity was calculated as percent ratio
of mass of incorporated drug to total mass of drug-loaded NGs without water.
5.2.4 Physicochemical characterization of the NGs.
The effective hydrodynamic diameter (Deff) and -potential of NGs were determined using
a Malvern Zetasizer (Malvern Instruments Ltd., Malvern, UK). All measurements were
performed in automatic mode at 25C. Software provided by the manufacturer was used to
calculate size, polydispersity indices and -potential of NGs. All measurements were
performed at least in triplicate to calculate the mean values ± SD.
5.2.5 Drug release studies.
Drug release from NGs was examined in PBS (pH 7.4, 0.14M NaCl) by dialysis method
using a membrane with 3500 Da cutoff. The concentrations of 17-AAG and Dox released
were determined by HPLC and UV spectrophotometry, respectively, and expressed as a
percentage of the total 17-AAG or Dox available vs. time.
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5.2.6 Cell culture.
The ErbB2-overexpressing cell lines used in this study were 21MT-1 and BT-474. MCF7 cells were used as a representative ErbB2-low cell line for comparison. The ErbB2overexpressing breast cancer cell line 21MT-1 was established by Band et al [26] and has
been previously described. BT-474 and MCF-7 cell lines were obtained from the
American Type Culture Collection (ATCC). All cell lines were maintained as previously
described [27, 28].
5.2.7 Confocal microscopy on live cells.
Cellular uptake and localization studies of (DOX+17-AAG)/NG were conducted using
live cell confocal microscope (Carl Zeiss LSM 510 Meta, Peabody, MA). 21MT-1 human
breast cancer cells (1×106/chamber) were grown in live cell chambers (Fischer Scientific,
Waltham, MA) for two days (37oC, 5% CO2) and exposed to (DOX+17-AAG)/NG for 30
min followed by incubation with Lysotracker Green for 5 min. After exposure cells were
washed with PBS and kept in complete media prior to visualization by live cell confocal
imaging (Carl Zeiss LSM 510 Meta, Peabody, MA).
5.2.8 ErbB2 degradation.
ErbB2-overexpressing cells plated in 6-well plates were treated with free 17-AAG or the
drug-loaded NG formulations, following which the samples were lysed using RIPA lysis
buffer, supplemented with protease and phosphatase inhibitors. Analysis of the kinetics
and dose-response of ErbB2 degradation induced by free 17-AAG or 17-AAG/NG
formulations were done using SDS-PAGE/WB [27, 28].
5.2.9 In vitro cytotoxicity studies.
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Cytotoxicity of drug-loaded NGs was assessed in 21MT-1, BT-474, and MCF-7 cells by
a standard MTT assay [29]. Briefly, cells were seeded in 96-well plates (5,000 cells/well)
and allowed to adhere for 24 h prior to the assay. Cells were exposed to various
concentrations of free drugs (0 - 10 μg/mL Dox or 0 - 17.2 µM 17-AAG), drug-loaded
NGs for 48 h at 37 °C. Cells were then washed with PBS and MTT indicator dye (25 μL,
5 mg/mL) was added to each well and the cells were incubated for 2 h at 37°C in the
dark. A solution of 50% DMF-20% SDS (100 μL) was added to each well and kept
overnight at 37 °C. Absorbance was read at 570 nm using a plate reader (SpectraMax
M5, Molecular Devices Co., USA). Cell survival rates were calculated as normalized to
control untreated wells. All measurements were taken eight times. Based on the results of
the test, the IC50 values and synergic effects of DOX and 17-AAG in these cells were
calculated by using CampuSyn Software (Combosyn, USA). Combination index (CI)
values less than 1 indicate synergism while CI values equal or more than 1 represent
additive and antagonistic effects of drug combination, respectively.
5.2.10 Animal Studies.
All animal studies were conducted in accordance with an approved protocol by the
University of Nebraska Medical Center Institutional Animal Care and Use Committee
(IACUC). 107 BT-474 cells (an ErbB2 overexpressing human breast cancer cell line)
reconstituted in 50% Matrigel (BD Biosciences, California) in media were injected
directly into the mammary fat pad of 4-6 week old female Athymic NCr-nu/nu mice
(NCI, Fredrick National Lab, Fredrick, MD). 17--Estradiol pellets (0.72mg/pellet; 60
day release; Innovative Research of America, Sarasota, Fl) were implanted
subcutaneously on the lateral side of the neck of the mice three days prior to the injection
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of the tumor cells. The mice were randomized when the average tumor size reached 100200 mm3 (14 days after tumor inoculation) into treatment groups (n = 10), and treated
with DOX/NG or 17-AAG/NG or (DOX+17-AAG)/NG or combination of free Dox and
17-AAG in the same ratio as in (DOX+17-AAG)/NG at an equivalent dose of 6 mg/kg
DOX, or 1 mg/kg 17-AAG or (6 mg/kg DOX + 1 mg/kg 17-AAG) or 5% dextrose
solution. 17-AAG was formulated in Chemophor-EL : propylene glycol : ethanol (2:3:5
by volume) mixture for injections as a component of the free drug combination.
Treatments were administered via tail vein injections at 4-day intervals. Animal body
weight and tumor volume were monitored every second day. Tumor volume (V = 0.5 x L
x W2) was estimated by measuring two orthogonal diameters (longer dimension: L, and
smaller dimension: W) of the tumor using electronic calipers. The T/C values were
determined from changes in average tumor volumes of drug-treated groups relative to
control group. Animals were sacrificed when tumor volume exceeded 3000 mm3, greatest
tumor dimension exceeded 20 mm, tumor became necrotic, or animal exhibited a body
weight loss of more than 20%. All other animals were sacrificed by day 23.
5.2.11 Cell proliferation assay.
Tumors from mice that received different treatments were excised at day 14 (3 mice per
group). The tumors were dissected and fixed in 10% neutral buffered formalin. Then, the
tissues were processed routinely into paraffin, sectioned at a thickness of 4 μm.
Proliferation was detected using an antibody against Ki-67 (Biocare medical, CA)
followed by visualization by incubation with DAB+ (brown, for Ki-67) for 2 min. After
rinsing with distilled water, the sections were counterstained with hematoxylin. For
quantification of Ki-67 expression, the number of Ki-67 positive cells was determined
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(Image J) in 5 random high power fields (20X magnification) and divided by the total
number of cells for each field of slice.
5.2.12 Histopathology analysis.
Specific tissues (liver, spleen, heart kidney and lung) were fixed in buffered formalin and
were sectioned, inserted into tissue cassettes, dehydrated in 70% ethanol overnight, and
paraffin embedded (UNMC Tissue Sciences acility, Omaha, NE). Serial 5 μm sections
were stained with hematoxylin and eosin (H&E). For histopathological diagnosis, H&Estained slides were examined by light microscopy.
5.2.13 Statistical analysis.
Statistical comparisons for in vitro studies were carried out using Student t-test. For the
antitumor study and toxicity studies, group means for tumor volume and body weights
were evaluated using repeated measures analysis of variance. Survival was estimated
using Kaplan–Meier analysis and compared using log-rank test. P values less than 0.05
were considered significant. Analysis of variance and Kaplan–Meier analysis with logrank test were performed using GraphPad Prism 5 (GraphPad Software, Inc.).
5.3. Results and Discussion
5.3.1 Preparation and characterization of nanogels co-encapsulating 17-AAG and
Dox
PEG-b-PGlu diblock copolymer, in which about 30% of GA units were modified
with hydrophobic phenylalanine moieties, were utilized for the synthesis of
biodegradable NGs. NGs were prepared as previously described by template-assisted
method involving condensation of these hydrophobically-modified block copolymers by
Ca2+ ions into polyion complex micelles, followed by chemical cross-linking of the
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polyion chains in their cores [23]. A cleavable diamine crosslinker, cystamine, was used
for synthesis of the NGs with targeted density of cross-links of 20% (based on the molar
ratio of cross-linker to carboxylic acid groups of the Glu residues). The resulting coreshell NGs displayed an effective diameter of about 80 nm (ζ-potential = −45 mV) and
were uniform (monomodal, narrow size distribution) as determined by dynamic light
scattering (DLS). We have previously shown that water-soluble anticancer drugs such as
DOX or cisplatin can be encapsulated with high loading efficiency into NGs ionic cores
through electrostatic or coordination interactions [23, 30]. In addition, it was
demonstrated that hydrophobic domains formed by phenylalanine moieties within the
ionic cores of NGs could solubilize hydrophobic molecules and, therefore, such hybrid
NGs provide unique opportunities for combinational drug delivery especially for the
drugs that possess different solubility.
It has been reported that HSP90 inhibitors including 17-AAG show additive or
synergistic activities with agents commonly used to treat advanced malignancies [31-35].
Particularly,

it

was demonstrated that

17-AAG synergistically enhances the

antiproliferative effect of DOX chemotherapy. The mechanism of synergy is thought to
involve 17-AAG-mediated degradation of many of the proteins required for DNAdamage response (such as ATM/ATR or Chk1 kinase), the activities of which are
dependent on HSP90 chaperoning function [36]. Additionally, in the case of ErbB2driven cancers, given the ability of 17-AAG to attenuate hyperactive ErbB2 signaling
(which is known to be involved in transcriptional upregulation of genes encoding DNAdamage repair enzymes) [37], it can potentially enhance the cytotoxic effect of DOXinduced DNA damage. Based on these considerations, we attempted to encapsulate both
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hydrophilic DOX and hydrophobic 17-AAG into NGs with hydrophobically modified
ionic cores. At first, DOX was incubated with aqueous dispersion of NGs for 24 h at pH
7.0. As expected, the net negative charge and particle size of Dox-loaded NGs (Dox/NG)
decreased upon DOX loading due to progressive neutralization and condensation of the
PGA segments upon DOX binding to carboxylate groups (Table 5.1).
Table 5.1. Physicochemical characterization of NGs before and after drug loading a
Formulation

Deff (nm)

PDI

ζ-potential
(mV)

LC (% w/w)b
Dox

17-AAG

Empty NG

82 ± 1

0.18

-45.0 ± 5.2

-

-

DOX/NG

69 ± 2

0.20

-19.1 ± 1.5

18.1

-

17-AAG/NG

95 ± 1

0.17

-25.7 ± 1.7

-

2.7

(DOX+17-AAG)/NG

63 ± 5

0.16

-21.5 ± 0.47

18.1

3.1

Effective diameter (Deff), polydispersity index (PDI) and ζ-potential were determined in water
(pH 6.5).
b
Dox and 17-AAG content were determined by UV and HPLC, respectively.
Loading capacity (LC) is expressed as mass of incorporated drug per mass of
drug-loaded nanogels (w/w).
a

Under these conditions DOX loading capacity of NGs was about 18% w/w as measured
by UV-Vis spectroscopy. Binary drug formulation, (DOX+17-AAG)/NG, was prepared
by solubilization of 17-AAG into DOX/NG using an extraction method. A similar
procedure was used to prepare single 17-AAG/NG formulations. 17-AAG content was
determined by HPLC. Comparable loading capacity values for 17-AAG were achieved
for NGs with binary drug combination (3.1%) and for single 17-AAG/NG (2.7%). A total
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loading capacity of NGs for the binary drug combination was about 21% w/w and
corresponds to 6:1 DOX/17-AAG molar ratio. The physicochemical characteristics of
drug-loaded NGs are presented in Table 1. The size and ζ-potential of the (DOX+17AAG)/NG were comparable to those of DOX/NG indicating that an inclusion of 17-AAG
into the NG cores did not affect the macroscopic characteristics of DOX-loaded NGs.
Importantly, single and binary drug formulations exhibited excellent stability in aqueous
dispersions: no changes in sizes and loading capacities were observed for at least two
months.
The release profile of the encapsulated drug from the nanocarrier is crucial for the
synergy of the drugs [20]. Profound synergistic effects were observed when 17-AAG was
administered prior to DOX while the sequence of DOX before 17-AAG had less
cytotoxic activity in vitro [20, 34]. Figure 5.1 shows the cumulative release profiles of
DOX and 17-AAG from the NGs at physiological pH and temperature.

Figure 5.1. Drug release profiles from single drug-loaded NGs (solid line) and binary drug
combination-loaded NGs (dotted line) for DOX (●) and 17-AAG (■) in PBS buffer, pH 7.4. The
loading amount of DOX for each sample is 200 μg. The data represent averaged values and
standard deviations calculated based on three independent experiments.

As seen from these data, sustained but temporally distinct release of DOX and 17-AAG
was observed. For example, during 12 hrs (DOX+17-AAG)/NG released ~ 90% of
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loaded 17-AAG and only ~ 17% of loaded DOX. Notably, 17-AAG release was much
faster than that of DOX, which is expected since 17-AAG is physically entrapped into the
hydrophobic domains in the cores of NGs. In contrast, DOX binds with PGlu chains
through electrostatic and van der Waals interactions and its release usually proceeds via
ion exchange reactions, thus delaying its liberation from the NGs. Furthermore,
intermolecular interactions between the anthraquinone moiety of DOX and phenylalanine
hydrophobic domains of NGs in combination with more compact cross-linked core [23]
could account for the delayed and controlled release of DOX from the NGs. It is also
interesting that the individual drug release rates practically did not change for binary drug
formulations compared to the single drug-loaded NGs (Fig. 5.1).
5.2.2 Intracellular uptake of drug-loaded NGs.
NG-based drug-carriers (made of biodegradable materials) are designed to be
internalized by cancer cells via the endocytic pathway and disintegrate under lysosomal
pH and reducing environment, to release the anticancer drugs into the cytosol. It was
important to confirm that the (DOX+17-AAG)/NG uptake into the cells was indeed a
result of internalization of intact drug-loaded NGs and subsequent drug release. We
therefore compared the kinetics of uptake of free DOX or DOX/NG into 21MT-1 cells,
monitoring the intrinsic fluorescence of DOX, using a fluorescence microscope. Images
were taken using a 10x and a 20x microscope lens.
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Figure 5.2. Comparison of kinetics of cellular DOX distribution in ErbB2 overexpressing 21MT1 cells after treatment with Free DOX or DOX/NG. Cells, grown on glass coverslips, were
exposed to free DOX or DOX/NG (10 µg/mL DOX equivalents) for the indicated time periods
following which the cells were washed 3X in PBS and fixed using 4% PFA for 20 min. The cells
on the coverslips were then imaged using a regular fluorescence microscope, using a 20X
objective. Shown here is a comparison of the distribution of DOX-fluorescence (red) within the
cells, as a function of time, when added in the free form vs the NG-formulation.

As shown in Fig. 5.2, the free DOX, which rapidly partitions across the plasma
membrane, was found within the nuclei of cells as early as 15 min. On the other hand, the
fluorescence of DOX followed by treatments with DOX/NG (at the same concentration
of DOX) at early time points (15 and 30 min) was very weak and diffused throughout the
cytoplasm; nuclear localization of DOX could only be seen at longer time points (120
min, Fig. 5.2). Confocal microscopy tracking the DOX uptake in live cells confirmed that
the DOX/NG accumulated in Transferrin positive early endosomes within 15 min (seen
as co-localized yellow punctate structures in Fig. 5.3A, merged panel) and trafficked into
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lysosomes within 30 min (as seen by colocalization with Lysotracker dye in Fig. 3B,
merged panel).

Figure 5.3. Confocal immunofluorescence analysis of cellular distribution of DOX/NG. 21MT-1
cells grown on coverslips were loaded with 10 µg/ml Alexa488-labeled transferrin (early
endosomal marker) or Lysotracker Green (lysosomal marker; 100nM) for 10 min at 370C.
DOX/NG (10 µg/mL Dox equivalents) was then added and the uptake and intracellular
distribution of DOX/NG (red) within Transferrin- or Lysotacker green-positive compartments,
was followed using live cell imaging. Shown here the distribution of DOX fluorescence (red)
within transferrin-positive (panel A) early endosomes after 15 min, and in lysosomal
compartment (lysotracker green positive) after 30 min (panel B). Clear nuclear localization is
seen after 60 min of incubation.

As seen in the low-resolution microscopy images shown in Fig. 5.3, after 30 min
incubation most of the fluorescence from DOX was within the cytosol and not the
nucleus. However, by 60 min, the DOX fluorescence was found in the nucleus,
confirming diffusion of DOX from the lysosomes. Lysosomal trapping of drug-loaded
NGs is expected to modulate the release of the drug as well as control the degradation of
the carrier. We have previously shown that DOX release rate from NGs is higher at the
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acidic pH, which is likely due to protonation of carboxylic groups of PGlu and abating
the drug and micelle electrostatic coupling. Since intracellular endocytotic vesicles are
acidic (pH≈4.0 to 6.0), the transport of the NGs in these compartments can potentially
trigger a release of a bolus of drug from the carrier. Degradation of the PGlu-based NGs
in the presence of lysosomal proteases such as cathepsin B or cleavage of reductively
labile disulfide bonds in the NGs ionic cores can further facilitate the Dox release.
While the intrinsic fluorescence of DOX served as a method to follow the uptake
of drug-loaded NGs and DOX-release, we followed ErbB2 degradation using a Western
blot technique as a means to assess the release of 17-AAG and its ability to inhibit
intracellular HSP90. The data shown in Fig. 5.4 clearly demonstrate that the encapsulated
17-AAG is released into the cytosol and can inhibit HSP90 leading to ErbB2degradation.

Figure 5.4. 17-AAG-loaded NGs can induce ErbB2-degradation in 21MT-1 cell lines as
efficiently as free 17 AAG. Cells were treated with the indicated concentrations of free 17-AAG
or the NG-formulations for 8h (Dose response experiment; panel A) or with fixed concentration
(1 µM) of free 17-AAG or the NG-formulations for the indicated time periods (kinetics; panel B).
Samples were lysed in Triton X-100 lysis buffer and 25 µg aliquot of total protein was analyzed
by SDS-PAGE/WB. Shown here are changes in ErbB2-levels as a result of HSP90-inhibition.
Hsc70 is shown as loading control.
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As seen in Fig. 4A, 17AAG/NG or (DOX+17AAG)/NG induced ErbB2
degradation at the same level as the treatment with free 17-AAG in a dose-dependent
manner. Notably, the kinetics of ErbB2 degradation were also comparable for NGformulations and free 17-AAG (Fig. 5.4B).
Previous studies from our laboratory has shown that NGs with cross-linked ionic
cores can be selectively endocytosed into cancer cells, which lack epithelial cell tight
junctions, in contrast to normal epithelial cells that form tight junctions [38]. The
internalization route appeared to be predominantly via the caveolar pathway. While the
current studies report the ability of untargeted NGs to be internalized into ErbB2overexpressing breast cancer cells, we anticipate that integration of targeting anti-ErbB2
antibody on to the surface of NGs could further facilitate selective delivery of their
payload specifically into ErbB2-overexpressing breast cancer cells. In conjunction with
passive targeting, ErbB2-targeted drug delivery should further reduce side effects of the
chemotherapeutics. In contrast to the untargeted NGs, the ErbB2-specific uptake of the
targeted NGs will be dictated by the ErbB2 endocytic pathway. However, one anticipated
caveat is that the rate of Trastuzumab-induced ErbB2 internalization is very slow [28,
39]. Immunogold labeled electron microscopy has revealed that gold-labeled
Trastuzumab can be detected within microvili-like protrusions and clathrin-coated pits at
the cell surface as well as within recycling endosomes [39, 40]. We have shown that
HSP90-inhibition induces ErbB2-ubiquitinylation, resulting in accelerated internalization,
ubiquitin-dependent sorting into multivesicular bodies and subsequent lysosomaldegradation [28]. Accordingly, we hypothesize that the uptake of the chemotherapeutic
payload being delivered via ErbB2-targeted NGs can be significantly enhanced by
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concomitant treatment with HSP90-inhibitors, which can accelerate the internalization of
the ErbB2-bound targeted drug cargo and routing them to the lysosomes leading to
efficient drug-release and induction of cytotoxicity. These studies are ongoing in our
laboratories and will be reported elsewhere.
5.2.3 In vitro cytotoxicity of DOX, 17-AAG or drug combination against ErbB2-high
and ErbB2-low breast cancer cell lines.
DOX is among the most active cytotoxic agents for the treatment of breast cancer. DOX
induces DNA damage, and many DNA-repair components are HSP90 client proteins
[41]. To test a hypothesis that 17-AAG contentment leads to sensitization of cancer cells
to cytotoxic effects of DOX, we determined the cytotoxicity of various drug formulations
in a panel of breast cancer cell lines with differential ErbB2 expression using MTT cell
cytotoxicity assay (Supplementary Fig. 1-3). Calculated IC50 values (the concentration
that inhibited cell growth by 50%) are summarized in Table 5.2.
Table 5.2. Comparison of IC50 values for drug-loaded NGs and free drugs against various
breast cancer cell lines as determined by the MTT assay.
Formulation

Free DOX
Free 17-AAG

IC50 (µM) [with respect to Dox]
BT-474

21MT-1

MCF-7

0.60 ± 0.08

0.13 ± 0.17

0.65 ± 0.13

0.011 ± 0.003 0.005 ± 0.002 0.09 ± 0.04
0.09 ± 0.03

0.007 ± 0.002 0.63 ± 0.17

(CIb = 0.055)

(CI = 0.043) (CI = 0.85)

Free DOX + 17-AAGa

DOX/NG
17-AAG/NG

2.40 ± 0.22

0.47 ± 0.20

1.05 ± 0.02

0.022 ± 0.002 0.009 ± 0.003 0.14 ± 0.04
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0.13 ± 0.05

0.08 ± 0.03* 0.81 ± 0.18

(CI = 0.043)

(CI = 0.060) (CI = 0.93)

(DOX+17-AAG)/NGa
a
b

The molar ratio of DOX :17-AAG of 6:1 was used for the drug combination studies.
CI values were calculated at IC50.

We first confirmed that the DOX and 17-AAG combination at a 6:1 molar ratio
(corresponding to the drug content encapsulated into NGs) was indeed synergistic in its
cytotoxicity against high-level ErbB2-expressing BT-474 and 21MT-1 cell lines after
concomitant treatment for 48 h. An approximately 6- and 18-fold reduction in the IC50 for
DOX was seen in BT-474 and 21MT-1 cells, respectively, after treatment with drug
combination. Chou-Talalay analysis of the data clearly indicated a combination index
below 1 (such as 0.055 for BT-474 and 0.043 for 21MT-1) confirming strong
pharmacological synergy. Similarly, we found that (DOX+17-AAG)/NG combination
was significantly more effective in killing ErbB2-overexpressing cells than single
DOX/NG formulation and displayed very pronounced synergistic cytotoxicity. The
corresponding CI values of (DOX+17-AAG)/NG combination at IC50 were 0.043 and
0.06 for BT-474 and 21MT-1cells, respectively. On the other hand, no appreciable
differences between the combination treatment and DOX alone (either free or loaded in
NGs) were detected in similar experiments conducted on the ErbB2-low MCF-7 cells
(Table 2), suggesting that 17-AAG plus DOX combination can induce synergistic antiproliferative effects selectively in ErbB2-overexpressing breast cancer cells.
5.2.4 Anti-tumor activity of (DOX+17-AAG)/NG in ErbB2-driven xenograft model.
Motivated by the enhanced in vitro efficacy of (DOX+17-AAG)/NG formulation, we
evaluated its antitumor efficacy in vivo in ErbB2-driven xenograft model. Intravenous
administrations of each formulation were given 4 times at 4-day intervals at an equivalent
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dose of 6 mg-DOX/kg. Animals injected with (DOX+17-AAG)/NG or free drug
combination received 6mg/kg DOX and 1 mg/kg 17-AAG equivalents per dose. The
changes in the relative tumor volume, body weight and animal lifespan are shown in Fig.
5.5A, 5.5B and 5.5C, respectively.

Fig. 5.5. In vivo antitumor efficacy of (DOX + 17-AAG)/NG in ErbB2+ - BT-474 breast cancer
mice model. Relative changes in (A) tumor volume and (B) body weight were measured
following intravenous administration of (DOX + 17-AAG)/NG (▲) or DOX/NG (●) or DOX +
17-AAG (♦) or ree DOX (Ø) or 17-AAG/NG (■) or 5% dextrose (▼). Drug formulations were
injected in 100 μL at a dose of 6 mg DOX or 1mg 17-AAG equivalents/kg body weight 4 times at
4-day intervals as indicated by the arrows. Values indicated are means ± SEM (n = 10). (C)
Kaplan–Meier analysis of overall survival in (DOX + 17-AAG)/NG group (1) or DOX/NG group
(2) or DOX + 17-AAG group (3) or DOX alone (4) or 17-AAG/NG group (5) or control group
(6). Tumor volume and body weight are normalized with respect to tumor volume or body weight
at day 0. * P<0.05, ** P<0.01.

Tumor growth inhibition ratio between treated versus control groups (T/C value) was
calculated on day 14 after treatment initiation according to the formula: T/C = (V tVo)treated tumor/(Vt-Vo)control tumor, where Vt and Vo represent the mean tumor volume on the
evaluation day and at the start of the experiment, respectively.

Consistent with the in

vitro findings, combination treatment with (DOX+17-AAG)/NG formulation resulted in a
more significant tumor volume reduction (T/C = 0.13), which translated into increased
overall survival of the animals compared to the animal groups treated with a combination
of free drugs (DOX+17-AAG) at equivalent drug concentrations (P<0.05, Fig. 5.5A &
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5.5C). Although not as prominent as (DOX+17-AAG)/NG formulation, tumor burden
was also decreased by treatments with DOX alone (T/C = 0.54) or combination of free
drugs (DOX+17-AAG, T/C = 0.47) or Dox/NG (T/C = 0.39) compared to control (Fig.
5.5A). Notably, survival of the animals treated with DOX/NG was higher than in animals
treated with the combination of free drugs or DOX alone, which could be attributed to the
pronounced systemic toxicity of (DOX+17-AAG) and DOX treatments (Fig. 5.5C).
Figure 5.5B shows that animals treated with either single or binary drug-loaded NGs only
lost ~5% body weight during the 2-week study period compared to control group while
the same dose of Dox or the free drug combination (DOX+17-AAG) produced a
considerable body weight loss (>15%, P < 0.05). These results indicate that DOX-loaded
NGs have a much-improved therapeutic index when compared with free DOX. Notably,
treatment with 17-AAG/NG did not have any substantial effect on the tumor growth (T/C
= 0.87) and only minor increase in survival was observed over controls. To further
corroborate the superior antitumor efficacy of binary drug combination in NGs, the
tumors were excised post-treatment (on 10th day after last injection) and processed for
staining of Ki-67 to examine the effect of treatment on cell proliferation.
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Fig. 5.6: Ki-67-caspase-3 apoptosis assay of excised tumors from mice treated with free drugs or
NG-formulations. Panel A - Quantification of Ki-67 positive cells in tumor tissue from mice from
various groups. Data are presented as mean ± SD (n = 5 random microscopic fields for each
tumor slice). * P<0.05, *** P<0.001. Panel B shows a comparison of the tumor size for each
treatment condition.

The number of Ki-67 positive cells were significantly lower in tumors from mice that
received (DOX+17-AAG)/NG compared to tumors in control (P<0.001) or DOX+17AAG (P<0.01) or DOX/NG (P<0.05) (Fig. 5.6A), which reflected the decrease in the size
of the excised tumors (Fig. 6B). Light microscopic examination of H&E-stained tissue
(liver, spleen, heart kidney and lung) sections from sacrificed animals (day 22) did not
show any evidence of toxicity (data not shown). Collectively, these data provide in vivo
evidence that biodegradable PEG-polypeptide NGs carrying DOX and 17-AAG drug
combination exerted superior antitumor efficacy, both in terms of tumor inhibition and
survival, which could be attributed to the preferential simultaneous accumulation, and
increased potency.
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5.4 Conclusions
Using an ErbB2-driven breast cancer model, we demonstrated the potential of PEGpolypeptide nanogels as novel nanocarriers for the delivery of synergistic combinations
of chemotherapeutics with the HSP90 inhibitor, 17-AAG. Importantly, the binary drug
combination of 17-AAG and DOX simultaneously delivered using NGs exhibited
superior antitumor efficacy compared to a combination of free drugs and single drug NGs
analogues. Inhibition of HSP90, which leads to degradation and down-regulation of
several oncogenic client proteins, is a strategy being extensively explored as treatment for
various types of cancers. HSP90 inhibitors, such as 17-AAG, which can synergize with
various currently used anticancer agents has shown significant potential in initial phase II
clinical trials, including in ErbB2-driven breast cancers. We have previously
demonstrated the potential of 17-AAG to synergize with Trastuzumab and induce
cytotoxicity in ErbB2-driven breast cancer models. Our studies with biodegradable and
biocompatible polymeric NGs provide an alternative to the formulation issues that have
impeded the development of 17-AAG. Moreover, these nanocarriers provide an
opportunity to encapsulate multiple drugs with various physicochemical properties and
modes of action. While doxorubicin was chosen as a model chemotherapeutic in this
study, we anticipate that the multidrug loaded NGs represent an attractive platform for
the development of potent combinations of HSP90 inhibitors with cytotoxic agents and,
thus, further investigations of these NGs are warranted.
Acknowledgements
We acknowledge the assistance of NMR and Confocal Microscopy Core Facilities
at UNMC (supported by the NCI Cancer Center Support Grant to Buffett Cancer Center)

182

for excellent technical assistance.
5.5. References
[1] D.J. Slamon, W. Godolphin, L.A. Jones, J.A. Holt, S.G. Wong, D.E. Keith, W.J. Levin, S.G.
Stuart, J. Udove, A. Ullrich, Studies of the HER-2/neu proto-oncogene in human breast and
ovarian cancer, Science, 244 (1989) 707-712.
[2] C.M. Perou, T. Sørlie, M.B. Eisen, M. van de Rijn, S.S. Jeffrey, C.A. Rees, J.R. Pollack, D.T.
Ross, H. Johnsen, L.A. Akslen, Molecular portraits of human breast tumours, Nature, 406 (2000)
747-752.
[3] T. Sørlie, R. Tibshirani, J. Parker, T. Hastie, J. Marron, A. Nobel, S. Deng, H. Johnsen, R.
Pesich, S. Geisler, Repeated observation of breast tumor subtypes in independent gene expression
data sets, Proc Natl Acad Sci U S, 100 (2003) 8418-8423.
[4] C. Sotiriou, S.-Y. Neo, L.M. McShane, E.L. Korn, P.M. Long, A. Jazaeri, P. Martiat, S.B.
Fox, A.L. Harris, E.T. Liu, Breast cancer classification and prognosis based on gene expression
profiles from a population-based study, Proc Natl Acad Sci U S, 100 (2003) 10393-10398.
[5] D.J. Slamon, B. Leyland-Jones, S. Shak, H. Fuchs, V. Paton, A. Bajamonde, T. Fleming, W.
Eiermann, J. Wolter, M. Pegram, Use of chemotherapy plus a monoclonal antibody against HER2
for metastatic breast cancer that overexpresses HER2, N Engl J Med, 344 (2001) 783-792.
[6] D. Graus-Porta, R.R. Beerli, J.M. Daly, N.E. Hynes, ErbB-2, the preferred heterodimerization
partner of all ErbB receptors, is a mediator of lateral signaling, EMBO J, 16 (1997) 1647-1655.
[7] M.M. Moasser, The oncogene HER2: its signaling and transforming functions and its role in
human cancer pathogenesis, Oncogene, 26 (2007) 6469-6487.
[8] T.A. Bailey, H. Luan, R.J. Clubb, M. Naramura, V. Band, S.M. Raja, H. Band, Mechanisms
of Trastuzumab resistance in ErbB2-driven breast cancer and newer opportunities to overcome
therapy resistance, J Carcinog, 10 (2011) 28.
[9] C.A. Hudis, Trastuzumab—mechanism of action and use in clinical practice, N Engl J Med,
357 (2007) 39-51.
[10] E.G. Mimnaugh, C. Chavany, L. Neckers, Polyubiquitination and proteasomal degradation
of the p185c-erbB-2 receptor protein-tyrosine kinase induced by geldanamycin, J Biol Chem, 271
(1996) 22796-22801.
[11] T.W. Schulte, L.M. Neckers, The benzoquinone ansamycin 17-allylamino-17demethoxygeldanamycin binds to HSP90 and shares important biologic activities with
geldanamycin, Cancer Chemother Pharmacol, 42 (1998) 273-279.
[12] L. Neckers, Heat shock protein 90 is a rational molecular target in breast cancer, Breast Dis,
15 (2002) 53-60.
[13] S. Modi, A. Stopeck, H. Linden, D. Solit, S. Chandarlapaty, N. Rosen, G. D'Andrea, M.
Dickler, M.E. Moynahan, S. Sugarman, HSP90 inhibition is effective in breast cancer: a phase II
trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic
breast cancer progressing on trastuzumab, Clin Cancer Res, 17 (2011) 5132-5139.
[14] W. Xu, E. Mimnaugh, M.F. Rosser, C. Nicchitta, M. Marcu, Y. Yarden, L. Neckers,
Sensitivity of mature Erbb2 to geldanamycin is conferred by its kinase domain and is mediated by
the chaperone protein Hsp90, J Biol Chem, 276 (2001) 3702-3708.
[15] A.D. Basso, D.B. Solit, P.N. Munster, N. Rosen, Ansamycin antibiotics inhibit Akt
activation and cyclin D expression in breast cancer cells that overexpress HER2, Oncogene, 21
(2002) 1159.
[16] M.V. Powers, P. Workman, Targeting of multiple signalling pathways by heat shock protein
90 molecular chaperone inhibitors, Endocrine-Related Cancer, 13 (2006) S125-S135.
[17] J. Trepel, M. Mollapour, G. Giaccone, L. Neckers, Targeting the dynamic HSP90 complex in
cancer, Nat Rev Cancer, 10 (2010) 537-549.

183
[18] P.N. Münster, A. Basso, D. Solit, L. Norton, N. Rosen, Modulation of Hsp90 Function by
Ansamycins Sensitizes Breast Cancer Cells to Chemotherapy-induced Apoptosis in an RB-and
Schedule-dependent Manner See The Biology Behind: EA Sausville, Combining Cytotoxics and
17-Allylamino, 17-Demethoxygeldanamycin: Sequence and Tumor Biology Matters. Clin Cancer
Res, 7 (2001) 2228-2236.
[19] G. Georgakis, Y. Li, A. Younes, Preclinical evaluation of the HSP-90 inhibitor 17AAG in
Hodgkin’s and non-Hodgkin’s lymphomas: Induction of apoptosis and potentiation of
chemotherapy cytotoxicity, in: Proc Annu Meet Am Soc Clin Onco, 2005, pp. 6570.
[20] U. Sarangi, K.R. Paithankar, J.U. Kumar, V. Subramaniam, A.S. Sreedhar, 17AAG
Treatment Accelerates Doxorubicin Induced cellular senescence: Hsp90 Interferes with enforced
senescence of Tumor cells, Drug target insights, 6 (2012) 19.
[21] S.S. Desale, S.M. Cohen, Y. Zhao, A.V. Kabanov, T.K. Bronich, Biodegradable hybrid
polymer micelles for combination drug therapy in ovarian cancer, J Control Release, 171 (2013)
339-348.
[22] M.E. Godsey, S. Suryaprakash, K.W. Leong, Materials innovation for co-delivery of diverse
therapeutic cargos, RSC Adv, 3 (2013) 24794-24811.
[23] H.S.O. Jong Oh Kim, Swapnil Desale, Alexander V. Kabanov, and Tatiana K. Bronich,
Polypeptide nanogels with hydrophobic moieties in the cross-linked ionic cores: synthesis,
characterization and implications for anticancer drug delivery, J Drug Taget, (2013).
[24] Y. Han, Z. He, A. Schulz, T.K. Bronich, R. Jordan, R. Luxenhofer, A.V. Kabanov,
Synergistic combinations of multiple chemotherapeutic agents in high capacity poly (2-oxazoline)
micelles, Mol Pharm, 9 (2012) 2302-2313.
[25] C.C. Lee, E.R. Gillies, M.E. Fox, S.J. Guillaudeu, J.M. Fréchet, E.E. Dy, F.C. Szoka, A
single dose of doxorubicin-functionalized bow-tie dendrimer cures mice bearing C-26 colon
carcinomas, Proc Natl Acad Sci U S A, 103 (2006) 16649-16654.
[26] V. Band, D. Zajchowski, K. Swisshelm, D. Trask, V. Kulesa, C. Cohen, J. Connolly, R.
Sager, Tumor progression in four mammary epithelial cell lines derived from the same patient,
Cancer Res, 50 (1990) 7351-7357.
[27] S.M. Raja, R.J. Clubb, C. Ortega-Cava, S.H. Williams, T.A. Bailey, L. Duan, X. Zhao, A.L.
Reddi, A.M. Nyong, A. Natarajan, Anticancer activity of Celastrol in combination with ErbB2targeted therapeutics for treatment of ErbB2-overexpressing breast cancers, Cancer Biol Ther, 11
(2011) 263-276.
[28] S.M. Raja, R.J. Clubb, M. Bhattacharyya, M. Dimri, H. Cheng, W. Pan, C. Ortega-Cava, A.
Lakku-Reddi, M. Naramura, V. Band, A combination of trastuzumab and 17-AAG induces
enhanced ubiquitinylation and lysosomal pathway-dependent ErbB2 degradation and cytotoxicity
in ErbB2-overexpressing breast cancer cells, Cancer Biol Ther, 7 (2008) 1630-1640.
[29] M. Ferrari, M.C. Fornasiero, A.M. Isetta, MTT colorimetric assay for testing macrophage
cytotoxic activity in vitro, J Immunol Methods, 131 (1990) 165-172.
[30] N.V. Nukolova, H.S. Oberoi, S.M. Cohen, A.V. Kabanov, T.K. Bronich, Folate-decorated
nanogels for targeted therapy of ovarian cancer, Biomaterials, 32 (2011) 5417-5426.
[31] M. Scaltriti, S. Dawood, J. Cortes, Molecular pathways: targeting hsp90—who benefits and
who does not, Clin Cancer Res, 18 (2012) 4508-4513.
[32] C.S. Mitsiades, N.S. Mitsiades, C.J. McMullan, V. Poulaki, A.L. Kung, F.E. Davies, G.
Morgan, M. Akiyama, R. Shringarpure, N.C. Munshi, Antimyeloma activity of heat shock
protein-90 inhibition, Blood, 107 (2006) 1092-1100.
[33] O. Ayrault, M.D. Godeny, C. Dillon, F. Zindy, P. Fitzgerald, M.F. Roussel, H.M. Beere,
Inhibition of Hsp90 via 17-DMAG induces apoptosis in a p53-dependent manner to prevent
medulloblastoma, Proc Natl Acad Sci U S A, 106 (2009) 17037-17042.
[34] G.V. Georgakis, Y. Li, G.Z. Rassidakis, L.J. Medeiros, A. Younes, The HSP90 inhibitor 17AAG synergizes with doxorubicin and U0126 in anaplastic large cell lymphoma irrespective of
ALK expression, Exp Hematol, 34 (2006) 1670-1679.

184
[35] C. Lai, K. Park, D. Lee, A. Alberobello, M. Raffeld, M. Pierobon, E. Pin, E. Petricoin III, Y.
Wang, G. Giaccone, HSP-90 inhibitor ganetespib is synergistic with doxorubicin in small cell
lung cancer, Oncogene, 33 (2013) 4867-4876.
[36] S.J. Arlander, A.K. Eapen, B.T. Vroman, R.J. McDonald, D.O. Toft, L.M. Karnitz, Hsp90
inhibition depletes Chk1 and sensitizes tumor cells to replication stress, J Biol Chem, 278 (2003)
52572-52577.
[37] N.L. Spector, K.L. Blackwell, Understanding the mechanisms behind trastuzumab therapy
for human epidermal growth factor receptor 2–positive breast cancer, J Clin Oncol, 27 (2009)
5838-5847.
[38] G. Sahay, D.Y. Alakhova, A.V. Kabanov, Endocytosis of nanomedicines, J Control Release,
145 (2010) 182-195.
[39] C.D. Austin, A.M. De Mazière, P.I. Pisacane, S.M. van Dijk, C. Eigenbrot, M.X.
Sliwkowski, J. Klumperman, R.H. Scheller, Endocytosis and sorting of ErbB2 and the site of
action of cancer therapeutics trastuzumab and geldanamycin, Mol Biol Cell, 15 (2004) 52685282.
[40] L.A. Maier, F.J. Xu, S. Hester, C.M. Boyer, S. McKenzie, A.M. Bruskin, Y. Argon, R.C.
Bast, Requirements for the internalization of a murine monoclonal antibody directed against the
HER-2/neu gene product c-erbB-2, Cancer Res, 51 (1991) 5361-5369.
[41] K.B. Kaplan, R. Li, A prescription for ‘stress’–the role of Hsp90 in genome stability and
cellular adaptation, Trends Cell Biol, 22 (2012) 576-583.

185

CHAPTER VI
SUMMARY

Combination chemotherapy is preferred over treatment with single agents to combat most
cancers as it targets multiple cell-survival pathways at the same time and delays the onset
of resistance. This helps in achieving long-term tumor remission and increases median
survival. Cisplatin (CDDP)-based therapy has been the standard treatment for ovarian
cancer since its discovery. After paclitaxel (PTX) was shown to be effective in ovarian
cancer, multiple clinical trials studied the overall efficacy of CDDP and PTX and found
significant benefit over the pre-existing treatments. Since then, this combination has been
the treatment of choice for both early stage as well as advanced cases of ovarian cancer.
However, administration of two different agents comes with the inconvenience of
repeated or extended duration of drug infusion in patients. Moreover, the most
extensively used conventional formulation of paclitaxel, Taxol®, utilizes Cremophor EL
(polyethoxylated castor oil) that has been linked to significant toxicities including
allergic, hypersensitivity and anaphylactic reactions during infusion that require
premedication and prolonged peripheral neuropathy. Combining such drugs in one
delivery carrier is therefore a well-suited and convenient strategy for controlling the
pharmacokinetics and co-delivery of the desired drug ratio in vivo, to maximize the
therapeutic potency and minimize drug-associated toxicities.
Cross-linked nanogels have been found to be promising drug carriers to achieve this
goal. Being mostly hydrophilic in nature, nanogels are highly biocompatible with a high
loading capacity for guest molecules. The nanogel structure can be readily adjusted to
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integrate features of different materials and, thus, offer advantages for combinatorial
encapsulation of drugs with varying physicochemical properties. One of the widespread
synthetic techniques for the synthesis of nanogels is the crosslinking of preformed coreshell self-assemblies such as polymer micelles that allows introducing a high degree of
spatial organization into the nanogels. Cross-linking is known to impart control over the
swelling behavior of the nanogels and thus helps in achieving controlled release of the
incorporated cargo, which is an added advantage over the structural integrity imparted to
the carrier system upon in vivo administration. The enhanced stability also makes the
prolonged circulation of the nanogels possible, which in turn allows for increased drug
accumulation at the target site by enhanced permeability and retention effect (EPR). We
report in Chapter II design of multi-compartment cross-linked nanogels based on hybrid
triblock copolymers, poly(ethylene glycol)-block-poly(L-glutamic acid)-block-poly(Lphenylalanine) (PEG-b-PGlu-b-PPhe) for simultaneous loading and delivery of binary
CDDP and PTX combination. Such nanogels have 1) a hydrophobic core formed by PPhe
chains, which serves as a reservoir for PTX solubilization, 2) an anionic layer, which
incorporates CDDP through coordination with the carboxylic groups of PGlu, and 3) an
outer PEG shell stabilized, which stabilizes micelles in aqueous dispersion. The
crosslinks incorporated into PGlu block layer ensure that the PEG-b-PGlu-b-PPhe
micelles remain stable until they encounter proteases, which degrade the micelles by
cleaving the polypeptide chains of the block copolymers. This work demonstrates that
such biodegradable hybrid micelles carrying CDDP and PTX drug combination exert
superior antitumor efficacy in treatment of ovarian cancer in xenograft mouse tumor
model.
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Regardless of the importance and popularity of EPR effect-based drug delivery, this
strategy has some limitations related to the inter- and intra-tumor heterogeneity,
variations in the density as well as permeability of the tumor vasculature that can affect
the accumulation of nanocarriers. One of the popular approaches to circumvent these
problems is by surface-functionalization of the drug carrier with ligands that can target
receptors with differential expression on the cancer cell surface, which helps in
increasing the mean residence time of the delivery system at the tumor site and improving
target cell uptake. One such receptor of interest is the folate receptor (FR). Malignant
cells, due to their high rate of cell division, have an increased requirement of folic acid
(FA), since it is essential component of cell metabolism and DNA synthesis and repair.
To fulfill this higher need of FA, FR is known to be over-expressed in a large number of
malignant tissues, including ovarian cancer, compared to normal tissues with the
exception of the kidney and choroid plexus. Furthermore, this receptor becomes
accessible via the plasma compartment only after the cells lose their polarity owing to
malignant transformation which makes it a differential target for cancer tissue that is
easily accessible for intravenously administered FA conjugated systems. Its natural
ligand, FA, comes with the advantages of high binding affinity, stability and a simple
chemical structure together with ease of availability, making it a suitable targeting ligand
for ovarian cancer therapy. FA can thus be successfully conjugated to macromolecular
systems without loss of binding affinity to its receptor. Many different agents targeting
the folate pathway are currently in clinical development. To date, FA-targeted agents
showed significant promise in phase II clinical trials but it has not been confirmed in
phase III studies. Accordingly, there is a need for further identification of new therapeutic
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combinations and refinement of patient selection. To this end, FA-conjugated imaging
agents could be used for pre-selection of patients based on the expression of FR and
several methods have been already developed for this purpose.
Our group has previously demonstrated a tumor-specific delivery and improved anticancer effect in vivo of CDDP-loaded nanogels decorated with FA targeting groups. In
our Chapter III, we designed FA-linked nanogels incorporating platinum-taxane
combination, and examined whether FR-targeted concurrent delivery of synergistic
combination of CDDP and PTX can lead to enhanced therapeutic efficacy compared to
nontargeted NG system.
The oncogenic receptor tyrosine kinase ErbB2, overexpressed in over 20% of breast
cancers, has served as a major target for the development of targeted drug delivery
strategies. However, ErbB2 is thought to be either impaired in endocytosis or to rapidly
recycle back to the cell-surface, which can significantly dampen the efficacy of ErbB2targeted drug delivery. Such altered trafficking dynamics is believed to be due to its
constitutive association with HSP90 which can be anticipated to significantly dampen the
efficacy of ErbB2-targeted drug delivery. We therefore hypothesized that HSP90inhibition will enhance ErbB2-targeted drug delivery by promoting the endocytic uptake
of ErbB2-bound nano-encapsulated cargo and facilitating its re-routing from a recycling
pathway to the lysosomes. Using Trastuzumab-conjugated NGs (Trast-NG) encapsulating
the DNA-damaging drug Doxorubicin (DOX) as a model chemotherapeutic, we
demonstrate in Chapter IV through both in vitro and in vivo studies that HSP90inhibition can indeed lead to an enhancement of targeted delivery of DOX specifically
into ErbB2-overexpressing breast cancer cells. As a consequence, a sub-therapeutic and
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non-toxic dose of the HSP90 inhibitor 17AAG markedly improves the efficacy of ErbB2targetd nanogels in vivo. In a follow up study, we attempted to co-encapsulate DOX and
17-AAG since combining drugs in one delivery carrier is a well-suited strategy for
controlling the pharmacokinetics and co-delivery of the desired drug ratio in vivo.
However, co-incorporation of drug molecules with different physicochemical properties,
such as hydrophilic DOX and hydrophobic 17-AAG, has been challenging. In Chapter
V, we have described biodegradable polymeric nanogels (NGs) based on poly(ethylene
glycol)-b-poly(L-glutamic acid) (PEG-b-PGA) with pendant phenylalnine functionalities.
Such NGs have multiple hydrophobic domains formed by phenylalanine moieties within
the cross-linked PGA polyion cores surrounded by a hydrophilic PEG shell. Herein, we
explored these novel NGs for co-encapsulation of 17-AAG and DOX. The potency of this
co-delivery system was evaluated in a panel of human breast cancer lines and in an
ErbB2-driven orthotopic xenograft model. We demonstrate that NGs-based co-delivery
of synergistic combination of 17-AAG and DOX exhibited superior antitumor efficacy
compared to a combination of free drugs in ErbB2-positive breast cancer cells. The
implications of our results may support a new platform for delivery of combinations of
HSP90 inhibitors with cytotoxic agents for treatment of various types of cancers.
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LIMITATIONS AND FUTURE DIRECTIONS
The data reported in chapter II showed the preclinical evaluation of platinum-taxaneloaded nanogels. Our work demonstrated that such biodegradable hybrid nanogels
carrying CDDP and PTX drug combination exert superior antitumor efficacy in treatment
of ovarian cancer in xenograft mouse tumor model. However, our system relied solely on
the EPR effect to facilitate the delivery of the drug combination to the tumor site. No
matter what the importance and popularity of EPR effect-based drug delivery is, this
strategy has some limitations related to the inter- and intra-tumor heterogeneity,
variations in the density as well as permeability of the tumor vasculature that can affect
the accumulation of nanocarriers. One of the popular approaches to circumvent these
problems is by surface-functionalization of the drug carrier with ligands that can target
receptors with differential expression on the cancer cell surface, which helps in
increasing the mean residence time of the delivery system at the tumor site and improving
target cell uptake. In our Chapter III, we designed FA-linked nanogels incorporating
platinum-taxane combination, and examined whether FR-targeted concurrent delivery of
synergistic combination of CDDP and PTX can lead to enhanced therapeutic efficacy
compared to nontargeted NG system. Many recent studies have shown that the particulate
system with the size less than 50 nm has profound effect on its tumor accumulation.
Although we were able to generate particles with the size less than 100 nm, it wasn’t
small enough for the very effective tumor accumulation as per recent reports. Another
limitation of current triblock copolymer-based nanogels system is loading same drug
combination at different ratios. Although our current drug ratio is very synergetic, we are
also exploring the different block length ratios which would allow us to have system with
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different ratios of same drug combination. Current and future studies planned in our
group include design and fabrication of sub-100 nm particulate system. One such a
system under investigation is based on diblock copolymers of PEG and poly(L-leucin).
This copolymer assembles into a uniform micellar aggregates in aqueous solutions. The
resulting micelles have size of less than 50 nm. It also allows for loading to highly
synergistic combination of hydrophobic drug molecules including paclitaxel.
The binding of FA-(CDDP + PTX)/NG to and/or their uptake by FR+ cancer cells
can retain them within the tumor for a longer period of time, prevent their rapid reentering into systemic circulation and, thus, provide some benefits over passively
targeted formulations. The introduction of FA moieties can also have an effect on
pharmacokinetics and biodistribution of NGs and influence tumor uptake. Our future
efforts include detailed pharmacokinetic study which may help to elucidate the
relationship between the therapeutic effect of the FR-targeted NGs and distribution at the
tumor and the whole body. FA targeting achieved desirable tumor inhibition in our
present study but its distribution in other organs especially kidney (main site of platinum
toxicity) which still remains a concern. Selecting an alternative targeting moiety with a
better selectivity to tumor target is therefore desirable. We also would like to try our
treatment regimen on the cisplatin-resistant cell line to see if targeted combination
therapy can induce a therapeutic response in them.
Current clinical therapy for ErbB2-positive breast cancer includes the administration
of Trastuzumab monoclonal antibody (Herceptin™). This therapy suffers from several
limitations. Firstly, its long-term clinical use is questionable because tumor cells acquire
resistance to the therapy and secondly, ErbB2 is either impaired in endocytosis or rapidly
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recycles back to the cell surface. In chapter IV, our studies demonstrated, both in vitro
and in vivo, that HSP90 inhibition facilitates the uptake and delivery of trastuzumabbased ErbB2-targeted nanoparticle therapy carrying a model chemotherapeutic agent,
Doxorubicin, specifically into ErbB2-overexpressing breast cancer cells. These novel
findings highlight the importance of considering oncogene-specific alterations in receptor
dynamics towards the design of targeted drug delivery strategies. We suggest that
combination of ADCs or ANPs with therapeutic agents that enhance receptor endocytosis
and lysosomal routing can provide a novel strategy with significantly higher therapeutic
benefit. Based on our studies, we suggest that the endocytic traffic itinerary of receptors
selected for targeting of ADCs and ANPs should receive careful consideration. An
understanding of mechanisms that may impair the endolysomal traffic of a targeted
receptor (as with ErbB2) may help overcome an efficacy barrier on newer agents in
development and potentially improve the efficacy of agents already in the clinic. In this
regard, the potential combination of HSP90 inhibitors that are already in clinical trials
together with the ErbB2-targeted TDM-1 will be of considerable interest and is under
study in our group. It is of interest that HSP90 is also thought to regulate the activity of
Rab GTPase-dependent endocytic recycling by its association with a Rab Guanine
Nucleotide Displacement Inhibitor (GDI), and HSP90 inhibitors could potentially help
attenuate Rab-dependent recycling of transmembrane receptors that are not direct HSP90
clients to enhance ADC or ANP delivery inside the tumor cell. Other factors that may
control trafficking of oncogenic cell-surface receptors such as the non-receptor tyrosine
kinase c-Src, endocytic adaptor proteins, E3 ubiquitin ligases, deubiquitinating enzymes,
RAB GTPases, ESCRT proteins and EHD family proteins may offer future opportunities
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to develop facilitators of ADC and ANP traffic to endolysomal compartments as
approaches of therapeutic potentiation.
Our studies also provide evidence that sub-therapeutic doses of an HSP90 inhibitor (1
mg/Kg 17AAG in our studies, which has little efficacy against BT-474 xenografts;
unpublished data), dramatically enhances tumor killing by DOX-loaded ErbB2-targeted
NGs. Such a combination led to not just inhibition of xenograft tumor growth but in fact
a significant shrinkage of tumor masses from their pre-treatment volume. This was
associated with a significant shift from a merely cytostatic to a significantly cytotoxic
effect on tumors as demonstrated by Ki67 and caspase-3 staining of tumors among
surviving mice at the end of therapy. Not surprisingly, combination with low dose
17AAG markedly improved the survival of tumor-bearing mice. We must point out that
DOX was used in our proof-of-principle studies as the polymer design we have
previously established allows efficient loading of this clinically-used chemotherapeutic
agent. However, DOX enhances cardiotoxicity associated with ErbB2-targeted antibody
therapeutics, including Trastuzumab, and as such the approach will need modifications to
incorporate more appropriate agents for ErbB2+ cancers. Such studies are currently
ongoing in our laboratories. The current nanocarrier design should however be applicable
to other tumors where a targeting antibody or other moiety is available. We have tested
the efficacy of our regimen on the Trast-sensitive cell lines. Our ongoing efforts are to
test the efficacy of our regimen on trast-resistant cell lines and also choose a transgenic
mouse model to test our treatment regimen.

